CN1161060A - Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories - Google Patents
Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories Download PDFInfo
- Publication number
- CN1161060A CN1161060A CN95195699A CN95195699A CN1161060A CN 1161060 A CN1161060 A CN 1161060A CN 95195699 A CN95195699 A CN 95195699A CN 95195699 A CN95195699 A CN 95195699A CN 1161060 A CN1161060 A CN 1161060A
- Authority
- CN
- China
- Prior art keywords
- seq
- bacterial
- probe
- sample
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims abstract description 676
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 137
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 102
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 50
- 230000003321 amplification Effects 0.000 title claims abstract description 49
- 244000052616 bacterial pathogen Species 0.000 title abstract description 24
- 230000002906 microbiologic effect Effects 0.000 title abstract description 9
- 238000011309 routine diagnosis Methods 0.000 title description 6
- 108020004414 DNA Proteins 0.000 claims abstract description 501
- 230000001580 bacterial effect Effects 0.000 claims abstract description 371
- 238000000034 method Methods 0.000 claims abstract description 295
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 190
- 239000002773 nucleotide Substances 0.000 claims abstract description 189
- 238000009396 hybridization Methods 0.000 claims abstract description 150
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 99
- 241000894007 species Species 0.000 claims abstract description 98
- 238000001514 detection method Methods 0.000 claims abstract description 67
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 41
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 37
- 241000588770 Proteus mirabilis Species 0.000 claims abstract description 35
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims abstract description 35
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 34
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 30
- 241000194032 Enterococcus faecalis Species 0.000 claims abstract description 27
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract description 26
- 229940032049 enterococcus faecalis Drugs 0.000 claims abstract description 26
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract description 26
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 24
- 229940047650 haemophilus influenzae Drugs 0.000 claims abstract description 23
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 264
- 102000039446 nucleic acids Human genes 0.000 claims description 263
- 108020004707 nucleic acids Proteins 0.000 claims description 263
- 241000894006 Bacteria Species 0.000 claims description 240
- 238000012360 testing method Methods 0.000 claims description 166
- 239000007787 solid Substances 0.000 claims description 110
- 230000000295 complement effect Effects 0.000 claims description 104
- 238000006243 chemical reaction Methods 0.000 claims description 95
- 239000000243 solution Substances 0.000 claims description 81
- 206010034133 Pathogen resistance Diseases 0.000 claims description 75
- 238000000926 separation method Methods 0.000 claims description 61
- 238000003752 polymerase chain reaction Methods 0.000 claims description 47
- 229940126575 aminoglycoside Drugs 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 36
- 102000053602 DNA Human genes 0.000 claims description 34
- 201000008225 Klebsiella pneumonia Diseases 0.000 claims description 34
- 206010035717 Pneumonia klebsiella Diseases 0.000 claims description 34
- 230000000968 intestinal effect Effects 0.000 claims description 33
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 32
- 230000015572 biosynthetic process Effects 0.000 claims description 31
- 238000007599 discharging Methods 0.000 claims description 31
- 239000002751 oligonucleotide probe Substances 0.000 claims description 31
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 29
- 239000003242 anti bacterial agent Substances 0.000 claims description 29
- 229940088710 antibiotic agent Drugs 0.000 claims description 29
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 101150100833 aacC3 gene Proteins 0.000 claims description 13
- 238000012408 PCR amplification Methods 0.000 claims description 12
- 241000191940 Staphylococcus Species 0.000 claims description 12
- 238000009007 Diagnostic Kit Methods 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 101100214700 Acinetobacter baumannii aacC2 gene Proteins 0.000 claims description 7
- 101100214699 Pseudomonas aeruginosa aacC1 gene Proteins 0.000 claims description 7
- 101150016019 aacA4 gene Proteins 0.000 claims description 7
- 101150047863 aacA-aphD gene Proteins 0.000 claims description 6
- 101150014550 aadB gene Proteins 0.000 claims description 6
- 238000007403 mPCR Methods 0.000 claims description 6
- 101150114434 vanA gene Proteins 0.000 claims description 6
- 101100049034 Enterococcus faecalis (strain ATCC 700802 / V583) vanXB gene Proteins 0.000 claims description 5
- 101100102350 Enterococcus faecium vanH gene Proteins 0.000 claims description 5
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 claims description 5
- 101150052154 MSRA1 gene Proteins 0.000 claims description 5
- 108010059993 Vancomycin Proteins 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 5
- 101150084095 ddpX gene Proteins 0.000 claims description 5
- 229960003276 erythromycin Drugs 0.000 claims description 5
- 238000007834 ligase chain reaction Methods 0.000 claims description 5
- 101150021123 msrA gene Proteins 0.000 claims description 5
- 101150114366 msrA2 gene Proteins 0.000 claims description 5
- 101150006794 msrAB gene Proteins 0.000 claims description 5
- 101150109310 msrAB1 gene Proteins 0.000 claims description 5
- 101150052209 msrAB2 gene Proteins 0.000 claims description 5
- 101150096103 vanX gene Proteins 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 101100116914 Drosophila melanogaster shv gene Proteins 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000007857 nested PCR Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 30
- 230000008021 deposition Effects 0.000 claims 30
- 238000011081 inoculation Methods 0.000 claims 30
- 230000000717 retained effect Effects 0.000 claims 30
- 238000004445 quantitative analysis Methods 0.000 claims 21
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 claims 9
- 108010080702 Virginiamycin Proteins 0.000 claims 9
- 239000004188 Virginiamycin Substances 0.000 claims 9
- 238000012797 qualification Methods 0.000 claims 9
- 229960003842 virginiamycin Drugs 0.000 claims 9
- 235000019373 virginiamycin Nutrition 0.000 claims 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 8
- 229940049547 paraxin Drugs 0.000 claims 8
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 8
- 229960001082 trimethoprim Drugs 0.000 claims 8
- 108010015791 Streptogramin A Proteins 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- DAIKHDNSXMZDCU-FQTGFAPKSA-N pristinamycin IIA Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-FQTGFAPKSA-N 0.000 claims 6
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 claims 6
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010062679 Gentamicin 2''-nucleotidyltransferase Proteins 0.000 claims 2
- 108091008324 binding proteins Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 101710108032 rRNA adenine N-6-methyltransferase Proteins 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 101100027004 Aspergillus novofumigatus (strain IBT 16806) nsrA gene Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 238000011895 specific detection Methods 0.000 abstract description 4
- 241000588655 Moraxella catarrhalis Species 0.000 abstract 1
- 239000002585 base Substances 0.000 description 180
- 210000002700 urine Anatomy 0.000 description 31
- 238000013467 fragmentation Methods 0.000 description 27
- 238000006062 fragmentation reaction Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 238000010367 cloning Methods 0.000 description 25
- 230000001717 pathogenic effect Effects 0.000 description 22
- 230000008859 change Effects 0.000 description 19
- 241000193830 Bacillus <bacterium> Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 12
- 108020004465 16S ribosomal RNA Proteins 0.000 description 10
- 102000042567 non-coding RNA Human genes 0.000 description 10
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 9
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000019206 urinary tract infection Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 241000589513 Burkholderia cepacia Species 0.000 description 5
- 241000588921 Enterobacteriaceae Species 0.000 description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- 241000607715 Serratia marcescens Species 0.000 description 5
- 241000218636 Thuja Species 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 150000003952 β-lactams Chemical class 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- 241000192041 Micrococcus Species 0.000 description 4
- 241001430197 Mollicutes Species 0.000 description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 108700022487 rRNA Genes Proteins 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- 241000148131 Colibacter Species 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 238000011325 biochemical measurement Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- -1 ethidium bromides Chemical class 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000000272 myelencephalon Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 241000593508 Garcinia Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 241000588729 Hafnia alvei Species 0.000 description 2
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000588772 Morganella morganii Species 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000588768 Providencia Species 0.000 description 2
- 241000947836 Pseudomonadaceae Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000003375 selectivity assay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101100422536 Bacillus subtilis (strain 168) satA gene Proteins 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001078665 Cardiostigma Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241001600125 Delftia acidovorans Species 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 101100372548 Enterococcus faecium vatD gene Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000588659 Neisseria mucosa Species 0.000 description 1
- 101100534581 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tca-8 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 101100316746 Rattus norvegicus Slc18a3 gene Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000173347 Tonsilla Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000922011 Trilamellaxis proteus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 241000261236 bacterium 1.1 Species 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 101150012699 vat gene Proteins 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a universal DNA-based bacterial detection method for the specific detection of Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as the specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes, directly from clinical samples or from bacterial colonies. The above bacterial species may account for a total of 80% of bacterial pathogens isolated in routine microbiological laboratories. The core of the present invention mainly includes DNA sequences from all species-specific genomic DNA fragments selected from genomic libraries by hybridization or from databases, as well as any oligonucleotide sequences derived from these sequences, which can be used as probes or amplification primers for PCR or any other nucleotide amplification method. The invention also includes DNA sequences of selected clinically relevant antibiotic resistance genes.
Description
The classics of background of invention bacterium are differentiated
The classics of bacterium differentiate it is by using biochemical method (as API20E
TMSystem) measuring them utilizes different substrates to differentiate as the ability of carbon source and nitrogenous source.The sensitivity test of gram negative bacillus develops into little dilution test.Although API and little dilution system expense are feasible, owing to must carry out continuous two incubated overnight to separate and to differentiate bacterium from sample, obtaining preliminary result needs two days at least.Also develop some and used the detection method faster of advanced and expensive instrument.For example, the fastest identification system (autoSCAN-Walk-AwayTM system) can identify Gram-negative and gram positive bacterium from the isolated bacterial bacterium colony in 2 hours, and only just can identify antibiotic responsive mode in 7 hours.Yet the amplitude of makeing mistakes of this system can't be accepted the people, and when especially differentiating the bacterial species of non-enterobacteriaceae (York etc., 1992, the Clinical microorganism magazine, 30:2903-2910).But even this method the most fast also needs at first bacterium to be separated into pure growth, this process will spend at least 18 hours when needing pure growth, and this process will spend at least 2 to 3 days when needing mixed culture.
Urine sample
Most of sample (40-50%) that bacterium differentiates in routine diagnosis Microbiological Lab being used for of accepting be urine sample (Pezzlo, 1988, clinical microbiology is looked back, 1:268-280).Urinary tract infection (UTI) is extremely common, and the women of infection nearly 20%, and sickness rate is very high in inpatient, mortality ratio also increase (Johnson and Stamm, 1989, international medical science year comments, 111:906-917).UTI is relevant with bacteria pathogeny usually, needs antimicrobial therapy.Up to the present, the Gram-negative intestinal bacteria are most popular urinary tract disease substances, account for UTI 50 to 60% (Pezzlo, 1988, op.cit.).From recently " Hospitalier de 1 ' Universit é Laval center (CHUL) " observed urine sample the distribution situation of isolated bacterial pathogenic agent in table 1 and table 2, provide.
The discriminating of common disease substance in the urine sample
The research of pathogenic agent in the urine sample accounted in conventional Microbiological Lab have great advantage, so that developed many experimental techniques.Gold standard remains classical sxemiquantitative plating method, wherein purine of having measured diameter of delineation on flat board, and cultivation 18-24 hour.To the sum of enumeration with colony-forming unit (CFU) in definite every liter of urine sample.Bacterium UTI is usually and in the urine 〉=and 10
7The CFU/L bacterial count is relevant.Yet, in the urine less than 10
7The infection of CFU/L also is possible, especially in (catheterized) patient that the patient or the conduit of high incidence inserted (Stark and Maki, 1984, Britain country medical journal, 311:560-564).It should be noted that in the urine sample of being surveyed and be considered to (＜10 of feminine gender near 80%
7CFU/L, table 3).
Accurately and fast the screening method of urine bacterial pathogens makes the quick discriminating of negative findings and patient's more effectively clinical examination patient become possibility.Recently, several method for quick identification (Uriscreen have been compared
TM, UTIscreen
TM, Flash Track
TMDna probe and other method) and the slower standard biochemical method based on the bacterial pathogens cultivation.Although these Rapid identification are faster, sensitivity and specificity are lower, and many false negatives and false positive results (Koening etc., 1992 are arranged, the clinical microbiology magazine, 50:342-345, Pezzlo etc., 1992, the clinical microbiology magazine, 30:640-684).
Be found to be the biochemical measurement that uses standard in the male urine sample by cultivation and further determine its feature, these biochemical measurements can be differentiated bacterial pathogens, and urine sample also is used for test to antibiotic susceptibility.
Any clinical sample
With the urine sample as example is the same here, our probe and amplimer also can be applicable to any other clinical sample.According to principle fast and accurately, it is better that the used mensuration based on DNA of the present invention is compared with the current standard method that is used for routine diagnosis.When the high percentage of urine sample feminine gender, surpassing 95% culture in other clinical sample is negative (table 4).These data have further proved the purposes of general probe on the negative clinical sample of screening.Also can use inhuman other organic clinical sample (as other primates, Mammals, livestock or poultry).
Exploitation is fast based on the direction of the diagnostic test of DNA
The quick diagnosis test should form effective influence to infection control.To the discriminating of pathogenic agent in the clinical sample and antibiotics resistance gene, dna probe has been compared several advantages with the DNA cloning technology with ordinary method.This method does not need succeeding transfer culture, so organism can directly differentiate in clinical sample, thereby has reduced cost and the time relevant with separating of pathogenic agent.Be proved to be for being extremely useful based on the technology of DNA in the breadboard special application of Clinical microorganism.For example, the test kit that detects based on the fatal organism that uses hybridization probe or DNA cloning directly to detect the pathogenic agent in the clinical sample is commercially available product (Persing etc., 1993, diagnosis molecular microbiology: principle and application, U.S. microbiology association, the Washington D.C.).
The present invention is the alternative method that has superiority to cultivation differential method commonly used in the private clinic of hospital clinical Microbiological Lab and routine diagnosis.Except faster, more accurate based on the diagnostic test of DNA than present diagnostic standard biochemical measurement, because bacterial gene type (as dna level) is more stable than bacterium phenotype (as biochemical characteristic).Creativeness of the present invention is that the specific gene group dna fragmentation (size is at least 100 base pairs) to the bacterial pathogens of 12 kinds of common bacterial species is chosen from genomic library or database; Deutero-amplimer or oligonucleotide probe (the two length is all less than 100 Nucleotide) are as the basis of exploitation diagnostic test from the sequence (these sequences are by differentiating with genomic library or the hybridization of selected database sequence) of species specificity dna fragmentation.Be also included within the scope of the present invention with Oligonucleolide primers clinically important bacterial resistance gene and probe as detection is common.For example, appendix I and appendix II have listed suitable oligonucleotide probe and PCR primer, and these probes and primer all derive out from the species specificity dna fragmentation that is selected from genomic library or database sequence.It will be apparent to those skilled in that: the oligonucleotide sequence of the unlisted specific detection that is suitable for above-mentioned bacterial species can be derived from species specificity fragment or selected database sequence among appendix I and the appendix II.For example, oligonucleotide can be selected shorter or longer than us, also can be in office what selects in the database sequence of its species specificity sequence of differentiating or selection.In addition, can design oligonucleotides to be used for the amplification method of non-PCR.Thereby, core of the present invention be derive from bacterial genomes DNA library the species specificity genomic DNA fragment discriminating and derive from the selection of the genomic DNA fragment of database sequence, wherein database sequence is as the source of (ubiquitous) oligonucleotide of (specific) of species specificity and ubiquity.Although from the database sequence of species specificity fragments sequence or selection, select to be fit to the more effort of oligonucleotide needs of diagnostic uses, but for a person skilled in the art, from we fragment or the database sequence of selection to derive the suitable oligonucleotide fragment (fragment of appendix I and appendix II) that is different from us and selects as an example and test be most probably.
Other have the people developed based on DNA be used to detect and differentiate some we have differentiated the test method of the bacterial pathogens (PCT patent application serial number WO9303186) of species specificity sequence.Yet their strategy based on the amplification of the 16S rRNA gene of high conservative and with endogenous species specificity oligonucleotide hybridization.Method of the present invention is simpler fast, because it can the deutero-oligonucleotide directly increases the species specificity target from species specificity bacterial genomes dna fragmentation by using.
Because the ratio of clinical sample feminine gender is higher, whether infects for determining clinical sample, selection Oligonucleolide primers and probe are to detect the bacterial pathogens that all may be run in clinical sample from the 16S rRNA of high conservative or 23S rRNA gene.This strategy makes and can rapid screening to go out a large amount of negative clinical sample for biological test.
We have also developed other test method based on DNA, with bacterium differentiate finish simultaneously with by orientation common determine the susceptibility of the bacterial antibiotic of inferring fast with clinical relevant bacterial resistance gene.Although can obtain from the sequence of the antibiotics resistance gene of selecting and be used to develop the test method based on DNA (Ehrlich and the Greenberg that detects these antibiotics resistance genes, 1994. the transmissible disease of PCR-based diagnosis, Blackwell science and technology press, Boston, Massachusetts, Persing etc., 1993, diagnosis molecular microbiology: principle and application, U.S. microorganism association, the Washington D.C.), but our method is innovative, it represented common based on " gold standard " diagnostic method of microbial culture on bigger raising because this method can be differentiated the existence of specificity bacterial pathogens fast and a hour this pathogenic agent of inner evaluation to directly deriving from the antibiotic susceptibility of clinical sample.
We believe: we will progressively replace the conventional slowly bacterium discrimination method that uses at present by the fast and simply diagnostic test (not being based on microbial culture) of exploitation in hospital clinical microbiology laboratory and private clinic.It seems with regard to us, these to serious and common bacterial pathogens and antibiotics resistance fast based on the diagnosis of DNA will: (I) save life by optimum the processing, (II) use by reducing Broad spectrum antibiotics is to reduce antibiotics resistance and (III) by prevention or shorten the treatment phase and spend so that comprehensive minimizings is healthy.
Summary of the invention
(size is at least 100 base pairs to the invention provides the sequence that derives from genomic DNA fragment, all all describes in sequence table), these genomic DNA fragments are selected from genomic library or database by hybridization, they are to detecting bacterial pathogens common in the clinical sample (as intestinal bacteria, Klebsiella pneumonia, pseudomonas aeruginosa, unusual sex change bacterium, streptococcus pneumoniae, streptococcus aureus, staphylococcus epidermidis, Staphylococcus saprophyticus, Haemophilus influenzae, morazella catarrhalis) be specific.These bacterial species and about 90% urinary tract infection are relevant with other serious infection (comprising septicemia, meningitis, pneumonia, intra-abdominal infection, skin infections and many other serious respiratory tract infection).Generally speaking, above-mentioned bacterial species can account for 80% of bacterial pathogens that conventional Microbiological Lab is separated to.
The synthetic oligonucleotide that is used for hybridization (probe) or DNA cloning (primer) is that the DNA fragment specific (magnitude range is that 0.25 to 5.0 kilobase is to (kbp)) from above-mentioned species or derive from the database sequence of selecting (GenBank and EMBL) obtains.The bacterial species that some oligonucleotide probe and amplimers of deutero-are suitable for from selected database sequence is: intestinal bacteria, enterococcus faecalis, streptococcus pyogenes and pseudomonas aeruginosa.It will be obvious to those skilled in the art that important in the present invention innovation is to differentiate the species specificity dna fragmentation of selecting from the bacterial genomes library by hybridization or select from database sequence.Being suitable for selecting oligonucleotide the fragment of diagnostic uses from these also is novelty.Being different from practice, the special of test is used as embodiment of the present invention with general oligonucleotide.
Being used for detecting the hybridization (with fragment or oligonucleotide probe) of clinical sample pathogenic agent or the exploitation of DNA cloning scheme makes bacterium discriminating extremely fast become possibility.This will greatly reduce current in clinical labororatory's required time of pathogenic agent discriminating.Because these technology can be used for directly from clinical sample detect and differentiate bacterium when discharging DNA of bacteria to the minimum pre-treatment of any biological sample needs.In addition, because 100% specificity, the bacterial species during probe and amplimer make directly and to fall from clinical sample or isolate is differentiated and is become possibility.It is quicker than hybridization assays that DNA cloning measure to also have, and sensitive advantage more is because DNA cloning is measured the quick and exponential replication in vitro that derives from bacterial genomes and target fragment.Be selected from the screening method that (universal) probe of versatility of conservative 16S rRNA of bacterium camber or 23S rRNA gene and amplimer (it makes can detect any pathogenic agent) will be used for a large amount of negative clinical samples of accepting the diagnostic test chamber.Differentiating that with the bacterial gene complementary oligonucleotide probe of definite feature or the primer of coding antibiotics resistance the common purposes with on the clinically important resistant gene is also included within the scope of the present invention.The detailed description of invention
The exploitation of species specificity dna probe
Developed the dna fragmentation probe that is used for following bacterial species: intestinal bacteria, Klebsiella pneumonia, pseudomonas aeruginosa, unusual sex change bacterium, streptococcus pneumoniae, streptococcus aureus, staphylococcus epidermidis, Staphylococcus saprophyticus, Haemophilus influenzae, morazella catarrhalis (only the oligonucleotide sequence of enterococcus faecalis and streptococcus pyogenes being derived from the database sequence of selecting).These species specificity fragments are by selecting from the bacterial genomes library with different types of Gram-positive and gram negative bacterium species (table 5) hybridization.
Use standard method to separate the chromosomal DNA (therefrom seeking probe) of each bacterial species.DNA cuts restriction enzyme (as Sau3AI) digestion with high frequency, connects to advance bacterial plasmid vector pGEM3Zf (Promega), and this carrier is by suitable restriction endonuclease digestion linearizing.Recombinant plasmid is used for transformed competence colibacillus coli strain DH5 α, produces genomic library thus.The plasmid inclusion of the bacterial cell that transforms is analyzed with standard method.The size of target bacteria cuts down from carrier by digesting recombinant plasmids with various restriction endonucleases the dna fragmentation between (kbp) in 0.25 to 5.0 kilobase.Insertion sequence separates and purifying low-melting sepharose from carrier by agarose gel electrophoresis.The bacterial genomes dna fragmentation of each purifying can be used as the probe of specificity test then.
For each given species, the restriction fragment of the gel-purified of unknown coding potentiality (coding potential) radioactive nuleus thuja acid α-
32P (dATP) mark, α-
32P (dATP) mixes dna fragmentation by the random primer labelling reaction.The Nucleotide that on-radiation is modified also can mix DNA by this method to be used for mark.
Then, each dna fragmentation probe (be at least the segment of 100bp as the length in bacterial genomes library, this fragment cuts down from the clone who is selected from genomic library at random) by and its specificitys of DNA (table 5) cross experiment of various bacterial species.The double chain DNA probe thermally denature that makes mark is to produce the single stranded DNA of mark.This single stranded DNA can and any be fixed on the solid support or solution in the strand target DNA hybridize.Target DNA is made up of the cell all DNA of a series of bacterial species of finding in clinical sample (table 5).Each target DNA all can discharge from bacterial cell, uses the ordinary method sex change, irreversibly is fixed on the solid support (as nylon or nitrocellulose filter) then or enters in the solution.Fixed strand target DNA and single-stranded probe hybridization then.Condition after prehybridization, hybridization and the hybridization is as follows: (i) prehybridization; In the salmon sperm DNA of 1M NaCl+10% dextran sulfate+1%SDS (sodium laurylsulfonate)+100 μ g/ml under 65 ℃ 15 minutes, (II) hybridization; Under 65 ℃, comprise in the fresh prehybridization solution of label probe and spend the night.(III) after the hybridization; With the 3 * SSC that contains 1%SDS (1 * SSC is 0.15M NaCl, the 0.015M Trisodium Citrate) washed twice; Again with the 0.1 * SSC washed twice that contains 0.1%SDS; All these washings are all carried out each 15 minutes under 65 ℃.The feasible probe that can detect selective cross of the radioautograph of the filter membrane after the washing.The hybridization of probe and specificity target DNA shows the similarity of height between the nucleotide sequence of this two kinds of DNA.
The species specificity dna fragmentation (size is between 0.25 to 5.0kbp) that is selected from various bacterial genomes library is isolating for 10 kinds of common pathogenic agent (table 6), as mentioned above, separates based on hybridizing with various bacterial chromosomal dnas.The bacterial species of all tests (66 species listing in the table 5) may be from clinical sample, separate with common infection or the relevant pathogenic agent of potentially contaminated.The dna fragmentation probe only when the pathogenic agent of only and therefrom isolating it is hybridized separately, just can be thought specific.Subsequently by and about 10 to 80 clinical isolates of interest species (table 6) in DNA of bacteria hybridization, test is found to be the ubiquity (ubiquity) (promptly discerning the ubiquity probe of most of isolates of target species) of specific dna fragmentation probe.Make the DNA sex change, be fixed on the nylon membrane, hybridize as mentioned above.
The order-checking of species specificity fragment probe
The all or part of nucleotide sequence of isolating species specificity dna fragmentation uses two deoxidation end sequencing methods to measure, and this method uses Sequenase (USB biological chemistry) or T7 archaeal dna polymerase (Pharmacia) to carry out.These nucleotide sequences in sequence table, have been listed.In addition, be selected from the sequence of database (GenBank and EMBL) as diagnosis intestinal bacteria, enterococcus faecalis, the source of the oligonucleotide of streptococcus pyogenes and pseudomonas aeruginosa.This strategy need test from the range gene group dna fragmentation (size is greater than 100bp) that is selected from database a series of suitable nucleotide primers of deutero-or probe to detect them in PCR as described below and specificity in the cross experiment and ubiquity.Notice that it is very important selecting database sequence according to effective sequence information on the basis of sequence species specificity potential.The present invention only comprises that those can derive the database sequence of species specificity oligonucleotide.
Deutero-oligonucleotide probe and amplimer are synthetic with automatization dna synthesizer (Millipore) from the species specificity fragment that is selected from genomic library or database sequence.Before synthetic, use standard program by Computer Analysis (for example, hereditary computer group (GCG) and Oligo
TM(4.0 national bio-science)) estimate the suitability of all oligonucleotide (probe that is used to hybridize and the primer that is used for DNA cloning) by polymerase chain reaction (PCR) to hybridization and DNA cloning.The right potential suitability of PCR primer can not exist unwanted feature (as a kind of long-chain of Nucleotide by confirmation before synthetic yet, at 3 ' end a high proportion of G or C residue and 3 ' terminal T residue are arranged) estimate (Persing etc., 1993, diagnosis molecular microbiology: principle and application, U.S. microorganism association, the Washington D.C.).
Use oligonucleotide probe hybridization
In hybrid experiment, oligonucleotide (size less than 100 Nucleotide) is used for Bacteria Detection has some advantages than the dna fragmentation probe, as is easy to a large amount of preparations, each batch result one chemically stable of making peace.In brief, the oligonucleotide for hybridization is to use the radioactive nuleus thuja acid by T4 polynucleotide kinase (Pharmacia)
32γ P (ATP) 5 ' end mark.The radioactive nuleus thuja acid that does not mix is through removing the single stranded oligonucleotide of mark by Sephadex sephadex G 50 posts.In addition, oligonucleotide by at its 3 ' end enzymatic labelling or when synthetic, directly mix 5 ' hold with biotin labeling or use the digoxigenin mark.The marking method that it will be apparent to those skilled in that non-above-mentioned three kinds of marking methods can be used.
As mentioned above, to the dna probe fragment, make the target DNA sex change, be fixed on the solid support and hybridize.The condition of prehybridization and hybridization all as previously mentioned.The post-hybridization washing condition is as follows: wash twice in comprising 3 * SSC of 1%SDS, in comprising 2 * SSC of 1%SDS, wash twice, in comprising 1 * SSC of 1%SDS, wash again twice (all these washings were all carried out under 65 ℃ 15 minutes), under 25 ℃, comprised at last among 0.1 * SSC of 1%SDS washing 15 minutes.For radiolabeled probe, crossbred detects by foregoing radioautograph.Carry out for available colorimetry of nonradioactive labeling's detection or chemoluminescence method.
Oligonucleotide probe can be derived from any chain of duplex DNA chain.Probe is by base A, G, and C, T or analogue are formed.Probe can have any suitable length, can be in being selected from the species specificity genomic DNA fragment of genomic library or database sequence any choice of location.
DNA cloning
PCR (polymerase chain reaction) method by widespread use is carried out DNA cloning, and primer is to can or deriving in the database sequence from the species specificity dna fragmentation of order-checking.In addition, primer is to also can being the form of the shortening of oligonucleotide probe.Before synthetic, by service routine Oligo
TM4.0 (national bio-science) analyzes the potential primer to check them whether may be used for pcr amplification.
By during the DNA cloning of PCR, be attached to two oligonucleotide on each bar chain of the double-stranded target DNA of sex change that derives from bacterial genomes respectively and be used at the external index target DNA that doubly increases.This amplification makes DNA sex change, primer annealing and synthetic new target DNA carry out (Persing etc., 1993, diagnosis molecular microbiology: principle and application, U.S. microbiology association, Washington D.C.) by the successive thermal cycling.In brief, the PCR scheme is as follows: clinical sample or bacterial colony are added to directly (wherein comprise 50mM KCl, pH is 8.3 10mM Tris-Hcl, 2.5mM MgCl in the PCR reaction mixture of 50 μ l
2, each 0.4 μ M of two kinds of primers, the Taq archaeal dna polymerase (Perkin Elmer) of four kinds of each 200 μ M of dNTPs and 1.25 units).Perkin Elmer480 is used in the PCR reaction
TMThermo cycler carry out thermal cycling (95 ℃ following 3 minutes, 95 ℃ following 1 second with 55 ℃ following 1 second, circulate 30 times), use the agarose gel electrophoresis analysis of the ethidium bromide staining of standard subsequently.Obviously can use the method (quicker or more practical in routine diagnosis) of other detection specificity amplified production.These methods can (as derive from the Taqman of Perkin Elmer based on the fluoroscopic examination of amplification back
TMThe Amplisensor of system or Biotronics
TMSystem) or with the solution hybridization that is attached to the oligonucleotide on the specific amplification products internal sequence.These new probes can be produced by our species specificity fragment probe.In fact, it is promising especially being used for routine diagnosis based on the detection method of fluorescence, but this method fast, quantitatively and automatization.
For guaranteeing PCR efficient, glycerine, dimethyl sulfoxide (DMSO) (DMSO) or other relevant solvent can be used to increase the sensitivity of PCR and can overcome the relevant problem of amplification with the target DNA that high GC content or stable secondary structure are arranged.The concentration range of glycerine and DMSO is respectively 5-15% (V/V) and 3-10% (V V), for the PCR reaction mixture, and amplimer and MgCl
2Concentration be respectively 0.1-1.0 μ M and 1.5-3.5mM.Use outer primer also can use (Persing etc. to the modification protocols of (being multiplex PCR) Standard PC R with nested primers (being nested PCR) or more than one primer, 1993, diagnosis molecular microbiology: principle and application, U.S. microbiology association, Washington D.C.).About the more details of PCR scheme and amplicon detection method referring to embodiment 7 and embodiment 8.
The technician in DNA cloning field knows that the rapid amplifying method that has other is (as ligase chain reaction (LCR), based on the amplification system of transcribing (TAS), self-sustained sequence replication (3SR), amplification (NASBA) based on nucleotide sequence, strand displacement amplification (SDA) and branched DNA (bDNA) (Persing etc., 1993, diagnosis molecular microbiology: principle and application, U.S. microbiology association, the Washington D.C.).Scope of the present invention is not limited to the use of pcr amplification, and comprises that any quick nucleic acid amplification method or other are any and can be used for increasing the rapidity of test and the method for susceptibility.The oligonucleotide that any method by non-PCR in this application that is included in is suitable for nucleic acid amplification be also included within the scope of the present invention from species specificity segment and antibiotics resistance gene sequence deutero-oligonucleotide.
The specificity of oligonucleotide probe and primer and ubiquity test
From the species specificity fragment that checked order or database sequence the specificity of deutero-oligonucleotide probe by with foregoing and table 5 in DNA in the bacterial species listed hybridize and test.Then be found to be specific oligonucleotide by with its ubiquities of DNA of bacteria cross experiment of about 80 isolates of target species (as relevant segment probe described).When the DNA of probe and at least 80% isolate is hybridized specifically, can think that these probes are ubiquity (ubiquitous).In table 6, summarized result with oligonucleotide probe test specificity and ubiquity.Specificity that amplimer is right and ubiquity can directly be tested from the culture (seeing embodiment 7) of same bacterial isolates.Be to measure specificity and ubiquity, directly in the bacterial colony of about 80 isolates of target species, carry out the PCR test.The result is summarized in table 7.All specificitys of each species and ubiquity oligonucleotide probe and amplimer in 12 bacterial species of research are listed in appendix I and appendix II respectively.Divergence (divergence) can appear in the dna fragmentation that has checked order, and these sequences or the divergence of one partial sequence up to the present do not influence the specificity of probe or amplimer, and therefore the DNA of bacteria of variation also belongs to scope of the present invention.
General Bacteria Detection
The percentage higher (table 4) that in conventional Microbiological Lab, is used for the clinical sample feminine gender of bacterium discriminating.As in the period in 2 years, about 80% the urine samples that " Hospitalier 1 ' Universit Laval center (CHUL) " laboratory is accepted be negative (promptly＜10
7CFU/l) (table 3).Earlier with the existence of universal probes and versatility amplimer bacterial detection, carry out specificity then and identify when detecting clinical sample, filter out a large amount of negative samples.This method is useful, because it can be cut down expenses and can determine clinical treatment to the patient rapidly.Thereby can be from the bacterial 16 S that obtains at database (appendix III and IV) or several the oligonucleotide of partial synthesis and the amplimer of 23S ribosomal rna gene sequence high conservative.In cross experiment, one group of 7 oligonucleotide (appendix I, table 6) consumingly with table 5 in the DNA hybridization of all bacterial species of listing.Thereby this universal probes with radioactive nuleus thuja acid or any other modified nucleotide mark is of great use to the bacterium that detects in the urine samples, its sensitivity range 〉=10
7CFU/l.These probes also are applicable to the Bacteria Detection in other clinical sample.
Amplimer derived from the ribosomal rna gene sequence of high conservative also can be used as the general directly alternative strategy of bacterial detection from clinical sample (appendix IV, table 7).For improving the susceptibility and the rapidity of test, developed the DNA cloning strategy.Because DNA amplification in 23 kinds of different bacterium species that this amplification test is run into from clinical sample specifically, thereby be general.
The bacterial gene of the high conservative of non-ribosomal rna gene also is the general directly better candidate of bacterial detection from clinical sample.These genes may be relevant with the necessary process of some bacteria livings (as protein synthesis, DNA is synthetic, and cell fission or DNA repair) thereby be very stable during evolution.We are studying candidate gene to develop the accelerated test procedures of new general direct detection from the bacterium in the clinical sample.
Antibiotics resistance gene
Antimicrobial resistance makes treatment complicated and often cause treatment failure, and, use microbiotic too much to cause the appearance of bacterial resistance inevitably.Our target is that clinical diagnosis (clinicians) was provided in one hour, promptly opens the required information of prescription of optimum treatment.Except the test based on DNA of carrying out general Bacteria Detection is differentiated the existence of specific pathogen in negative clinical sample and the positive fast, the ability of bacterial pathogens opposing antibiotic treatment also will be in time understood in clinical diagnosis.We think that the efficient strategy of rapid evaluation bacterium combating microorganisms agent resistance is directly to detect the modal and most important antibiotics resistance gene test of the detect antibiotics resistant gene of DNA (promptly based on) from clinical sample.Because the sequence of most important and modal bacterial antibiotic resistance gene can obtain from database, our strategy is that this oligonucleotide can be used as the basis of exploitation based on the short-time test of DNA with the special oligonucleotide of the sequences Design of part or all gene.With the clinical correlation (being high incidence and importance) of bacterium serves as that the sequence of the bacterial antibiotic resistance gene selected of basis provides in sequence table.Table 8 has been summarized the feature of the antibiotics resistance gene of some selections.
The embodiment the following examples are intended to illustrate the whole bag of tricks of the present invention and compound.Embodiment 1:
Pulsating separation and clone.Use standard method to prepare e. coli strains ATCC25922, Klebsiella pneumonia CK2, pseudomonas aeruginosa strain ATCC27853, proteus mirabilis strain ATCC35657, streptococcus pneumoniae strain ATCC27336, streptococcus aureus strain ATCC25923, staphylococcus epidermidis strain ATCC12228, Staphylococcus saprophyticus strain ATCC15305, relevant bacterial strain Rd of Haemophilus influenzae and the genomic dna of morazella catarrhalis ATCC53879.Be appreciated that bacterial genomes DNA separates (to enterococcus faecalis and streptococcus pyogenes, oligonucleotide comes from database) in the bacterial strain of above-mentioned bacterial strains.Each DNA digests with the Restriction Enzyme (as Sau3AI) of frequent cutting DNA.The dna fragmentation that forms connects into plasmid vector (pGEM3ZF) producing recombinant plasmid, and transforms competence Bacillus coli cells (DH5 α).Be appreciated that carrier and corresponding competent cell are not limited in this paper concrete carrier and cell as an example.The purpose that obtains recombinant plasmid and transformant provides the source of the dna fragmentation that is used as probe that is easy to produce.Therefore, up to the present, be specificity and optionally for target bacteria DNA because insert segment, any recombinant plasmid and transformed host cell is also within the scope of the invention accordingly.The plasmid content standard method analysis of transform bacteria cell, the target bacteria dna segment of size between 0.25 to 5.0kbp cuts down from carrier with various restriction endonuclease digestion recombinant plasmids.With agarose gel electrophoresis insertion sequence is separated from carrier, again purifying in low-melting sepharose.Carry out the specificity test with each purifying segment then.
The mark of dna fragmentation probe
The mark that uses is α
32P (dATP), this radioactive nuleus thuja acid can mix double chain DNA molecule by enzymatic reaction.The interest fragment at first by 95 ℃ of heating sex change in 5 minutes down, makes the mixture annealing of random primer form the sheet chain rupture then.These primers are in case annealing just provides a DNA synthetic initiation site.Archaeal dna polymerase (normally Klenow fragment) provides with four kinds of Nucleotide, and wherein a kind of is radioactive.Behind reaction terminating, the sex change again of the mixture of new dna molecular produces radioactive single strand dna (being probe).As previously mentioned, the Nucleotide of other modification also can be used to label probe.
The specificity of dna segment probe and the test of ubiquity.The species specificity dna segment of size between 0.25 to 5.0kbp to 10 kinds of (table 6) common bacteria pathogenic agent separates based on hybridizing with various bacterial chromosomal dnas.Use Dot blot device to nylon membrane, washs and make its sex change to the global DNA sample transfer of every kind of bacterial isolates cell listing in the table 5, and is irreversibly fixing then.Hybridization conditions as previously mentioned.When the dna segment probe only and is therefrom isolated its pathogenic agent hybridization, just can think specific.Can only can test its ubiquity by hybridizing with the marker DNA segment of target bacteria species specificity hybridization (promptly specific) with the DNA of about 10-80 bacterium colony of aforesaid interest species.The condition of prehybridization, hybridization, post-hybridization washing as mentioned above.Afterwards, the specificity of each probe can be determined in radioautograph (or other detection methods that the nonradioactive labeling is suitable for).Each probe that discovery has specificity (promptly only can hybridize with the bacterial species DNA that therefrom isolates it) and ubiquity (promptly hybridizing with most of isolates of target species) remains with further experiment.
Embodiment 2:
Except that the bacterial strain test is by identical with embodiment 1 colony hybridization.Bacterial isolates is inoculated on the nylon membrane that places nutrient agar medium, and film was cultivated two hours down at 37 ℃, carried out bacterium cracking and DNA sex change according to standard method then.DNA hybridization is carried out as previously mentioned.
Embodiment 3:
Except that directly identical the bacterial detection from clinical sample with embodiment 1.Any biological sample directly is loaded on the Dot blot device, and the cell in-situ cracking is to carry out Bacteria Detection.Make the blood sample heparinization, be loaded into condensing on the Dot blot device easily to avoid interference.
Embodiment 4:
Measure the nucleotide sequence of dna fragmentation.Each discovery be all or part of nucleotide sequence of special and general segment (embodiment 1) use two deoxidation end sequencing methods measure (Sanger etc., 1977, Proc. Natl. Acad. Sci.USA, 74:5463-5467).These dna sequence dnas provide in sequence table, select nucleotide oligonucleotide probe and amplimer from these nucleotide sequences or from the database sequence of selecting, and use the phosphoramidite chemical method at Biosearch automatic DNA synthesizer DNA (Millipore then
TM) go up and synthesize.
The oligonucleotide mark.As previously mentioned, each oligonucleotide is used γ by T4 polynucleotide kinase (Pharmacia)
32P-ATP 5 '-the end mark.This mark also can be inactive.
The specificity test of oligonucleotide probe.By with the specificity of all labeled oligonucleotide probe of the DNA cross experiment of foregoing Gram-positive and gram negative bacterium species.The species specificity probe be those only can with the probe of the bacterial species DNA hybridization that therefrom separates this probe.The specific oligonucleotide probe of being found is carried out following ubiquity test.
The ubiquity test of oligonucleotide probe.In the ubiquity test that about 80 the kind bacterial strains with the target species carry out, use specific oligonucleotide probe.As described in the test of above-mentioned specificity, the chromosomal DNA of isolate is transferred on the nylon membrane, and with the oligonucleotide probe hybridization of mark.Comprise reference ATCC bacterial strain and many clinical isolates that obtains from various sources by the group of 80 isolates approximately for what each target species made up.The ubiquity probe is the probe of the hybridization of 80%DNA at least of those energy and target species clinical isolates group.Special example with general oligonucleotide probe is listed in appendix I.
Embodiment 5:
It is identical with embodiment 4 except one group of special oligonucleotide probe is used for the bacterium discriminating.The special oligonucleotide of this group can (I) improves sensitivity and guarantees 100% ubiquity or (II) differentiate more than one bacterial species simultaneously.Bacterium is differentiated and can fall or directly carry out from clinical sample from isolate.
Embodiment 6:
Pcr amplification.Use round pcr can improve the susceptibility and the rapidity of test.The shorter derivative (table 6) of a lot (extensive) group oligonucleotide that is used for hybridization assays that the PCR primer that uses had normally before been developed.This group primer is tested to determine their specificity and ubiquity (table 7) in the PCR that directly carries out from bacterial colony or bacterial suspension (seeing embodiment 7) measures.The right example of special and general PCR primer is listed in appendix II.
The specificity of amplimer and ubiquity test
The PCR primer of testing all selections is to the specificity (table 5) at Gram-negative that is used for the pilot oligonucleotide probe and gram positive bacterium group.Test finds that to each species be the right ubiquity of specific primer to guarantee can increase at least 80% DNA of every group of primer from about 80 isolates of one group of target bacteria then.The various clinical isolates that the isolate that makes up for each species comprises reference ATCC bacterial strain and represents each species clinical variety.
The prevention method that should take standard is to avoid false positive PCR result.The method of deactivation pcr amplification product (as by uridylic-N-glycosylase) can be used for controlling PCR and leaves over.
Embodiment 7:
Directly amplification from bacterial colony or suspension.PCR measures and can directly carry out from bacterial colony or bacterial suspension, and bacterial suspension is adjusted to the McFarland 0.5 of standard (corresponding to 1.5 * 10
8Individual bacterium/ml).Under situation about directly increasing, use sticking plaster a part of bacterium colony to be transferred to directly (contain 50mM KCl, pH is 8.3 10mM Tris, 2.5mM MgCl in the PCR reaction mixture of 50 μ l from bacterium colony
2, two kinds of each 0.4 μ M of primer, the Taq archaeal dna polymerase (Perkin Elmer) of four kinds of each 200 μ M of dNTP and 1.25 units).For bacterial suspension, the cell suspending liquid of 4 μ l is added in the same PCR reaction mixture of 46 μ l.Two kinds of strategies all are added to the mineral oil of 50 μ l on the reaction mixture, and pcr amplification follows these steps to carry out: the first step is 95 ℃ of following sex change 3 minutes, then under 95 ℃ at Perkin Elmer 480
TMCarry out 30 circulations (each circulation is formed by 95 ℃ of following denaturing steps of 1 second with at 55 ℃ of following annealing steps of 1 second) in the thermo cycler.Use sepharose (2%) the electrophoretic analysis pcr amplification product of standard then.This product can contain under 254 millimicrons ultraviolet ray in the sepharose of 2.5 μ g/ml ethidium bromides and shows.Whole PCR measures and can all finish in about one hour.
In addition, all undertaken except using " heat is initial " scheme from the amplification of bacterial cultures by aforesaid method.In such cases, comprise target DNA, primer and dNTPs initial reaction mixture are heated to 85 ℃, and then add other component of PCR reaction mixture.The ultimate density of all reagent as mentioned above.Subsequently, carry out circulation of PCR reaction heat and analysis by above-mentioned method.
Embodiment 8:
Directly from clinical sample, increase.For the amplification from urine sample, by preceding method (1: 10) urine of the undiluted of 4 μ l or dilution directly is added in the above-mentioned PCR reaction mixture of 46 μ l and increases.
For strengthening bacteria cell cracking and eliminating the restraining effect of PCR in the clinical sample, usually diluted sample in containing the lysis buffer of washing agent.Subsequently, lysate directly is added in the PCR reaction mixture.Before DNA cloning, lysate is heat-treated to improve the efficient of lysis with thermo cycler or microwave oven.
Our strategy is the fast and convenient scheme of exploitation to eliminate PCR retarding effect in clinical sample and the cracked bacterial cell so that directly carry out DNA cloning from various biological samples.PCR has and slightly puies forward the compatible advantage of DNA goods.For example, blood, cerebrospinal fluid and serum can directly use in PCR measures after the brief thermal treatment.We plan with the method for quick and easy like this strategy Development rapid amplifying DNA from various clinical samples.
Embodiment 9:
The detection of antibiotics resistance gene.The existence of common and clinical relevant specific antibiotic resistant gene is differentiated with described pcr amplification of previous section or crossing scheme.Be selected from the antibiotics resistance gene sequence as specific oligonucleotide based on the basis of the test of DNA.These tests can directly be carried out from clinical sample or bacterial colony, and should replenish the diagnostic test that the specificity bacterium is differentiated.
Embodiment 10:
Except mensuration is by identical with embodiment 8 with embodiment 7 multiplex PCR (promptly using several to primer in a PCR reaction), use multiplex PCR can (I) to reach ubiquity, (II) detect several bacterial pathogens simultaneously specific target pathogenic agent 100%.
For example, detecting intestinal bacteria needs three pairs of PCR primers to guarantee 100% ubiquity.Therefore, the multiplex PCR assays (with " heat is initial " scheme (embodiment 7)) that use three primers right have been developed.This strategy also can be used for other needs more than one primers to reach the bacterial pathogens of 100% ubiquity.
Multiplex PCR test also is used for (I) and detects several bacterial species simultaneously or (II) differentiate bacterial pathogens and directly from clinical sample or bacterial colony detection specificity antibiotics resistance gene simultaneously.
Use for these, the amplicon detection method should be fit to distinguish the various amplicons of generation.Can use the agarose gel electrophoresis of standard because it can based on the size discrimination of amplicon they.The another kind of useful strategy that is applicable to this purposes is to use the various detection of fluorescent dyes that excite at the different wave length place, every kind of fluorescence dye can with the specific oligonucleotide coupling mutually on being connected to the fluorescent quenching thing, this fluorescent quenching thing is degraded in amplification procedure and is discharged fluorescence (as TaqMan
TM, PerkinElmer).
Embodiment 11:
The detection of amplified production.Those skilled in the art know that the alternative method of off-gauge agarose gel electrophoresis (embodiment 7) can be used for the announcement of amplified production.These class methods can be based on the fluoroscopic examination after the amplification (as Amplisensor
TM, Biotronics, TaqMan
TM) or marker such as vitamin H (SHARP Signal
TMSystem, Digene Diagnostics) detection.These methods are quantitative and are easy to automatization.Amplimer or internal oligonucleotide probe (its to be special) and fluorescence dye or any other mark coupling from species specificity fragment probe deutero-amplicon.Method based on fluoroscopic examination is specially adapted to diagnostic test, because this method is fast and flexibly when the fluorescence dye that can obtain launching different wave length (Perkin Elmer).
Embodiment 12: species amplimer special, ubiquity and antibiotics resistance gene can be used for other fast amplification method (as ligase chain reaction (LCR), based on the amplification system of transcribing (TAS), self-sustained sequence replication (3SR), amplification (NASBA) based on nucleotide sequence, strand displacement amplification (SDA), and branched DNA (bDNA) or other any method that is used to increase assay sensitivity.Amplification can be from the isolated bacterial bacterium colony or is directly carried out from clinical sample.Thereby scope of the present invention is not limited to the use of PCR, and comprises and anyly differentiate DNA of bacteria specifically and can increase the rapidity of test and the use of the scheme of susceptibility.
Embodiment 13:
Test kit comprises every kind of probe groups and one group of general probe that bacterium is special.Test kit is to provide with the form of testing component, is made up of the general probe and the specific probe that is used for the mark of clinical sample interest Bacteria Detection of one group of non-radioactive marker's mark.Test kit also comprises and carries out prehybridization, hybridization, and washing step and crossbred detect essential seizure test agent.At last, test kit also comprises the test component that is used to detect known antibiotics resistance gene (or their derivative).Certainly, test kit also comprises the standard model of and positive control negative as each cross experiment.
The component that is included in the test kit is applicable to every kind of sample type, and is suitable for detecting pathogenic agent common in this sample.Test kit also comprises the reagent that is used for the detection of bacterium versatility.Based on sites of infection, developed the following test kit that is used for the pathogen specific detection:
The test kit of the bacterial pathogens in the most clinical samples of-general detection wherein comprises the probe groups special to the bacterial genomes high conservative region.
-be used for detecting the test kit of the bacterial pathogens of obtaining from urine sample, wherein comprise eight specific specificity test component and (be used to test intestinal bacteria, enterococcus faecalis, Klebsiella pneumonia, unusual sex change bacterium, pseudomonas aeruginosa, Staphylococcus saprophyticus, streptococcus aureus and staphylococcus epidermidis).
Be used to detect the test kit of respiratory disease substance, wherein comprise seven specific specificity test component and (be used to detect streptococcus pneumoniae, morazella catarrhalis, Haemophilus influenzae, Klebsiella pneumonia, pseudomonas aeruginosa, the probe groups of streptococcus pyogenes and streptococcus aureus).
-be used for detecting the test kit of the pathogenic agent that obtains from blood, wherein comprise 11 specific specificity test group branches and (be used to check streptococcus pneumoniae, morazella catarrhalis, Haemophilus influenzae, unusual sex change bacterium, Klebsiella pneumonia, pseudomonas aeruginosa, intestinal bacteria, enterococcus faecalis, streptococcus aureus, the probe groups of streptococcus pyogenes and staphylococcus epidermidis).
-be used to detect the test kit of the pathogenic agent that causes meningitis, wherein comprise four specific specificity test component (being used to test Haemophilus influenzae, streptococcus pneumoniae, the probe groups of intestinal bacteria and pseudomonas aeruginosa).
-be used to detect the test kit of clinically important antibiotics resistance gene, wherein comprise and be used for detecting specifically the following 19 kinds of probe groups that the gene relevant with bacterial resistance is at least a: bla
TemBla
Rob, bla
Shv, aadB, aacC1, aacC2, aacC3, aacA4, mecA, vanA, vanH, vanX, satA, aacA-aphD, vat, vga, msrA, sul and int.
-developed other to be applicable to detection the test kit of the pathogenic agent of trauma of abdomen or any other clinical relevant test kit from skin.
Embodiment 14:
Except test kit contain all reagent that carry out DNA cloning test and contrast identical with embodiment 13.Diagnostic kit is applicable to the amplification of directly being undertaken by PCR (or other amplification method) from clinical sample or bacterial colony.Comprise also that in test kit general Bacteria Detection, bacterium are differentiated and antibiotics resistance gene detects required component.
Amplification assay can carry out in test tube or on the titer plate.To the mensuration on the titer plate, the hole is applied with specificity amplification primer and contrast dna molecular, the detection of amplified production can automatization.For from clinical sample, directly detecting, in test kit, comprise the reagent and the amplimer that are used for general Bacteria Detection.Directly comprise that also bacterium is differentiated and antibiotics resistance gene detects required component in test kit of from bacterium colony, testing or the direct test kit of from clinical sample, testing.
Described based on the diagnostic kit of hybridization as embodiment 13, this test kit is applicable to the sample of each type.
Embodiment 15:
Be appreciated that the use of probe that is used for Bacteria Detection and discriminating of the present invention and amplimer is not limited to the application of clinical microbiology.In fact, we feel that other department also can be benefited from these new technologies.For example, these tests can be used for food, water, medicament production or other needs the quality control of the product of microbiological manipulation industrial.These tests also can be used for detecting and identifying from the bacterium in the biological sample of inhuman other organism (other primates, mammals, farm-animals, livestock).These diagnostic tools are very useful to the research that comprises clinical trial and epidemiological study.
The positive urine sample (〉=10 in Hospitalier de 1 ' Universit é Laval center (CHUL) during table 1. 1992-1994
7CFU/L) distribution of urine isolate in.
Isolate percentage (%) organism
In January, 94 93 year July of April, 92 year 93 year November
N=267
aN=265 n=238 n=281 Escherichia coli 53.2 51.7 53.8 54.1 enterococcus faecalis 13.8 12.4 11.7 11.4 klepsiella pneumoniae 6.4 6.4 5.5 5.3 MRSE 7.1 7.9 3.0 6.4 proteus mirabilis 2.6 3.4 3.8 2.5 pseudomonas aeruginosa 3.7 3.0 5.0 2.9 staphylococcus saprophyticus 3.0 1.9 5.4 1.4 otherb10.2 13.3 11.8 16.0
aThe sum of isolate in the month that n=points out
bReferring to table 2
The positive urine sample (〉=10 in Hospitalier de 1 ' Universit é Laval center (CHUL) during table 2. 1992-1994
7CFU/L) rare in
aThe distribution of urine isolate.
Isolate percentage (%) organism
aIn January, 94 in July 93 year April of 92 year 93 year November, several kinds of 0.4 0.4 0.0 1.1 morganella morganiis of several kinds of 0.8 0.0 0.5 0.0 proteus belonging to of several kinds of 1.5 1.1 1.3 1.4 acid-producing Klebsiella bacterium 1.1 1.5 2.5 1.8 Serratias of several kinds of 1.4 0.8 0.4 0.7 Enterobacters of several kinds of 0.0 0.0 0.4 0.7 enterococcus faecalis 0.4 0.4 1.3 1.4 Citrobacters of several kinds of 2.2 4.9 1.7 6.0 Micrococcus of staphylococcus aureus 0.4 1.1 1.3 1.4 staphylococcus belonged to and Providencia 0.4 0.8 0.4 0.0 hafnia alvei 0.8 0.0 0.0 0.0NFBb0.0 several kinds 0.8 1.9 0.7 0.4 of 0.4 1.3 1.1 mycocandidas
aRare urine isolate is that those differentiate the isolate for " other " in table 1
bNFB: the positive (bacterial count 〉=10 of Hospitalier de 1 ' Universite Laval center (CHUL) test during non-fermentation bacillus (as oligotrophy zygosaccharomyces and acinetobacter) table 3. 1992-1994
7CFU/L) and negative (bacterial count＜10
7CFU/L) distribution of urine samples.
1116 (80.7) 1073 (80.2) 901 (79.1) 1064 (79.1) of 1383 (100) 1338 (100) 1139 (100) 1345 (100) male, 267 (19.3) 265 (19.8) 238 (20.9) 281 (20.9) feminine genders of isolate number (%) sample reception in January, 94 in July 93 year April of 92 year 93 year November
aOn the basis of the diagnostic method of standard, the minimum quantity of bacterial pathogens is generally 10 in the urine sample of indication urinary tract infection
7CFU/L.
The positive that detects in the Microbiological Lab of table 4.CHUL and the distribution of negative clinical sample.Clinical sample
aInstitute's test sample product negative sample positive
Number percentage % percentage % urine 17,981 19.4 80.6 hemoculture thing/marrow 10,010 6.9 93.1 salivas 1,266 68.4 31.6 surperficial fester 1,136 72.3 27.7 celiolymph 553 1.0 99.0 synovia-synovial fluid 523 2.7 97.3 segmental bronchuses/tracheae/tonsillas/throat 502 56.6 43.4 deep fester 473 56.8 43.2 ears, 289 47.1 52.9 pleuras and pericardial fluid 132 1.0 99.0 peritoneal fluids 101 28.6 71.4
aSample from detection in January in February, 1994 to nineteen ninety-five
Table 5. is used to detect dna fragmentation probe, oligonucleotide probe and PCR primer
Specific bacterial species (66) the bacterial species bacterial species that detects detect
number of strains, the number of strains Gram-negative bacteria, the gram-positive bacteria proteus mirabilis, 5, Hemophilus parainfluenzae, 2 Friedlanders bacillus, 5, pertussis Boulder Salmonella, 2 pseudomonas aeruginosas, 5, secondary vacuolar membrane hemolytic haemophilic bacterium, 2 Escherichia coli, 5, the hemolytic haemophilic bacterium, 2 morazella catarrhalis, 5, Hemophilus aegyptius, 1 proteus vulgaris, 2, produce the Yin Sa Salmonella that pauses of trembling, 1 morganella morganii strain, 2, the Atlanta catarrhalis, 1 enterobacter cloacae, 2, the cavy Neisser's coccus, 1 providencia stuartii, 1, little yellow Neisser's coccus, 1 Providencia species, 1, the urethra catarrhalis, 1 pantoea agglomerans, 2, bacillus ceylonensis A, 1 Lei Shi Pu Luoweisideng bacterium, 2, shigella flexneri, 1 Neisseria mucosa, 1, acid-producing Klebsiella bacterium belongs to, 2 produce the alkali Providence, 1, serratia marcescens, 2 Laplace Pu Luoweisideng bacterium, 1, salmonella typhimurium, 1 Burkholderia, 2, yersinia enterocolitica, 1 clostridium perfringen, 2, Acinetobacter calcoaceticus, 1 has a liking for the maltose Stenotrophomonas, 2, the Lu Wofushi acinetobacter calcoaceticus, 1 Pseudomonas fluorescens, 1, hafnia alvei, 2 Comamonas acidovorans, 2, the difference citric acid bacillus, 1 pseudomonas putida, 2, labor Di Shi citric acid bacillus not, 1 Hemophilus influenzae, 5, the salmonella species, 1
Table 5 (continuing) is used to detect dna fragmentation probe, oligonucleotide probe and PCR primer
Specific bacterial species (66) bacterial species detect
Number of strains gram-positive bacteria streptococcus pneumonia 7 streptococcus salivarius 2 viridans streptococci 2 streptococcus pyogenes 2 staphylococcus aureus 2 MRSE 2 staphylococcus saprophyticus 5 Micrococcus species 2 corynebacteria species 2 streptococcus B groups 2 are imitated staphylococcus 2 tunnel Deng staphylococcus 2 head staphylococcus 2 MRSH 2 people staphylococcus 2 enterococcus faecalis 2 VREF 1 Wo Shi staphylococcus 1 Enterococcus durans 1 bargen's streptococcus 1Diphteroids 1 and are had a liking for lactic acid bacillus 1
Table 6. species specificity dna fragmentation and the oligonucleotide organism that is used to hybridize
aThe number of fragment probe
bThe number of oligonucleotide probe
The specific ubiquity of test
cThe intestinal bacteria of the specific ubiquity of synthetic
d---20 12 9
fIntestinal bacteria 14 2 2e---Klebsiella pneumonia
d---15 11 Klebsiella pneumonia, 33 33 18 12 8 proteus mirabilises
d332 proteus mirabilises, 14 3 3e of---, 15 87 Pseudomonas aeruginosas
d26 13 9 Pseudomonas aeruginosas, 62 2e of---, 600 Staphylococcus saprophyticus, 744 20 97 Haemophilus influenzaes
d---16 22 Haemophilus influenzaes, 111 20 11 streptococcus pneumoniaes---6,11 streptococcus pneumoniae
d19 22411 morazella catarrhalis, 222988 staphylococcus epidermidiss 62 1 1---streptococcus aureus 30 1 1---general probe
d7-the 7g of---
aDo not test dna fragmentation or the oligonucleotide of enterococcus faecalis and streptococcus pyogenes.
bThe size of dna fragmentation is between 0.25 to 5.0.
cTarget species isolate when at least 80% (about 80 isolates) is during by the identification of each specific probe, and this probe just is considered to ubiquity.Two or more probes are in conjunction with the isolate that can discern 100%.
dThese sequences are selected from database.
eIsolate test ubiquity with about 10 target species.
fMost of probes can not be distinguished intestinal bacteria and Shigella several kinds.
gWith one group of 7 the probe test ubiquity that detects 66 bacterial species listing in all tables 5.
The pcr amplification of common bacterial pathogens in table 7. urine, saliva, blood, myelencephalon and other sample.The organism primer is right
aThe big ubiquity of amplicon
bDNA cloning certainly
Little
# (SEQ ID NO) is bacterium colony (bp)
cSample
dIntestinal bacteria 1
e(55+56) 107 75/80++
2
e(46+47)?297????77/80???????+?????????+
3?42+43)???102????78/80???????+?????????+
4(131+132)?134????73/80???????+?????????+
1+3+4-80/80++ enterococcus faecalis 1
e(38+39) 200 71/80++
2
e(40+41)?121????79/80???????+?????????+
1+2-80/80++ Klebsiella pneumonia 1 (67+68) 198 76/80++
2(61+62)???143????67/80???????+?????????+
3
h(135+136)148???78/80???????+???????N.T.i
4(137+138)?116????69/80???????+???????N.T.
1+2+3-80/80+N.T. proteus mirabilis 1 (74+75), 167 73/80+N.T.
2(133+134)?123????80/80???????+???????N.T.
The pcr amplification organism primer of common bacterial pathogens is right in table 7 (continuing) urine, saliva, blood, myelencephalon and other sample
aAmplicon size ubiquity
bDNA cloning certainly
# (SEQ ID NO) is bacterium colony (bp)
cSample
dPseudomonas aeruginosa 1
e(83+84) 139 79/80+N.T.
2
e(85+86) 223 80/80+N.T. Staphylococcus saprophyticus 1 (98+99) 126 79/80++
2 (139+140), 190 80/80+N.T. morazella catarrhalis, 1 (112+113), 157 79/80+N.T.
2???(118+119)??118?????????80/80?????????+????N.T.
3 (160+119), 137 80/80+N.T. Haemophilus influenzae 1
e(154+155) 217 80/80+N.T. streptococcus pneumoniae 1
e(156+157) 134 80/80+N.T.
2
e?(158+159)??197?????????74/80?????????+????N.T.
3????(78+79)???175?????????67/80?????????+????N.T.
The pcr amplification organism primer of common bacterial pathogens is right in table 7 (continuing) urine, saliva, blood, myelencephalon and other sample
aAmplicon size ubiquity
bDNA cloning certainly
# (SEQ ID NO) is bacterium colony (bp)
cSample
dStaphylococcus epidermidis 1 (147+148) 175 80/80+N.T.
2 (145+146), 125 80/80+N.T. streptococcus aureus, 1 (152+153), 108 80/80+N.T.
2????(149+150)????151???????????80/80???????+????N.T.
3 (149+151), 176 80/80+N.T. streptococcus pyogenes
f1
e(141+142) 213 80/80+N.T.
2
e(143+144) 157 24/24+N.T. general 1
e(126-127) 241 194/195
g++
aAll primer is to all being specific in PCR measures, because with deriving from 66 different Gram-positives and gram negative bacterium (table 5) but not the DNA of interest bacterium does not observe amplification.
bUbiquity is tested with 80 bacterial strains of interest species usually.The primer of being withed a hook at the end is to the isolate of amplification at least 90%.When using the combination of primer, reached 100% ubiquity.
cFor all primers to and Multiple Combination, the pcr amplification that directly carries out from bacterial clone is 100% species specificity.
dPCR measures and directly carries out in urine sample.
eThe primer that derives from database sequence is right.The primer that does not have " e " is to deriving from our species specificity fragment.
fFor streptococcus pyogenes, primer is specific to #1 to streptococcus A group (GAS).It is specific that primer produces exotoxin A gene (SpeA) to #2 to GAS-.
gWith 195 isolate test ubiquities in 23 species representatives of pathogenic agent common in the clinical sample.
hBe optimized to eliminate with some bacterial species rather than the observed non-specific amplification of target species.
iN.T. not test (N.T.).
The diagnostic antibiotics resistance gene gene microbiotic bacterium that table 8. is selected
aSEQ ID NO (bla
Tem) TEM-1 beta-lactam enterobacteriaceae, pseudomonas section, 161
Haemophilus spp, pasteurella (bla
Rob) ROB-1 beta-lactam Klebsiella 162 (bla
Shv) SHV-1 beta-lactam and other enterobacteriaceae species 163aadB, aacC1, aacC2, the aminoglycoside enterobacteriaceae, pseudomonadaceae 164,165,166aacC3, aacA4 167,168mecA beta-lactam Staphylococcus 169vanH, vanA, vanx vancomycin Colibacter 170staA macrolide Colibacter 173aacA-aphvD aminoglycoside Colibacter, Staphylococcus 174vat macrolide Staphylococcus 175vga macrolide Staphylococcus 176msrA erythromycin Staphylococcus 177Int and Sul beta-lactam, front three benzyl chloride two enterobacteriaceaes 171,172 conserved sequence Aminometradines, aminoglycosides, the sterilization pseudomonadaceae
Agent, E.C. 2.3.1.28
aSpecial antibiotics resistance gene has higher occurrence rate.And be not precluded within other bacterium and exist.
The oligonucleotide SEQ ID NO nucleotide sequence initiate dna fragment of specificity that appendix I. is used to hybridize and ubiquity
SEQ ID nucleotide position
NO bacterial species intestinal bacteria 44 5 '-CAC CCG CTT GCG TGG CAA GCT GCC C 5
a213-23745 5 '-CGT TTG TGG ATT CCA GTT CCA TCC G 5
a489-51348 5 '-TGA AGC ACT GGC CGA AAT GCT GCG T 6
a759-78349 5 '-GAT GTA CAG GAT TCG TTG AAG GCT T 6
a898-92250 5 '-TAG CGA AGG CGT AGC AGA AAC TAA C 7
a1264-128851 5 '-GCA ACC CGA ACT CAA CGC CGG ATT T 7
a1227-125152 5 '-ATA CAC AAG GGT CGC ATC TGC GGC C 7
a1313-133753 5 '-TGC GTA TGC ATT GCA GAC CTT GTG GC 7
a111-13654 5 '-GCT TTC ACT GGA TAT CGC GCT TGG G 7
a373-397 bacterial species proteus mirabilis 70
b5 '-TGG TTC ACT GAC TTT GCG ATG TTT C 12 23-4771 5 '-TCG AGG ATG GCA TGC ACT AGA AAA T 12 53-7772
b5 '-these sequences of sequence b that CGC TGA TTA GGT TTC GCT AAA ATC TTA TTA 12 80-10973 5 '-TTG ATC CTC ATT TTA TTA ATC ACA TGA CCA 12 174-203a derive from database derive from the opposite DNA chain (opposite DNAstrand) of the sequence that provides in the sequence table
The oligonucleotide SEQ ID NO nucleotide sequence initiate dna fragment of specificity that appendix I. is used to hybridize and ubiquity
SEQ ID nucleotide position
NO bacterial species proteus mirabilis 76 5 '-CCG CCT TTA GCA TTA ATT GGT GTT TAT AGT 13 246-27577 5 '-CCT ATT GCA GAT ACC TTA AAT GTC TTG GGC 13 291-32080
b5 '-TTG AGT GAT GAT TTC ACT GAC TCC C 14 18-4281 5 '-GTC AGA CAG TGA TGC TGA CGA CAC A 15
a1185-120982 5 '-TGG TTG TCA TGC TGT TTG TGT GAA AAT 15
a1224-1250 bacterial species Klebsiella pneumonia 57 5 '-GTG GTG TCG TTC AGC GCT TTC AC 8 45-6758 5 '-GCG ATA TTC ACA CCC TAC GCA GCC A 9 161-18559
b5 '-GTC GAA AAT GCC GGA AGA GGT ATA CG 9 203-22860
b5 '-ACT GAG CTG CAG ACC GGT AAA ACT CA 9 233-25863
b5 '-CGT GAT GGA TAT TCT TAA CGA AGG GC 10 250-27564
b5 '-ACC AAA CTG TTG AGC CGC CTG GA 10 201-22365 5 '-GTG ATC GCC CCT CAT CTG CTA CT 10 77-9966 5 '-CGC CCT TCG TTA AGA ATA TCC ATC AC 10 249-27469 5 '-CAG GAA GAT GCT GCA CCG GTT GTT G 11
aThese sequences of sequence b that 296-320a derives from database derive from the opposite DNA chain of the sequence that provides in the sequence table
The oligonucleotide SEQ ID NO nucleotide sequence initiate dna fragment of specificity that appendix I. is used to hybridize and ubiquity
SEQ ID nucleotide position
NO bacterial species Pseudomonas aeruginosa 87 5 '-AAT GCG GCT GTA CCT CGG CGC TGG T 18
a2985-300988 5 '-GGC GGA GGG CCA GTT GCA CCT GCC A 18
a2929-295389 5 '-AGC CCT GCT CCT CGG CAG CCT CTG C 18
a2821-284590 5 '-TGG CTT TTG CAA CCG CGT TCA GGT T 18
a1079-110391 5 '-GCG CCC GCG AGG GCA TGC TTC GAT G 19
a705-72992 5 '-ACC TGG GCG CCA ACT ACA AGT TCT A 19
a668-69293 5 '-GGC TAC GCT GCC GGG CTG CAG GCC G 19
a505-52994 5 '-CCG ATC TAC ACC ATC GAG ATG GGC G 20
a1211-123595 5 '-GAG CGC GGC TAT GTG TTC GTC GGC T 20
a2111-2135 bacterial species streptococcus pneumoniae 120 5 '-TCT GTG CTA GAG ACT GCC CCA TTT C 30 423-447121 5 '-CGA TGT CTT GAT TGA GCA GGG TTA T 31
aThese sequences of sequence b that 1198-1222a derives from database derive from the opposite DNA chain of the sequence that provides in the sequence table
The oligonucleotide SEQ ID NO nucleotide sequence initiate dna fragment of specificity that appendix I. is used to hybridize and ubiquity
SEQ ID nucleotide position
NO bacterial species Staphylococcus saprophyticus 96 5 '-CGT TTT TAC CCT TAC CTT TTC GTA CTA CC 21 45-7397
b5 '-TCA GGC AGA GGT AGT ACG AAA AGG TAA GGG 21 53-82100 5 '-CAC CAA GTT TGA CAC GTG AAG ATT CAT 22 89-115101
b5 '-ATG AGT GAA GCG GAG TCA GAT TAT GTG CAG 23 105-134102 5 '-CGC TCA TTA CGT ACA GTG ACA ATC G 24 20-44103 5 '-CTG GTT AGC TTG ACT CTT AAC AAT CTT GTC 24 61-90104
b5% E2% 80% B2-GAC% 20GCG% 20ATT% 20GTC% 20ACT% 20GTA% 20CGT% 20AAT% 20GAG% 20CGA% 2024% 2019-48% E7% BB% 86% E8% 8F% 8C% E7% 89% A9% E7% A7% 8D% 20% E7% B2% 98% E8% 86% 9C% E7% 82% 8E% E8% 8E% AB% E6% 8B% 89% E6% B0% 8F% E8% 8F% 8C108% 205% E2% 80% B2-GCC% 20CCA% 20AAA% 20CAA% 20TGA% 20AAC% 20ATA% 20TGG% 20T% 2028% 2081-105109% 205% E2% 80% B2-CTG% 20CAG% 20ATT% 20TTG% 20GAA% 20TCA% 20TAT% 20CGC% 20C% 2028% 20126-150110% 205% E2% 80% B2-TGG% 20TTT% 20GAC% 20CAG% 20TAT% 20TTA% 20ACG% 20CCA% 20T% 2028% 20165-189111% 205% E2% 80% B2-CAA% 20CGG% 20CAC% 20CTG% 20ATG% 20TAC% 20CTT% 20GTA% 20C% 2028% 20232-256114% 205% E2% 80% B2-TTA% 20CAA% 20CCT% 20GCA% 20CCA% 20CAA% 20GTC% 20ATC% 20A% 2029% 2097-121115% 205% E2% 80% B2-GTA% 20CAA% 20ACA% 20AGC% 20CGT% 20CAG% 20CGA% 20CTT% 20A% 2029% 20139-163116% 205% E2% 80% B2-CAA% 20TCT% 20GCG% 20TGT% 20GTG% 20CGT% 20TCA% 20CT% 2029% 20178-200117% 205% E2% 80% B2-GCT% 20ACT% 20TTG% 20TCA% 20GCT% 20TTA% 20GCC% 20ATT% 20CA% 2029% 20287-312a% E5% BE% 97% E8% 87% AA% E6% 95% B0% E6% 8D% AE% E5% BA% 93% E7% 9A% 84% E5% BA% 8F% E5% 88% 97b% E8% BF% 99% E4% BA% 9B% E5% BA% 8F% E5% 88% 97% E5% BE% 97% E8% 87% AA% E5% BA% 8F% E5% 88% 97% E8% A1% A8% E4% B8% AD% E7% BB% 99% E5% 87% BA% E7% 9A% 84% E5% BA% 8F% E5% 88% 97% E7% 9A% 84% E7% 9B% B8% E5% 8F% 8DDNA% E9% 93% BE
The oligonucleotide SEQ ID NO nucleotide sequence initiate dna fragment of specificity that appendix I. is used to hybridize and ubiquity
SEQ ID nucleotide position
NO bacterial species Haemophilus influenzae 105
b5 '-GCG TCA GAA AAA GTA GGC GAA ATG AAA G 25 138-165106
b5 '-AGC GGC TCT ATC TTG TAA TGA CAC A 26
a770-794107
b5 '-GAA ACG TGA ACT CCC CTC TAT ATA A 27
a5184-5208
General probe
c122
b5 '-ATC CCA CCT TAG GCG GCT GGC TCC A--123 5 '-ACG TCA AGT CAT CAT GGC CCT TAC GAG TAG G--124
b5 '-GTG TGA CGG GCG GTG TGT ACA AGG C--125
b5 '-GAG TTG CAG ACT CCA ATC CGG ACT ACG A--128
b5 '-CCC TAT ACA TCA CCT TGC GGT TTA GCA GAG AG--129 5 '-GGG GGG ACC ATC CTC CAA GGC TAA ATA C--130
b5 '-CGT CCA CTT TCG TGT TTG CAG AGT GCT GTG TT--opposite DNA chain c general probe that these sequences of sequence b that a derives from database derive from the sequence that provides in the sequence table comes from 16S or the 23S ribosomal rna gene sequence that is not included in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO bacterial species intestinal bacteria 42 5 '-GCT TTC CAG CGT CAT ATT G 4 177-19543
b5 '-GAT CTC GAC AAA ATG GTG A 4 260-27846 5 '-TCA CCC GCT TGC GTG GC 5
a212-22847
b5 '-GGA ACT GGA ATC CAC AAA C 5
a490-50855 5 '-GCA ACC CGA ACT CAA CGC C 7
a1227-124556b 5 '-GCA GAT GCG ACC CTT GTG T 7
a1315-1333131 5 '-CAG GAG TAC GGT GAT TTT TA 3 60-79132
b5 '-ATT TCT GGT TTG GTC ATA CA 3 174-193 bacterial species enterococcus faecalis 38 5 '-GCA ATA CAG GGA AAA ATG TC 1
a69-8839
b5 '-CTT CAT CAA ACA ATT AAC TC 1
a249-26840 5 '-GAA CAG AAG AAG CCA AAA AA 2
a569-58841
b5 '-GCA ATC CCA AAT AAT ACG GT 2
aThese sequences of sequence b that 670-689a derives from database derive from the opposite DNA chain of the sequence that provides in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO bacterial species Klebsiella pneumonia 61 5 '-GAC AGT CAG TTC GTC AGC C 9 37-5562
b5 '-CGT AGG GTG TGA ATA TCG C 9 161-17967 5 '-TCG CCC CTC ATC TGC TAC T 10 81-9968
b5 '-GAT CGT GAT GGA TAT TCT T 10 260-278135 5 '-GCA GCG TGG TGT CGT TCA 8 40-57136
b5 '-AGC TGG CAA CGG CTG GTC 8 170-187137 5 '-ATT CAC ACC CTA CGC AGC CA 9 166-185138
b5 '-ATC CGG CAG CAT CTC TTT GT 9 262-281 bacterial species proteus mirabilises 74 5 '-GAA ACA TCG CAA AGT CAG T 12 23-4175
b5 '-ATA AAA TGA GGA TCA AGT TC 12 170-189133 5 '-CGG GAG TCA GTG AAA TCA TC 14 17-36134
b5 '-these sequences of sequence b that CTA AAA TCG CCA CAC CTC TT 14 120-139a derive from database derive from the opposite DNA chain of the sequence that provides in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO bacterial species Staphylococcus saprophyticus 98 5 '-CGT TTT TAC CCT TAC CTT TTC GTA CT 21 45-7099
b5 '-ATC GAT CAT CAC ATT CCA TTT GTT TTT A 21 143-170139 5 '-CTG GTT AGC TTG ACT CTT AAC AAT C 24 61-85140
b5 '-TCT TAA CGA TAG AAT GGA GCA ACT G 24 226-250 bacterial species Pseudomonas aeruginosas 83 5 '-CGA GCG GGT GGT GTT CAT C 16
a554-57284
b5 '-CAA GTC GTC GTC GGA GGG A 16
a674-69285 5 '-TCG CTG TTC ATC AAG ACC C 17
a1423-144186
b5 '-CCG AGA ACC AGA CTT CAT C 17
a1627-1645 bacterial species morazella catarrhalis 112 5 '-GGC ACC TGA TGT ACC TTG 28 235-252113
b5 '-AAC AGC TCA CAC GCA TT 28 375-391118 5 '-TGT TTT GAG CTT TTT ATT TTT TGA 29 41-64119
b5 '-CGC TGA CGG CTT GTT TGT ACC A 29 137-158160 5 '-GCT CAA ATC AGG GTC AGC 29 22-39119
b5 '-these sequences of sequence b that CGC TGA CGG CTT GTT TGT ACC A 29 137-158a derive from database derive from the opposite DNA chain of the sequence that provides in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO bacterial species staphylococcus epidermidis 145 5 '-ATC AAA AAG TTG GCG AAC CTT TTC A 36 21-45146
b5 '-CAA AAG AGC GTG GAG AAA AGT ATC A 36 121-145147 5 '-TCT CTT TTA ATT TCA TCT TCA ATT CCA TAG 36 448-477148
b5 '-AAA CAC AAT TAC AGT CTG GTT ATC CAT ATC 36 593-622 bacterial species streptococcus aureuses 149
b5 '-CTT CAT TTT ACG GTG ACT TCT TAG AAG ATT 37 409-438150 5 '-TCA ACT GTA GCT TCT TTA TCC ATA CGT TGA 37 288-317149
b5 '-CTT CAT TTT ACG GTG ACT TCT TAG AAG ATT 37 409-438151 5 '-ATA TTT TAG CTT TTC AGT TTC TAT ATC AAC 37 263-292152 5 '-AAT CTT TGT CGG TAC ACG ATA TTC TTC ACG 37 5-34153
b5 '-these sequences of sequence b that CGT AAT GAG ATT TCA GTA GAT AAT ACA ACA 37 83-112a derive from database derive from the opposite DNA chain of the sequence that provides in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO bacterial species Haemophilus influenzae 154 5 '-TTT AAC GAT CCT TTT ACT CCT TTT G 27
a5074-5098155
b5 '-ACT GCT GTT GTA AAG AGG TTA AAA T 27
a5266-5290 bacterial species streptococcus pneumoniae 78 5 '-AGT AAA ATG AAA TAA GAA CAG GAC AG 34 164-18979
b5 '-AAA ACA GGA TAG GAG AAC GGG AAA A 34 314-338156 5 '-ATT TGG TGA CGG GTG ACT TT 31
a1401-1420157
b5 '-GCT GAG GAT TTG TTC TTC TT 31
a1515-1534158 5 '-GAG CGG TTT CTA TGA TTG TA 35
a1342-1361159
b5 '-ATC TTT CCT TTC TTG TTC TT 35
a1519-1538 bacterial species streptococcus pyogenes 141 5 '-TGA AAA TTC TTG TAA CAG GC 32
a286-305142
b5 '-GGC CAC CAG CTT GCC CAA TA 32
a479-498143 5 '-ATA TTT TCT TTA TGA GGG TG 33
a966-985144
b5 '-ATC CTT AAA TAA AGT TGC CA 33
aThese sequences of sequence b that 1103-1122a derives from database derive from the opposite DNA chain of the sequence that provides in the sequence table
Appendix II. is used for the specificity of DNA cloning and the primer SEQ ID NO nucleotide sequence initiate dna fragment of ubiquity
SEQ ID nucleotide position
NO
Universal primer C126 5 '-GGA GGA AGG TGG GGA TGA CG--127b 5 '-ATG GTG TGA CGG GCG GTG TG--opposite DNA chain c general probe that these sequences of sequence b that a derives from database derive from the sequence that provides in the sequence table comes from 16S or the 23S ribosomal rna gene sequence that is not included in the sequence table
Appendix III. selects opposite strand (Reverse strand) the TGGAGCC AGCCGCCTAA GGTGGGAT of general probe SEQ ID NO:122 by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
The 1461 1510 common sex change bacterium of streptococcus salivarius TGAGGTAACC TTTTGGAGCC AGCCGCCTAA GGTGGGATAG ATGANNGGGG TAGCTTAACC TTCGGGAGGG CGCTTACCAC TTTGTGATTC ATGACTGGGG pseudomonas aeruginosa TAGTCTAACC GCAAGGGGGA CGGTTACCAC GGAGTGATTC ATGACTGGGG Diplococcus gonorrhoeae TAGGGTAACC GCAAGGAGTC CGCTTACCAC GGTATGCTTC ATGACTGGGG streptococcus lactis TTGCCTAACC GCAAGGAGGG CGCTTCCTAA GGTAAGACCG ATGACNNGGG
Appendix III. selects general probe SEQ ID NO:123 ACGTCAAGTC ATCATGGC CCTTACGAGT AGG by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
1251, 1300 Hemophilus influenzaes, GGTNGGGATG, ACGTCAAGTC, ..ATCATGGC, CCTTACGAGT, the AGGGCTACAC Diplococcus gonorrhoeae, GGTGGGGATG, ACGTCAAGTC, ..CTCATGGC, CCTTATGACC, the AGGGCTTCAC pseudomonas cepacia, GGTNGGGATG, ACGTCAAGTC, ..CTCATGGC, CCTTATGGGT, the AGGGCTTCAC serratia marcescens, GGTGGGGATG, ACGTCAAGTC, ..ATCATGGC, CCTTACGAGT, the AGGGCTACAC Escherichia coli, GGTGGGGATG, ACGTCAAGTC, ..ATCATGGC, CCTTACGACC, the common sex change bacterium of AGGGCTACAC, GGTGGGGATG, ACGTTAAGTC, GTATCATGGC, CCTTACGAGT, the AGGGCTACAC pseudomonas aeruginosa, GGTGGGGATG, ACGTCAAGTC, ..ATCATGGC, CCTTACGGCN, the AGGGCTACAC bacillus aerogenes capsulatus, GGTGGGGATG, ACGTNNAATC, ..ATCATGCC, CNTTATGTGT, the humanoid mycoplasmas of AGGGCTACAC, GGTGGGGATG, ACGTCAAATC, ..ATCATGCC, TCTTACGAGT, the GGGGCCACAC helicobacter pylori, GGTGGGGACG, ACGTCAAGTC, ..ATCATGGC, CCTTACGCCT, the AGGGCTACAC Mycoplasma pneumoniae, GGAAGGGATG, ACGTCAAATC, ..ATCATGCC, CCTTATGTCT, AGGGCTGCAA
Appendix III. selects opposite strand (Reverse strand) the GCCTTGTACA CACCGCCCGT CACAC of general probe SEQID NO:124 by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
1451, 1490 Escherichia coli, ACGTTCCCGG, GCCTTGTACA, CACCGCCCGT, the CACACCATGG Diplococcus gonorrhoeae, ACGTTCCCNG, NNCTTGTACA, CACCGCCCGT, the CACACCATGG pseudomonas cepacia, ACGTTCCCGG, GTCTTGTACA, CACNGCCCGT, the CACACCATGG serratia marcescens, ACGTTCCCGG, GCCTTGTACA, CACCGCCCGT, the common sex change bacterium of CACACCATGG, ACGTTCCCGG, GCCTTGTACA, CACCGCCCGT, the CACACCATGG Hemophilus influenzae, ACGTTCCCGG, GCNTTGTACA, CACCGCCCGT, the CACACCATGG pseudomonas aeruginosa, ACGTTCCCGG, GCCTTGTACA, CACCGCCCGT, the CACACCATGG bacillus aerogenes capsulatus, ACGTTCCCNG, GTCTTGTACA, CACCGCNCGT, the humanoid mycoplasmas of CACACCATGA, ACGTTCTCGG, GTCTTGTACA, CACCGCCCGT, the CACACCATGG helicobacter pylori, ACGTTCCCGG, GTCTTGTACT, CACCGCCCGT, the CACACCATGG Mycoplasma pneumoniae, ACGTTCTCGG, GTCTTGTACA, CACCGCCCGT, CAAACTATGA
Appendix III. selects opposite strand (Reverse strand) the TCG TAGTCCGGAT TGGAGTCTGC AACTC of general probe SEQ ID NO:125 by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
1361, 1400 Escherichia coli, AAGTGCGTCG, TAGTCCGGAT, TGGAGTCTGC, the AACTCGACTC Diplococcus gonorrhoeae, AAACCGATCG, TAGTCCGGAT, TGCACTCTGC, the AACTCGAGTG pseudomonas cepacia, AAACCGATCG, TAGTCCGGAT, TGCACTCTGC, the AACTCGAGTG serratia marcescens, AAGTATGTCG, TAGTCCGGAT, TGGAGTCTGC, the common sex change bacterium of AACTCGACTC, AAGTCTGTCG, TAGTCCGGAT, TGGAGTCTGC, the AACTCGACTC Hemophilus influenzae, AAGTACGTCT, AAGTCCGGAT, TGGAGTCTGC, the AACTCGACTC pseudomonas aeruginosa, AAACCGATCG, TAGTCCGGAT, CGCAGTCTGC, the AACTCGACTG bacillus aerogenes capsulatus, AAACCAGTCT, CAGTTCGGAT, TGTAGGCTGA, the humanoid mycoplasmas of AACTCGCCTA, AAGCCGATCT, CAGTTCGGAT, TGGAGTCTGC, the AATTCGACTC helicobacter pylori, ACACC..TCT, CAGTTCGGAT, TGTAGGCTGC, the AACTCGCCTG Mycoplasma pneumoniae, AAGTTGGTCT, CAGTTCGGAT, TGAGGGCTGC, AATTCGTCCT
Appendix III. selects the opposite strand CT CTCTGCTAAA CCGCAAGGTG ATGTATAGGG of general probe SEQ ID NO:128 by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
19912040 Lactococcus Bacillus AAACACAGCT CTCTGCTAAA CCGCAAGGTG ATGTATAGGG GGTGACGCCT E. AAACACAGCA CTGTGCAAAC ACGAAAGTGG ACGTATACGG TGTGACGCCT Pseudomonas aeruginosa AAACACAGCA CTCTGCAAAC ACGAAAGTGG ACGTATAGGG TGTGACGCCT onion Pseudomonas AAACACAGCA CTCTGCAAAC ACGAAAGTGG ACGTATAGGG TGTGACGCCT Bacillus stearothermophilus AAACACAGGT CTCTGCGAAG TCGTAAGGCG ACGTATAGGG GCTGACACCT Garcinia Micrococcus AAACACAGGT CCATGCGAAG TCGTAAGACG ATGTATATGG ACTGACTCCTSEQ ID NO: 129 GGGGGGACC ATCCTCCAAG GCTAAATAC
481 530 Escherichia coli TGTCTGAATA TGGGGGGACC ATCCTCCAAG GCTAAATACT CCTGACTGAC pseudomonas aeruginosa TGTCTGAACA TGGGGGGACC ATCCTCCAAG GCTAAATACT ACTGACTGAC pseudomonas cepacia TGTCTGAAGA TGGGGGGACC ATCCTCCAAG GCTAAATACT CGTGATCGAC lactic acid breast bacillus AGTTTGAATC CGGGAGGACC ATCTCCCAAC CCTAAATACT CCTTAGTGAC micrococcus luteus CGTGTGAATC TGCCAGGACC ACCTGGTAAG CCTGAATACT ACCTGTTGAC
Appendix III. selects the opposite strand AACACAGCA CTCTGCAAAC ACGAAAGTGG ACG of general probe SEQ ID NO:130 by the sequence contrast of bacterial 16 S and 23S ribosomal RNA gene
19812030 Pseudomonas aeruginosa TGTTTATTAA AAACACAGCA CTCTGCAAAC ACGAAAGTGG ACGTATAGGG E. TGTTTATTAA AAACACAGCA CTGTGCAAAC ACGAAAGTGG ACGTATACGG onion Pseudomonas TGTTTAATAA AAACACAGCA CTCTGCAAAC ACGAAAGTGG ACGTATAGGG Bacillus stearothermophilus TGTTTATCAA AAACACAGGT CTCTGCGAAG TCGTAAGGCG ACGTATAGGG Lactococcus Bacillus TGTTTATCAA AAACACAGCT CTCTGCTAAA CCGCAAGGTG ATGTATAGGG Garcinia Micrococcus TGTTTATCAA AAACACAGGT CCATGCGAAG TCGTAAGACG ATGTATATGG
Appendix IV. selects the opposite strand CA CACCGCCCGT CACACCAT of universal PC R primer SEQ ID NO:126 GGAGGAA GGTGGGGATG ACGSEQ ID NO:127 by the sequence contrast of bacterial 16 S ribosomal rna gene
1241, 1270......1461, 1490 Escherichia coli, ACTGGAGGAA, GGTGGGGATG, ACGTCAAGTC......GCCTTGTACA, CACCGCCCGT, the CACACCATGG Diplococcus gonorrhoeae, GCCGGAGGAA, GGTGGGGATG, ACGTCAAGTC......NNCTTGTACA, CACCGCCCGT, the CACACCATGG pseudomonas cepacia, ACCGGAGGAA, GGTNGGGATG, ACGTCAAGTC......GTCTTGTACA, CACNGCCCGT, the CACACCATGG serratia marcescens, ACTGGAGGAA, GGTGGGGATG, ACGTCAAGTC......GCCTTGTACA, CACCGCCCGT, the common sex change bacterium of CACACCATGG, ACCGGAGGAA, GGTGGGGATG, ACGTTAAGTC......GCCTTGTACA, CACCGCCCGT, the CACACCATGG Hemophilus influenzae, ACTGGAGGAA, GGTNGGGATG, ACGTCAAGTC......GCNTTGTACA, CACCGCCCGT, the CACACCATGG legionella pneumophilia, ACCGGAGGAA, GGCGGGGATG, ACGTCAAGTC......GCCTTGTACA, CACCGCCCGT, the CACACCATGG pseudomonas aeruginosa, ACCGGAGGAA, GGTGGGGATG, ACGTCAAGTC......GCCTTGTACA, CACCGCCCGT, the CACACCATGG bacillus aerogenes capsulatus, CCAGGAGGAA, GGTGGGGATG, ACGTNNAATC......GTCTTGTACA, CACCGCNCGT, the humanoid mycoplasmas of CACACCATGA, CTGGGAGGAA, GGTGGGGATG, ACGTCAAATC......GTCTTGTACA, CACCGCCCGT, the CACACCATGG helicobacter pylori, GGAGGAGGAA, GGTGGGGACG, ACGTCAAGTC......GTCTTGTACT, CACCGCCCGT, the CACACCATGG Mycoplasma pneumoniae, ATTGGAGGAA, GGAAGGGATG, ACGTCAAATC......GTCTTGTACA, CACCGCCCGT, CAAACTATGA
Sequence table (1) general information: (i) applicant: BERGERON, Michel G.
OUELLETTE，Marc
ROY, Paul H. is denomination of invention (ii): be used for the daily diagnosis of microbiology laboratory and detect rapidly and differentiate (iii) sequence number of the specificity of common bacterial pathogens and antibiotics resistance gene in the clinical sample and universal probes and amplimer: 177 (iv) addresses:
(A) contact person:
(B) street:
(C) city:
(D) state:
(E) country:
(F) computer-reader form ZIP:(v):
(A) media type: floppy disk, 800K
(B) computer: Macintosh IIci
(C) operation: system 7.0
(D) software: Word 5.la (the vi) data of current application:
(A) application number:
(B) applying date:
(C) classification number: (vii) in the data of first to file:
(A) application number:
(B) applying date: (viii) lawyer/proxy's data:
(A) name: JEAN C.BAKER
(B) registration number: (ix) telecom information:
(A) phone:
(B) fax: the information of (2) SEQ ID NO:1: (i) sequence signature:
(A) length: 1817 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis, (xi) sequence description: SEQ, ID, NO:1:ACAGTAAAAA, AGTTGTTAAC, GAATGAATTT, GTTAACAACT, TTTTTGCTAT, 50GGTATTGAGT, TATGAGGGGC, AATACAGGGA, AAAATGTCGG, CTGATTAAGG, 100AATTTAGATA, GTGCCGGTTA, GTAGTTGTCT, ATAATGAAAA, TAGCAACAAA, 150TATTTACGCA, GGGAAAGGGG, CGGTCGTTTA, ACGGGAAAAA, TTAGGGAGGA, 200TAAAGCAATA, CTTTTGTTGG, GAAAAGAAAT, AAAAGGAAAC, TGGGGAAGGA, 250GTTAATTGTT, TGATGAAGGG, AAATAAAATT, TTATACATTT, TAGGTACAGG, 300CATCTTTGTT, GGAAGTTCAT, GTCTATTTTC, TTCACTTTTT, GTAGCCGCAG, 350AAGAACAAGT, TTATTCAGAA, AGTGAAGTTT, CAACAGTTTT, ATCGAAGTTG, 400GAAAAGGAGG, CAATTTCTGA, GGCAGCTGCT, GAACAATATA, CGGTTGTAGA, 450TCGAAAAGAA, GACGCGTGGG, GGATGAAGCA, TCTTAAGTTA, GAAAAGCAAA, 500CGGAAGGCGT, TACTGTTGAT, TCAGATAATG, TGATTATTCA, TTTAGATAAA, 550AACGGTGCAG, TAACAAGTGT, TACAGGAAAT, CCAGTTGATC, AAGTTGTGAA, 600AATTCAATCG, GTTGATGCAA, TCGGTGAAGA, AGGAGTTAAA, AAAATTGTTG, 650CTTCTGATAA, TCCAGAAACT, AAAGATCTTG, TCTTTTTAGC, TATTGACAAA, 700CGTGTAAATA, ATGAAGGGCA, ATTATTTTAT, AAAGTCAGAG, TAACTTCTTC, 750ACCAACTGGT, GACCCCGTAT, CATTGGTTTA, TAAAGTGAAC, GCTACAGATG, 800GAACAATTAT, GGAAAAACAA, GATTTAACGG, AACATGTCGG, TAGTGAAGTA, 850ACGTTAAAAA, ACTCTTTTCA, AGTAACGTTT, AATGTACCAG, TTGAAAAAAG, 900CAATACGGGA, ATTGCTTTAC, ACGGAACGGA, TAACACAGGG, GTTTACCATG, 950CAGTAGTTGA, TGGCAAAAAT, AATTATTCTA, TTATTCAAGC, GCCATCACTA, 1000GCGACATTAA, ATCAGAATGC, TATTGACGCC, TATACGCATG, GAAAATTTGT, 1050GAAAACATAT, TATGAAGATC, ATTTCCAACG, ACACAGTATT, GATGATCGAG, 1100GGATGCCCAT, CTTGTCAGTT, GTTGATGAAC, AACATCCAGA, TGCTTATGAC, 1150AATGCTTTTT, GGGATGGAAA, AGCAATGCGT, TATGGTGAAA, CAAGTACACC, 1200AACAGGAAAA, ACGTATGCTT, CCTCTTTAGA, TGTAGTTGGT, CATGAAATGA, 1250CACATGGTGT, GACGGAACAT, ACTGCCGGTT, TAGAATATTT, AGGACAATCA, 1300GGTGCCTTGA, ATGAATCTTA, TTCTGATTTG, ATGGGTTATA, TTATTTCGGG, 1350TGCATCTAAT, CCAGAAATTG, GTGCGGATAC, TCAGAGTGTT, GACCGAAAAA, 1400CAGGTATTCG, AAATTTACAA, ACGCCAAGTA, AACACGGACA, ACCAGAAACC, 1450ATGGCTCAAT, ACGACGATCG, AGCACGGTAT, AAAGGAACGC, CTTATTATGA, 1500TCAAGGCGGT, GTTCATTATA, ACAGTGGAAT, TATTAATCGG, ATTGGTTACA, 1550CCATTATCCA, GAACTTAGGC, ATTGAAAAAG, CACAGACTAT, TTTCTACAGC, 1600TCGTTAGTAA, ATTACTTAAC, ACCTAAAGCA, CAATTCAGTG, ATGCTCGTGC, 1650TGCGATGCTT, GCTGCTGCAA, AAGTTCAATA, TGGCGATGAA, GCAGCTTCAG, 1700TGGTGTCAGC, AGCCTTTAAC, TCTGCTGGAA, TCGGAGCTAA, AGAAGACATT, 1750CAGGTAAACC, AACCAAGTGA, ATCTGTTCTG, GTCAATGAAT, GAAAAAAATT, 1800CCCCAATTAA, ATAAAAA, 1817, (2) SEQ, ID, the information of NO:2:, (i) sequence signature:
(A) length: 2275 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis, (xi) sequence description:, SEQ, ID, NO:2:GGTACCAAAG, AAAAAAACGA, ACGCCACAAC, CAACAGCCTC, TAAAGCAACA, 50CCTGCTTCTG, AAATTGAGGG, AGATTTAGCA, AATGTCAATG, AGATTCTTTT, 100GGTTCACGAT, GATCGTGTCG, GGTCAGCAAC, GATGGGAATG, AAAGTCTTAG, 150AAGAAATTTT, AGATAAAGAG, AAAATTTCAA, TGCCGATTCG, AAAAATTAAT, 200ATTAATGAAT, TAACTCAACA, AACACAGGCT, TTAATTGTCA, CAAAAGCTGA, 250ACTAACGGAA, CAAGCACGTA, AAAAAGCACC, GAAAGCGACA, CACTTATCAG, 300TAAAAAGTTA, TGGTTAATCC, CCAAAAATAT, GAAACAGTGG, GTTTCGCTCT, 350TAAAAGAAAG, TGCCTAGAGA, GGAAGAAAAC, AATGGAAAAT, CTTACGAATA, 400TTTCAATTGA, ATTAAATCAA, CAGTTTAATA, CAAAAGAAGA, AGCTATTCGC, 450TTTTCCGGCC, AGAAACTAGT, CGAGGCAGGC, TGTGTTGAGC, CCGCTTATAT, 500CGAAGCAATG, ATTGAAAGAG, ACCAATTGCT, ATCTGCCCAT, ATGGGGAATT, 550TTATTGCCAT, TCCTCATGGA, ACAGAAGAAG, CCAAAAAATT, AGTGAAAAAA, 600TCAGGAATCT, GTGTAGTGCA, AGTCCCAGAG, GGCGTTAATT, TTGGCACCGA, 650AGAAGATGAA, AAAATTGCTA, CCGTATTATT, TGGGATTGCC, GGAGTCGGTG, 700AAGAACATTT, GCAATTAGTC, CAACAAATTG, CACTTTATTG, TAGTGATATG, 750GATAACGTGG, TGCAACTTGC, CGATGCATTA, AGTAAAGAAG, AAATAACAGA, 800, (2) SEQ, ID, the information of NO:3:, (i) sequence signature:
(A) length: 227 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Escherichia coli (xi) sequence description: the information of SEQ ID NO:3:GATCCGCCAT GGGTTGTTTT CCGATTGAGG ATTTTATAGA TGGTTTCTGG 50CGACCTGCAC AGGAGTACGG TGATTTTTAA TTATTGCAAT TGCACAAGAG 100TCAGTTCTCC CCCAAAGACA GCACCGGTAT CAATATAATG CAGGTTGCCA 150ATATCCACGC GATGGCGCAA AGGTGTATGA CCAAACCAGA AATGATCGGC 200CACCTGCATC GCCAGTTCGC GAGTCGG 227 (2) SEQ ID NO:4: (i) sequence signature:
(A) length: 278 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Escherichia coli (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GATCTAAATC AAATTAATTG GTTAAAGATA ACCACAGCGG GGCCGACATA 50AACTCTGACA AGAAGTTAAC AACCATATAA CCTGCACAGG ACGCGAACAT 100GTCTTCTCAT CCGTATGTCA CCCAGCAAAA TACCCCGCTG GCGGACGACA 150CCACTCTGAT GTCCACTACC GATCTCGCTT TCCAGCGTCA TATTGGGGCG 200CGCTACGTTG GGGCGTGGGC GTAATTGGTC AATCAGGCGC GGGGTCAGCG 250GATAAACATT CACCATTTTG TCGAGATC 278 (2 ) SEQ ID NO: 5 information: (i) sEQUENCE CHARACTERISTICS:
(A) length: 1596 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Escherichia coli, (xi) sequence description: SEQ, ID, NO:5:ATGGCTGACA, TTCTGCTGCT, CGATAATATC, GACTCTTTTA, CGTACAACCT, 50GGCAGATCAG, TTGCGCAGCA, ATGGGCATAA, CGTGGTGATT, TACCGCAACC, 100ATATACCGGC, GCAAACCTTA, ATTGAACGCT, TGGCGACCAT, GAGTAATCCG, 150GTGCTGATGC, TTTCTCCTGG, CCCCGGTGTG, CCGAGCGAAG, CCGGTTGTAT, 200GCCGGAACTC, CTCACCCGCT, TGCGTGGCAA, GCTGCCCATT, ATTGGCATTT, 250GCCTCGGACA, TCAGGCGATT, GTCGAAGCTT, ACGGGGGCTA, TGTCGGTCAG, 300GCGGGCGAAA, TTCTCCACGG, TAAAGCCTCC, AGCATTGAAC, ATGACGGTCA, 350GGCGATGTTT, GCCGGATTAA, CAAACCCGCT, GCCGGTGGCG, CGTTATCACT, 400CGCTGGTTGG, CAGTAACATT, CCGGCCGGTT, TAACCATCAA, CGCCCATTTT, 450AATGGCATGG, TGATGGCAGT, ACGTCACGAT, GCGGATCGCG, TTTGTGGATT, 500CCAGTTCCAT, CCGGAATCCA, TTCTCACCAC, CCAGGGCGCT, CGCCTGCTGG, 550AACAAACGCT, GGCCTGGGCG, CAGCATAAAC, TAGAGCCAGC, CAACACGCTG, 600CAACCGATTC, TGGAAAAACT, GTATCAGGCG, CAGACGCTTA, GCCAACAAGA, 650AAGCCACCAG, CTGTTTTCAG, CGGTGGTGCG, TGGCGAGCTG, AAGCCGGAAC, 700AACTGGCGGC, GGCGCTGGTG, AGCATGAAAA, TTCGCGGTGA, GCACCCGAAC, 750GAGATCGCCG, GGGCAGCAAC, CGCGCTACTG, GAAAACGCAG, CGCCGTTCCC, 800GCGCCCGGAT, TATCTGTTTG, CTGATATCGT, CGGTACTGGC, GGTGACGGCA, 850GCAACAGTAT, CAATATTTCT, ACCGCCAGTG, CGTTTGTCGC, CGCGGCCTGT, 900GGGCTGAAAG, TGGCGAAACA, CGGCAACCGT, AGCGTCTCCA, GTAAATCTGG, 950TTCGTCCGAT, CTGCTGGCGG, CGTTCGGTAT, TAATCTTGAT, ATGAACGCCG, 1000ATAAATCGCG, CCAGGCGCTG, GATGAGTTAG, GTGTATGTTT, CCTCTTTGCG, 1050CCGAAGTATC, ACACCGGATT, CCGCCACGCG, ATGCCGGTTC, GCCAGCAACT, 1100GAAAACCCGC, ACCCTGTTCA, ATGTGCTGGG, GCCATTGATT, AACCCGGCGC, 1150ATCCGCCGCT, GGCGTTAATT, GGTGTTTATA, GTCCGGAACT, GGTGCTGCCG, 1200ATTGCCGAAA, CCTTGCGCGT, GCTGGGGTAT, CAACGCGCGG, CGGTGGTGCA, 1250CAGCGGCGGG, ATGGATGAAG, TTTCATTACA, CGCGCCGACA, ATCGTTGCCG, 1300AACTGCATGA, CGGCGAAATT, AAAAGCTATC, AGCTCACCGC, AGAAGACTTT, 1350GGCCTGACAC, CCTACCACCA, GGAGCAACTG, GCAGGCGGAA, CACCGGAAGA, 1400AAACCGTGAC, ATTTTAACAC, GTTTGTTACA, AGGTAAAGGC, GACGCCGCCC, 1450ATGAAGCAGC, CGTCGCTGCG, AACGTCGCCA, TGTTAATGCG, CCTGCATGGC, 1500CATGAAGATC, TGCAAGCCAA, TGCGCAAACC, GTTCTTGAGG, TACTGCGCAG, 1550TGGTTCCGCT, TACGACAGAG, TCACCGCACT, GGCGGCACGA, GGGTAA, 1596, (2) SEQ, ID, the information of NO:6:, (i) sequence signature:
(A) length: 2703 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Escherichia coli, (xi) sequence description:, SEQ, ID, NO:6:GACGACTTAG, TTTTGACGGA, ATCAGCATAG, TTAATCACTT, CACTGTGGAA, 50AATGAGGAAA, TATTATTTTT, TTTGCGCTTC, GTAATTAATG, GTTATAAGGT, 100CGGCCAGAAA, CCTTTCTAAT, GCAAGCGATG, ACGTTTTTTT, ATGTGTCTGA, 150ATTTGCACTG, TGTCACAATT, CCAAATCTTT, ATTAACAACT, CACCTAAAAC, 200GACGCTGATC, CAGCGTGAAT, ACTGGTTTCC, CTTATGTTCA, TCAGATTCAT, 250TTAAGCAAGG, GTTTCTTCTT, CATTCCTGAT, GAAAGTGCCA, TCTAAAAAGA, 300TGATCTTAAT, AAATCTATTA, AGAATGAGAT, GGAGCACACT, GGATATTTTA, 350CTTATGAAAC, TGTTTCACTC, CTTTACTTAA, TTTATAGAGT, TACCTTCCGC, 400TTTTTGAAAA, TACGCAACGG, CCATTTTTTG, CACTTAGATA, CAGATTTTCT, 450GCGCTGTATT, GCATTGATTT, GATGCTAATC, CTGTGGTTTG, CACTAGCTTT, 500AAGTGGTTGA, GATCACATTT, CCTTGCTCAT, CCCCGCAACT, CCTCCCTGCC, 550TAATCCCCCG, CAGGATGAGG, AAGGTCAACA, TCGAGCCTGG, CAAACTAGCG, 600ATAACGTTGT, GTTGAAAATC, TAAGAAAAGT, GGAACTCCTA, TGTCACAACC, 650TATTTTTAAC, GATAAGCAAT, TTCAGGAAGC, GCTTTCACGT, CAGTGGCAGC, 700GTTATGGCTT, AAATTCTGCG, GCTGAAATGA, CTCCTCGCCA, GTGGTGGCTA, 750GCAGTGAGTG, AAGCACTGGC, CGAAATGCTG, CGTGCTCAGC, CATTCGCCAA, 800GCCGGTGGCG, AATCAGCGAC, ATGTTAACTA, CATCTCAATG, GAGTTTTTGA, 850TTGGTCGCCT, GACGGGCAAC, AACCTGTTGA, ATCTCGGCTG, GTATCAGGAT, 900GTACAGGATT, CGTTGAAGGC, TTATGACATC, AATCTGACGG, ACCTGCTGGA, 950AGAAGAGATC, GACCCGGCGC, TGGGTAACGG, TGGTCTGGGA, CGTCTGGCGG, 1000CGTGCTTCCT, CGACTCAATG, GCAACTGTCG, GTCAGTCTGC, GACGGGTTAC, 1050GGTCTGAACT, ATCAATATGG, TTTGTTCCGC, CAGTCTTTTG, TCGATGGCAA, 1100ACAGGTTGAA, GCGCCGGATG, ACTGGCATCG, CAGTAACTAC, CCGTGGTTCC, 1150GCCACAACGA, AGCACTGGAT, GTGCAGGTAG, GGATTGGCGG, TAAAGTGACG, 1200AAAGACGGAC, GCTGGGAGCC, GGAGTTTACC, ATTACCGGTC, AAGCGTGGGA, 1250TCTCCCCGTT, GTCGGCTATC, GTAATGGCGT, GGCGCAGCCG, CTGCGTCTGT, 1300GGCAGGCGAC, GCACGCGCAT, CCGTTTGATC, TGACTAAATT, TAACGACGGT, 1350GATTTCTTGC, GTGCCGAACA, GCAGGGCATC, AATGCGGAAA, AACTGACCAA, 1400AGTTCTCTAT, CCAAACGACA, ACCATACTGC, CGGTAAAAAG, CTGCGCCTGA, 1450TGCAGCAATA, CTTCCAGTGT, GCCTGTTCGG, TAGCGGATAT, TTTGCGTCGC, 1500CATCATCTGG, CGGGGCGTGA, ACTGCACGAA, CTGGCGGATT, ACTAAGTTAT, 1550TCAGCTGAAC, GATACCCACC, CAACTATCGC, GATTCCAGAA, CTGCTGCGCG, 1600TGCTGATCGA, TGAGCACCAG, ATGAGCTGGG, ATGACGCTTG, GGCCATTACC, 1650AGCAAAACTT, TCGCTTACAC, CAACCATACC, CTGATGCCAG, AAGCGCTGGA, 1700ACGCTGGGAT, GTGAAACTGG, TGAAAGGCTT, ACTGCCGCGC, CACATGCAGA, 1750TTATTAACGA, AATTAATACT, CGCTTTAAAA, CGCTGGTAGA, GAAAACCTGG, 1800CCGGGCGATG, AAAAAGTGTG, GGCCAAACTG, GCGGTGGTGC, ACGACAAACA, 1850AGTGCATATG, GCGAACCTGT, GTGTGGTTGG, CGGTTTCGCG, GTGAACGGTG, 1900TTGCGGCGCT, GCACTCGGAT, CTGGTGGTGA, AAGATCTGTT, CCCGGAATAT, 1950CACCAGCTAT, GGCCGAACAA, ATTCCATAAC, GTCACCAACG, GTATTACCCC, 2000ACGTCGCTGG, ATCAAACAGT, GCAACCCGGC, ACTGGCGGCT, CTGTTGGATA, 2050AATCACTGCA, AAAAGAGTGG, GCTAACGATC, TCGATCAGCT, GATCAATCTG, 2100GTTAAATTGG, CTGATGATGC, GAAATTCCGT, CAGCTTTATC, GCGTGATCAA, 2150GCAGGCGAAT, AAAGTCCGTC, TGGCGGAGTT, TGTGAAAGTT, CGTACCGGTA, 2200TTGACATCAA, TCCACAGGCG, ATTTTCGATA, TTCAGATCAA, ACGTTTGCAC, 2250GAGTACAAAC, GCCAGCACCT, GAATCTGCTG, CGTATTCTGG, CGTTGTACAA, 2300AGAAATTCGT, GAAAACCCGC, AGGCTGATCG, CGTACCGCGC, GTCTTCCTCT, 2350TCGGCGCGAA, AGCGGCACCG, GGCTACTACC, TGGCTAAGAA, TATTATCTTT, 2400GCGATCAACA, AAGTGGCTGA, CGTGATCAAC, AACGATCCGC, TGGTTGGCGA, 2450TAAGTTGAAG, GTGGTGTTCC, TGCCGGATTA, TTGCGTTTCG, GCGGCGGAAA, 2500AACTGATCCC, GGCGGCGGAT, ATCTCCGAAC, AAATTTCGAC, TGCAGGTAAA, 2550GAAGCTTCCG, GTACCGGCAA, TATGAAACTG, GCGCTCAATG, GTGCGCTTAC, 2600TGTCGGTACG, CTGGATGGGG, CGAACGTTGA, AATCGCCGAG, AAAGTCGGTG, 2650AAGAAAATAT, CTTTATTTTT, GGTCATACGG, TCAAACAAGT, GAAGGCAATC, 2700GAC, 2703, (2) SEQ, ID, the information of NO:7:, (i) sequence signature:
(A) length: 1391 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Escherichia coli, (xi) sequence description: SEQ, ID, NO:7:AGAGAAGCCT, GTCGGCACCG, TCTGGTTTGC, TTTTGCCACT, GCCCGCGGTG, 50AAGGCATTAC, CCGGCGGGAT, GCTTCAGCGG, CGACCGTGAT, GCGGTGCGTC, 100GTCAGGCTAC, TGCGTATGCA, TTGCAGACCT, TGTGGCAACA, ATTTCTACAA, 150AACACTTGAT, ACTGTATGAG, CATACAGTAT, AATTGCTTCA, ACAGAACATA, 200TTGACTATCC, GGTATTACCC, GGCATGACAG, GAGTAAAAAT, GGCTATCGAC, 250GAAAACAAAC, AGAAAGCGTT, GGCGGCAGCA, CTGGGCCAGA, TTGAGAAACA, 300ATTTGGTAAA, GGCTCCATCA, TGCGCCTGGG, TGAAGACCGT, TCCATGGATG, 350TGGAAACCAT, CTCTACCGGT, TCGCTTTCAC, TGGATATCGC, GCTTGGGGCA, 400GGTGGTCTGC, CGATGGGCCG, TATCGTCGAA, ATCTACGGAC, CGGAATCTTC, 450CGGTAAAACC, ACGCTGACGC, TGCAGGTGAT, CGCCGCAGCG, CAGCGTGAAG, 500GTAAAACCTG, TGCGTTTATC, GATGCTGAAC, ACGCGCTGGA, CCCAATCTAC, 550GCACGTAAAC, TGGGCGTCGA, TATCGACAAC, CTGCTGTGCT, CCCAGCCGGA, 600CACCGGCGAG, CAGGCACTGG, AAATCTGTGA, CGCCCTGGCG, CGTTCTGGCG, 650CAGTAGACGT, TATCGTCGTT, GACTCCGTGG, CGGCACTGAC, GCCGAAAGCG, 700GAAATCGAAG, GCGAAATCGG, CGACTCTCAC, ATGGGCCTTG, CGGCACGTAT, 750GATGAGCCAG, GCGATGCGTA, AGCTGGCGGG, TAACCTGAAG, CAGTCCAACA, 800CGCTGCTGAT, CTTCATCAAC, CAGATCCGTA, TGAAAATTGG, TGTGATGTTC, 850GGTAACCCGG, AAACCACTAC, CGGTGGTAAC, GCGCTGAAAT, TCTACGCCTC, 900TGTTCGTCTC, GACATCCGTC, GTATCGGCGC, GGTGAAAGAG, GGCGAAAACG, 950TGGTGGGTAG, CGAAACCCGC, GTGAAAGTGG, TGAAGAACAA, AATCGCTGCG, 1000CCGTTTAAAC, AGGCTGAATT, CCAGATCCTC, TACGGCGAAG, GTATCAACTT, 1050CTACGGCGAA, CTGGTTGACC, TGGGCGTAAA, AGAGAAGCTG, ATCGAGAAAG, 1100CAGGCGCGTG, GTACAGCTAC, AAAGGTGAGA, AGATCGGTCA, GGGTAAAGCG, 1150AATGCGACTG, CCTGGCTGAA, AGATAACCCG, GAAACCGCGA, AAGAGATCGA, 1200GAAGAAAGTA, CGTGAGTTGC, TGCTGAGCAA, CCCGAACTCA, ACGCCGGATT, 1250TCTCTGTAGA, TGATAGCGAA, GGCGTAGCAG, AAACTAACGA, AGATTTTTAA, 1300TCGTCTTGTT, TGATACACAA, GGGTCGCATC, TGCGGCCCTT, TTGCTTTTTT, 1350AAGTTGTAAG, GATATGCCAT, GACAGAATCA, ACATCCCGTC, G, 1391, (2) SEQ, ID, the information of NO:8:, (i) sequence signature:
(A) length: 238 base pairs
(B) type: nucleic acid
(C) chain: chain
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Friedlanders bacillus (xi) sequence description: the information of SEQ ID NO:8:TCGCCAGGAA GGCGGCATTC GGCTGGGTCA GAGTGACCTG CAGCGTGGTG 50TCGTTCAGCG CTTTCACCCC CAACGTCTCG GGTCCCTTTT GCCCGAGGGC 100AATCTCGCGG GCGTTGGCGA TATGCATATT GCCAGGGTAG CTCGCGTAGG 150GGGAGGCTGT TGCCGGCGAG ACCAGCCGTT GCCAGCTCCA GACGATATCC 200TGCGCTGTAA TGGCCGTGCC GTCAGACCAG GTCAGACC 238 (2) SEQ ID NO:9: (i) sequence signature:
(A) length: 385 base pairs
(B) type: nucleic acid
(C) chain: chain
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Klebsiella pneumoniae (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CAGCGTAATG CGCCGCGGCA TAACGGCGCC ACTATCGACA GTCAGTTCGT 50CAGCCTGCAG CCTGGGCTGA ATCTGGGACC ATGGCGCCTG CCGAACTACA 100GCACCTATAG CCACAGCGAT AACAACAGCC GCTGGGAGTC GGTTTACTCC 150TATCTTGCCC GCGATATTCA CACCCTACGC AGCCAGCTGG TGGTCGGTAA 200TACGTATACC TCTTCCGGCA TTTTCGACAG TTTGAGTTTT ACCGGTCTGC 250AGCTCAGTTC GACAAAGAGA TGCTGCCGGA TAGCCTGCAT GCTTTGCGCC 300GACGATTCGA GGGATCGCGC GCACCACCGC GGAGGTCTCG GTTTATCAGA 350ATGGTTACAG CATTTATAAA ACCACCGTCG CTACC 385 (2) SEQ ID NO: 10 information: (i) sEQUENCE CHARACTERISTICS:
(A) length: 462 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Friedlanders bacillus, (xi) sequence description: SEQ, ID, NO:10:CTCTATATTC, AGGACGAACA, TATCTGGACC, TCTGGCGGGG, TCAGTTCCGG, 50CTTTGATCGC, CCTGCACCCG, CAGCGGGTGA, TCGCCCCTCA, TCTGCTACTG, 100CGGCGCTGCA, ACAGGCGACG, ATCGATGACG, TTATTCCTGG, CCAGCAAACA, 150GCAGACCAAT, TAAGGTCTGA, TAGTGGCTCT, CTTCCTCCGG, CGCGCGACGG, 200TCCAGGCGGC, TCAACAGTTT, GGTGCATAGC, GCTTTGCGGT, TGAGATGACG, 250CCCTTCGTTA, AGAATATCCA, TCACGATCTC, CGTCCATGGA, GAGTAGCGTT, 300TATTCCAGAA, TAGGGTTTTT, CAGGATCTCA, TGGATCTGCG, CCTGCTTATC, 350GCTATTTTGT, AACCAGATCG, CATAAAGTGG, ACGGGATAAC, GTAGCGCTGT, 400CCATGACCGT, ATGTAACCCA, TGCTTCTCTT, TCGCCCAGCG, AGCAGGTAGC, 450CAACAGCAGC, CG, 462, (2) SEQ, ID, the information of NO:11:, (i) sequence signature:
(A) length: 730 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Friedlanders bacillus, (xi) sequence description: SEQ, ID, NO:11:GCTGACCGCT, AAACTGGGTT, ACCCGATCAC, TGACGATCTG, GACATCTACA, 50CCCGTCTGGG, CGGCATGGTT, TGGCGCGCTG, ACTCCAAAGG, CAACTACGCT, 100TCAACCGGCG, TTTCCCGTAG, CGAACACGAC, ACTGGCGTTT, CCCCAGTATT, 150TGCTGGCGGC, GTAGAGTGGG, CTGTTACTCG, TGACATCGCT, ACCCGTCTGG, 200AATACCAGTG, GGTTAACAAC, ATCGGCGACG, CGGGCACTGT, GGGTACCCGT, 250CCTGATAACG, GCATGCTGAG, CCTGGGCGTT, TCCTACCGCT, TCGGTCAGGA, 300AGATGCTGCA, CCGGTTGTTG, CTCCGGCTCC, GGCTCCGGCT, CCGGAAGTGG, 350CTACCAAGCA, CTTCACCCTG, AAGTCTGACG, TTCTGTTCAA, CTTCAACAAA, 400GCTACCCTGA, AACCGGAAGG, TCAGCAGGCT, CTGGATCAGC, TGTACACTCA, 450GCTGAGCAAC, ATGGATCCGA, AAGACGGTTC, CGCTGTTGTT, CTGGGCTACA, 500CCGACCGCAT, CGGTTCCGAA, GCTTACAACC, AGCAGCTGTC, TGAGAAACGT, 550GCTCAGTCCG, TTGTTGACTA, CCTGGTTGCT, AAAGGCATCC, CGGCTGGCAA, 600AATCTCCGCT, CGCGGCATGG, GTGAATCCAA, CCCGGTTACT, GGCAACACCT, 650GTGACAACGT, GAAAGCTCGC, GCTGCCCTGA, TCGATTGCCT, GGCTCCGGAT, 700CGTCGTGTAG, AGATCGAAGT, TAAAGGTATC, 730, (2) SEQ, ID, the information of NO:12:, (i) sequence signature:
(A) length: 225 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:1 2:CGCTACTGTT TAAATCTCAT TTGAAACATC GCAAAGTCAG TGAACCACAT 50ATTCGAGGAT GGCATGCACT AGAAAATATT AATAAGATTT TAGCGAAACC 100TAATCAGCGC AATATCGCTT AATTATTTTA GGTATGTTCT CTTCTATCCT 150ACAGTCACGA GGCAGTGTCG AACTTGATCC TCATTTTATT AATCACATGA 200CCAATGGTAT AAGCGTCGTC ACATA 225 (2) SEQ ID NO:13: (i) sequence signature:
(A) length: 402 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Proteus mirabilis (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: ACATTTTAAA TAGGAAGCCA CCTGATAACA TCCCCGCAGT TGGATCATCA 50GATTTATAGC GGCATTTGGT ATCCGCTAGA TAAAAGCAGT CCAACGATCC 100CGCCAATTGT TAGATGAAAT TGGACTATTC TTTTTATTTG CTCCGCTTTA 150TCACAGTGGT TTTCGCTTTG CCGCCCCTGT GCGCCAACAG CTAAGAACAC 200GCACGCTCTT TAATGTGTTA GGCCCATTAA TTAATCCAGC GCGTTCCGCC 250TTTAGCATTA ATTGGTGTTT ATAGTCCTGA ATTATTAATG CCTATTGCAG 300ATACCTTAAA TGTCTTGGGC TACAAACGTG CGGCAGTGGT CCATAGTGGT 350GGAATGGATG AAGTGTCATT ACATGCTCCC ACACAAGTGG CTGAGTTACA 400CA 402 (2) SEQ ID NO: 14 information: (i) sEQUENCE CHARACTERISTICS:
(A) length: 157 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEO ID NO:14:CTGAAACGCA TTTATGCGGG AGTCAGTGAA ATCATCACTC AATTTTCACC 50CGATGTATTT TCTGTTGAAC AAGTCTTTAT GGCAAAAAAT GCAGACTCAG 100CATTAAAATT AGGCCAAGCA AGAGGTGTGG CGATTTTAGC GGCAGTCAAT 150AATGATC 157 (2) SEQ ID NO:15: (i) sequence signature:
(A) length: 1348 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis, (xi) sequence description: SEQ, ID, NO:15:TTTCTCTTTA, AAATCAATTC, TTAAAGAAAT, TATTAATAAT, TAACTTGATA, 50CTGTATGATT, ATACAGTATA, ATGAGTTTCA, ACAAGCAAAA, TCATATACGT, 100TTTAATGGTA, GTGACCCATC, TTTATGCTTC, ACTGCCCAGA, GGGAGATAAC, 150ATGGCTATTG, ATGAAAACAA, ACAAAAAGCA, TTGGCCGCAG, CACTTGGTCA, 200AATTGAAAAG, CAATTTGGTA, AAGGTTCTAT, CATGCGTCTG, GGCGAAGACC, 250GTTCCATGAA, CGTAGAAACT, ATCTCTACAG, GATCTTTATC, ATTAGACGTT, 300GCTTTAGGTG, CAGGTGGATT, GCCACGTGGC, CGTATTGTTG, AAATCTATGG, 350CCCTGAATCT, TCTGGTAAAA, CAACCTTGAC, TCTACAAGTT, ATTGCCTCTG, 400CTCAGCGTGA, AGGAAAAATT, TGTGCATTTA, TTGATGCTGA, ACATGCATTA, 450GACCCAATTT, ATGCTCAAAA, GCTAGGTGTC, GATATCGATA, ATCTACTCTG, 500CTCTCAACCT, GACACAGGTG, AACAAGCTCT, GGAAATTTGT, GATGCATTAT, 550CTCGCTCTGG, TGCGGTCGAT, GTTATTGTCG, TGGACTCCGT, GGCAGCATTA, 600ACACCAAAAG, CTGAAATTGA, AGGTGAAATT, GGTGATTCAC, ACGTTGGTTT, 650AGCCGCACGT, ATGATGAGCC, AAGCTATGCG, TAAACTAGCG, GGTAACCTTA, 700AAAACTCTAA, TACACTGCTG, ATTTTCATTA, ACCAAATTCG, TATGAAAATC, 750GGTGTTATGT, TTGGTAACCC, AGAAACCACG, ACCGGTGGTA, ATGCGCTTAA, 800ATTCTATGCT, TCTGTTCGTT, TAGACATTCG, TCGCATTGGC, TCTGTCAAAA, 850ATGGTGATGA, AGTCATTGGT, AGTGAGACTC, GCGTTAAAGT, TGTTAAAAAT, 900AAAGTGGCTG, CACCGTTTAA, ACAAGCTGAA, TTCCAAATTA, TGTACGGTGA, 950AGGTATTAAT, ACCTATGGCG, AACTGATTGA, TTTAGGTGTT, AAACATAAGT, 1000TAGTAGAGAA, AGCAGGTGCT, TGGTATAGCT, ACAATGGCGA, AAAAATTGGT, 1050CAAGGTAAAG, CTAACGCAAC, CAATTACTTA, AAAGAACATC, CTGAAATGTA, 1100CAATGAGTTA, AACACTAAAT, TGCGTGAAAT, GTTGTTAAAT, CATGCTGGTG, 1150AATTCACAAG, TGCTGCGGAT, TTTGCAGGTG, AAGAGTCAGA, CAGTGATGCT, 1200GACGACACAA, AAGAGTAATT, AGCTGGTTGT, CATGCTGTTT, GTGTGAAAAT, 1250AGACCTTAAA, TCATTGGCTA, TTATCACGAC, AGCATCCCAT, AGAATAACTT, 1300GTTTGTATAA, ATTTT, (2) SEQ, ID, the information of NO:16:, (i) sequence signature:
(A) length: 2167 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: pseudomonas aeruginosa, (xi) sequence description: SEQ, ID, NO:16:GGTACCGCTG, GCCGAGCATC, TGCTCGATCA, CCACCAGCCG, GGCGACGGGA, 50ACTGCACGAT, CTACCTGGCG, AGCCTGGAGC, ACGAGCGGGT, TCGCTTCGTA, 100CGGCGCTGAG, CGACAGTCAC, AGGAGAGGAA, ACGGATGGGA, TCGCACCAGG, 150AGCGGCCGCT, GATCGGCCTG, CTGTTCTCCG, AAACCGGCGT, CACCGCCGAT, 200ATCGAGCGCT, CGCACGCGTA, TGGCGCATTG, CTCGCGGTCG, AGCAACTGAA, 250CCGCGAGGGC, GGCGTCGGCG, GTCGCCCGAT, CGAAACGCTG, TCCCAGGACC, 300CCGGCGGCGA, CCCGGACCGC, TATCGGCTGT, GCGCCGAGGA, CTTCATTCGC, 350AACCGGGGGG, TACGGTTCCT, CGTGGGCTGC, TACATGTCGC, ACACGCGCAA, 400GGCGGTGATG, CCGGTGGTCG, AGCGCGCCGA, CGCGCTGCTC, TGCTACCCGA, 450CCCCCTACGA, GGGCTTCGAG, TATTCGCCGA, ACATCGTCTA, CGGCGGTCCG, 500GCGCCGAACC, AGAACAGTGC, GCCGCTGGCG, GCGTACCTGA, TTCGCCACTA, 550CGGCGAGCGG, GTGGTGTTCA, TCGGCTCGGA, CTACATCTAT, CCGCGGGAAA, 600GCAACCATGT, GATGCGCCAC, CTGTATCGCC, AGCACGGCGG, CACGGTGCTC, 650GAGGAAATCT, ACATTCCGCT, GTATCCCTCC, GACGACGACT, TGCAGCGCGC, 700CGTCGAGCGC, ATCTACCAGG, CGCGCGCCGA, CGTGGTCTTC, TCCACCGTGG, 750TGGGCACCGG, CACCGCCGAG, CTGTATCGCG, CCATCGCCCG, TCGCTACGGC, 800GACGGCAGGC, GGCCGCCGAT, CGCCAGCCTG, ACCACCAGCG, AGGCGGAGGT, 850GGCGAAGATG, GAGAGTGACG, TGGCAGAGGG, GCAGGTGGTG, GTCGCGCCTT, 900ACTTCTCCAG, CATCGATACG, CCCGCCAGCC, GGGCCTTCGT, CCAGGCCTGC, 950CATGGTTTCT, TCCCGGAGAA, CGCGACCATC, ACCGCCTGGG, CCGAGGCGGC, 1000CTACTGGCAG, ACCTTGTTGC, TCGGCCGCGC, CGCGCAGGCC, GCAGGCAACT, 1050GGCGGGTGGA, AGACGTGCAG, CGGCACCTGT, ACGACATCGA, CATCGACGCG, 1100CCACAGGGGC, CGGTCCGGGT, GGAGCGCCAG, AACAACCACA, GCCGCCTGTC, 1150TTCGCGCATC, GCGGAAATCG, ATGCGCGCGG, CGTGTTCCAG, GTCCGCTGGC, 1200AGTCGCCCGA, ACCGATTCGC, CCCGACCCTT, ATGTCGTCGT, GCATAACCTC, 1250GACGACTGGT, CCGCCAGCAT, GGGCGGGGGA, CCGCTCCCAT, GAGCGCCAAC, 1300TCGCTGCTCG, GCAGCCTGCG, CGAGTTGCAG, GTGCTGGTCC, TCAACCCGCC, 1350GGGGGAGGTC, AGCGACGCCC, TGGTCTTGCA, GCTGATCCGC, ATCGGTTGTT, 1400CGGTGCGCCA, GTGCTGGCCG, CCGCCGGAAG, CCTTCGACGT, GCCGGTGGAC, 1450GTGGTCTTCA, CCAGCATTTT, CCAGAATGGC, CACCACGACG, AGATCGCTGC, 1500GCTGCTCGCC, GCCGGGACTC, CGCGCACTAC, CCTGGTGGCG, CTGGTGGAGT, 1550ACGAAAGCCC, CGCGGTGCTC, TCGCAGATCA, TCGAGCTGGA, GTGCCACGGC, 1600GTGATCACCC, AGCCGCTCGA, TGCCCACCGG, GTGCTGCCTG, TGCTGGTATC, 1650GGCGCGGCGC, ATCAGCGAGG, AAATGGCGAA, GCTGAAGCAG, AAGACCGAGC, 1700AGCTCCAGGA, CCGCATCGCC, GGCCAGGCCC, GGATCAACCA, GGCCAAGGTG, 1750TTGCTGATGC, AGCGCCATGG, CTGGGACGAG, CGCGAGGCGC, ACCAGCACCT, 1800GTCGCGGGAA, GCGATGAAGC, GGCGCGAGCC, GATCCTGAAG, ATCGCTCAGG, 1850AGTTGCTGGG, AAACGAGCCG, TCCGCCTGAG, CGATCCGGGC, CGACCAGAAC, 1900AATAACAAGA, GGGGTATCGT, CATCATGCTG, GGACTGGTTC, TGCTGTACGT, 1950TGGCGCGGTG, CTGTTTCTCA, ATGCCGTCTG, GTTGCTGGGC, AAGATCAGCG, 2000GTCGGGAGGT, GGCGGTGATC, AACTTCCTGG, TCGGCGTGCT, GAGCGCCTGC, 2050GTCGCGTTCT, ACCTGATCTT, TTCCGCAGCA, GCCGGGCAGG, GCTCGCTGAA, 2100GGCCGGAGCG, CTGACCCTGC, TATTCGCTTT, TACCTATCTG, TGGGTGGCCG, 2150CCAACCAGTT, CCTCGAG, 2167, (2) SEQ, ID, the information of NO:17:, (i) sequence signature:
(A) length: 1872 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: pseudomonas aeruginosa, (xi) sequence description: SEQ, ID, NO:17:GAATTCCCGG, GAGTTCCCGA, CGCAGCCACC, CCCAAAACAC, TGCTAAGGGA, 50GCGCCTCGCA, GGGCTCCTGA, GGAGATAGAC, CATGCCATTT, GGCAAGCCAC, 100TGGTGGGCAC, CTTGCTCGCC, TCGCTGACGC, TGCTGGGCCT, GGCCACCGCT, 150CACGCCAAGG, ACGACATGAA, AGCCGCCGAG, CAATACCAGG, GTGCCGCTTC, 200CGCCGTCGAT, CCCGCTCACG, TGGTGCGCAC, CAACGGCGCT, CCCGACATGA, 250GTGAAAGCGA, GTTCAACGAG, GCCAAGCAGA, TCTACTTCCA, ACGCTGCGCC, 300GGTTGCCACG, GCGTCCTGCG, CAAGGGCGCC, ACCGGCAAGC, CGCTGACCCC, 350GGACATCACC, CAGCAACGCG, GCCAGCAATA, CCTGGAAGCG, CTGATCACCT, 400ACGGCACCCC, GCTGGGCATG, CCGAACTGGG, GCAGCTCCGG, CGAGCTGAGC, 450AAGGAACAGA, TCACCCTGAT, GGCCAAGTAC, ATCCAGCACA, CCCCGCCGCA, 500ACCGCCGGAG, TGGGGCATGC, CGGAGATGCG, CGAATCGTGG, AAGGTGCTGG, 550TGAAGCCGGA, GGACCGGCCG, AAGAAACAGC, TCAACGACCT, CGACCTGCCC, 600AACCTGTTCT, CGGTGACCCT, GCGCGACGCC, GGGCAGATCG, CCCTGGTCGA, 650CGGCGACAGC, AAAAAGATCG, TCAAGGTCAT, CGATACCGGC, TATGCCGTGC, 700ATATCTCGCG, GATGTCCGCT, TCCGGCCGCT, ACCTGCTGGT, GATCGGCCGC, 750GACGCGCGGA, TCGACATGAT, CGACCTGTGG, GCCAAGGAGC, CGACCAAGGT, 800CGCCGAGATC, AAGATCGGCA, TCGAGGCGCG, CTCGGTGGAA, AGCTCCAAGT, 850TCAAGGGCTA, CGAGGACCGC, TACACCATCG, CCGGCGCCTA, CTGGCCGCCG, 900CAGTTCGCGA, TCATGGACGG, CGAGACCCTG, GAACCGAAGC, AGATCGTCTC, 950CACCCGCGGC, ATGACCGTAG, ACACCCAGAC, CTACCACCCG, GAACCGCGCG, 1000TGGCGGCGAT, CATCGCCTCC, CACGAGCACC, CCGAGTTCAT, CGTCAACGTG, 1050AAGGAGACCG, GCAAGGTCCT, GCTGGTCAAC, TACAAGGATA, TCGACAACCT, 1100CACCGTCACC, AGCATCGGTG, CGGCGCCGTT, CCTCCACGAC, GGCGGCTGGG, 1150ACAGCAGCCA, CCGCTACTTC, ATGACCGCCG, CCAACAACTC, CAACAAGGTT, 1200GCCGTGATCG, ACTCCAAGGA, CCGTCGCCTG, TCGGCCCTGG, TCGACGTCGG, 1250CAAGACCCCG, CACCCGGGGC, GTGGCGCCAA, CTTCGTGCAT, CCCAAGTACG, 1300GCCCGGTGTG, GAGCACCAGC, CACCTGGGCG, ACGGCAGCAT, CTCGCTGATC, 1350GGCACCGATC, CGAAGAACCA, TCCGCAGTAC, GCCTGGAAGA, AAGTCGCCGA, 1400ACTACAGGGC, CAGGGCGGCG, GCTCGCTGTT, CATCAAGACC, CATCCGAAGT, 1450CCTCGCACCT, CTACGTCGAC, ACCACCTTCA, ACCCCGACGC, CAGGATCAGC, 1500CAGAGCGTCG, CGGTGTTCGA, CCTGAAGAAC, CTCGACGCCA, AGTACCAGGT, 1550GCTGCCGATC, GCCGAATGGG, CCGATCTCGG, CGAAGGCGCC, AAGCGGGTGG, 1600TGCAGCCCGA, GTACAACAAG, CGCGGCGATG, AAGTCTGGTT, CTCGGTGTGG, 1650AACGGCAAGA, ACGACAGCTC, CGCGCTGGTG, GTGGTGGACG, ACAAGACCCT, 1700GAAGCTCAAG, GCCGTGGTCA, AGGACCCGCG, GCTGATCACC, CCGACCGGTA, 1750AGTTCAACGT, CTACAACACC, CAGCACGACG, TGTACTGAGA, CCCGCGTGCG, 1800GGGCACGCCC, CGCACGCTCC, CCCCTACGAG, GAACCGTGAT, GAAACCGTAC, 1850GCACTGCTTT, CGCTGCTCGC, CA, 1872, (2) SEQ, ID, the information of NO:18:, (i) sequence signature:
(A) length: 3541 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: pseudomonas aeruginosa, (xi) sequence description: SEQ, ID, NO:18:TCGAGACGGG, AAGCCACTCT, CTACGAGAAG, ACAGAAGCCC, CTCACAGAGG, 50CCTCTGTCTA, CGCCTACTAA, AGCTCGGCTT, ATTCATATGT, ATTTATATTC, 100TTTCAATAGA, TCACTCAGCG, CTATTTTAAG, TTCACCCTCT, GTAAGTTCAC, 150CTGGGCGCTC, TTTCTTTCCT, TCGGTAAAGC, TGTCGGCCAG, ACCAAACATT, 200AAACTCAAGC, ATCTCCCAAG, CGATGCATCA, TCTTGGGCCA, GCATCCCTGA, 250ATCGCGCGTC, GGACCTCCAA, GTCTTAAAAA, ATTCTTCGCT, GAAGGTTTTC, 300CCATCAATCG, ATGAGGCTAA, TAGCTTCTTT, GCAATATCTA, TCATTTCCAT, 350GCTCACCTTA, AAGCACCTCA, TTTTTCATGT, AAAAATTGTA, TTGATCCGTG, 400CCAGACTCAA, TCCTCCACCC, AGAAACAAAC, ATCCCATCCT, CTCCAATGAT, 450AACAACAATA, TTAGTCCTGG, CATTGTAATG, TACTTTTGAG, TTTACTTCGG, 500AGTGGTAAGT, CCCTTTTTCT, ACGGTTGCAG, GATCAGCAAG, GTGCTCAAGA, 550ATTTTATCCC, TAAACTCTGC, AAGCGTTCCA, TTGTTGGCGC, TTTTTTCACC, 600CAGCCCAAAA, TCATATTTGT, GGCTATCAAA, TTTTTTCTGT, AGTTGCCTCC, 650GTGTGAAGAT, ACCACTATCA, AGAGGACTAC, TGAGCATTAC, ATAAACAGGT, 700TTGACTCCAG, AATCCGCCGG, GAAAATCACG, ATCAGATCGT, TTAGGTCCAG, 750TAGCATTCCC, GGATAGGACT, CCGGGCCGGT, CTTCAACGGT, GTGAGGGCCG, 800CTCCCTCATA, TACCGGCACC, GGCTTCGGTA, TGACCGGAGT, GGTACTCGAA, 850GGGTTCTGGT, TTCCTGGAGG, ACTCGCCGGC, GTCCAAGTCA, GGATCAGTGG, 900CGGCGCTTCT, GCGACCGTAG, AGGGAACCGT, AACCTCGTAC, AGTCCTGTTG, 950CGGCGTTATA, GGCCCCATCC, GGACCGGAAC, GCTTTCGGAA, CGCTCACACC, 1000ATCGGTCTGA, CCACCGAAAG, GTCGTCGTGT, TGCCTCGCGC, CTCGTTGGTC, 1050AGGCGCATCG, GCAGATCGAC, GGTACCGCTG, GCTTTTGCAA, CCGCGTTCAG, 1100GTTTACGCTT, GGGGGAAGCC, CCAATTTAGC, GGCATCCATG, CCCAGGGCGT, 1150AACGAACGCT, ATCGGGCGTT, TGGTCCTGCC, ATTGCTCGGC, AGTCCGGGAG, 1200AGTAGGTCAG, ACTGGCAAGC, CACGGCCATC, ACCGAGGTGC, TGAAGCCAGG, 1250ACCGCCAGGA, CGGCAATCGC, ATCGGAGATC, GCTTGAGCAA, GGGATGCGGC, 1300GCCTGTGCGA, CCTGGATCAG, ACCCCGCTGC, GGCGGTGGCG, CACCCGCTGC, 1350CATTGGCTGG, CATGGCATAA, GTATTGGCAG, CCCTGATCGC, CGCTTGACGA, 1400GCGATTTCCT, TGCGCCTTGC, CGTTTCGGCG, TTCAGCTTGT, CCAGCCGTGC, 1450TTGCAGGCTG, GCGATTTCAT, CCACTAGGTA, GGACATCGGC, GTTGTAGGTT, 1500GCCTTTTGTT, TCTCCAGTGC, ATTGGGTGCC, TTGGCAATCA, AGGCATTGTT, 1550TGCAGTCTGC, AATTCTTCTT, ATTGCGATCG, CCTGCGTAAG, GAGTTGAGTA, 1600GCGCGTTCAA, GCCACTGCTC, TGGCGTTGGA, TTGGTCAGTT, GAGGCAAAGC, 1650ATTCCCAGCC, TGGTCAAGCT, CGGACTGCAC, TTTTTTCTCG, ACATTTGCCT, 1700TCCTGGCCTT, GTAGTCCGCC, TCCACCTCAG, CAGCGGCTCG, CTGGGCTTCT, 1750GCTTCCAATG, ACCGGGCTTT, ATTCTCCAGC, TCTTGAGACG, TTTGTTTCAA, 1800GATAGCGATT, TGCGCCTTAT, AGATATCGGC, GCTGTACGCT, TTGGCCAGCT, 1850CACTCATATG, GCGATCCAGG, AACTCTCCAT, AGAATTTTCG, GCTGGCCAGC, 1900AACTGACTCT, GGTACATCGA, CTCTGACTTC, TGAGGAAAGT, CTGAAGCCGT, 1950ATAAAGATTG, GCCGGGCGAT, CCTCAATGAC, CTTTAGCGAT, TTTGCTTTGG, 2000CATCCATGAG, TGCATCAACG, ATACTCTTTT, CATCGCGGAT, GTCATTGGCA, 2050CTGACCGCTT, TACCTGGCAA, CCCCGCTTCA, CTCTTGAGTT, CATCAACCTC, 2100CTTCAGGGTT, TCATTTTTCA, GGTTTTTCTT, GAGTTCTGAA, TGGGACTTAT, 2150CAAGCGTACT, TCTTAGCTTC, CTGTACTCCT, GCATTCCAGT, ACCGACATAC, 2200GGACTTGGTC, CTGGTGGGAC, AAATGGTGGA, GTACCGTAGC, TTGATCGAGC, 2250AGGAATATAC, TGGATTATGT, CACGCCCACC, ACCCTGCACA, TGTGTAATAA, 2300CCATCGAACC, AGGTTCGTAA, TCATTGACAG, CCATAGATCG, CCCCTACATT, 2350AATTTGAAAG, TGTAATGTAT, TGAGCGACTC, CCACCTAGAG, AACCCTCTCC, 2400CAGTCAATAA, GCCCCAATGC, ATCGGCAATA, CACTGCAATC, AACTTCAATA, 2450TCCCGTGTTT, AGATGATCCA, GAAGGTGCGC, TCTCTCGCCT, CTTATAATCG, 2500CGCCTGCGTC, AAACGGTCAT, TTCCTTAACG, CACACCTCAT, CTACCCCGGC, 2550CAGTCACGGA, AGCCGCATAC, CTTCGGTTCA, TTAACGAACT, CCCACTTTCA, 2600AAATTCATCC, ATGCCGCCCC, TTCGCGAGCT, TCCGGACAAA, GCCACGCTGA, 2650TTGCGAGCCC, AGCGTTTTTG, ATTGCAAGCC, GCTGCAGCTG, GTCAGGCCGT, 2700TTCCGCAACG, CTTGAAGTCC, TGGCCGATAT, ACCGGCAGGG, CCAGCCATCG, 2750TTCGACGAAT, AAAGCCACCT, CAGCCATGAT, GCCCTTTCCA, TCCCCAGCGG, 2800AACCCCGACA, TGGACGCCAA, AGCCCTGCTC, CTCGGCAGCC, TCTGCCTGGC, 2850CGCCCCATTC, GCCGACGCGG, CGACGCTCGA, CAATGCTCTC, TCCGCCTGCC, 2900TCGCCGCCCG, GCTCGGTGCA, CCGCACACGG, CGGAGGGCCA, GTTGCACCTG, 2950CCACTCACCC, TTGAGGCCCG, GCGCTCCACC, GGCGAATGCG, GCTGTACCTC, 3000GGCGCTGGTG, CGATATCGGC, TGCTGGCCAG, GGGCGCCAGC, GCCGACAGCC, 3050TCGTGCTTCA, AGAGGGCTGC, TCGATAGTCG, CCAGGACACG, CCGCGCACGC, 3100TGACCCTGGC, GGCGGACGCC, GGCTTGGCGA, GCGGCCGCGA, ACTGGTCGTC, 3150ACCCTGGGTT, GTCAGGCGCC, TGACTGACAG, GCCGGGCTGC, CACCACCAGG, 3200CCGAGATGGA, CGCCCTGCAT, GTATCCTCCG, ATCGGCAAGC, CTCCCGTTCG, 3250CACATTCACC, ACTCTGCAAT, CCAGTTCATA, AATCCCATAA, AAGCCCTCTT, 3300CCGCTCCCCG, CCAGCCTCCC, CGCATCCCGC, ACCCTAGACG, CCCCGCCGCT, 3350CTCCGCCGGC, TCGCCCGACA, AGAAAAACCA, ACCGCTCGAT, CAGCCTCATC, 3400CTTCACCCAT, CACAGGAGCC, ATCGCGATGC, ACCTGATACC, CCATTGGATC, 3450C, 3451, (2) SEQ, ID, the information of NO:19:, (i) sequence signature:
(A) length: 744 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: pseudomonas aeruginosa, (xi) sequence description: SEQ, ID, NO:19:GGGTTCAGCA, AGCGTTCAGG, GGCGGTTCAG, TACCCTGTCC, GTACTCTGCA, 50AGCCGTGAAC, GACACGACTC, TCGCAGAACG, GAGAAACACC, ATGAAAGCAC, 100TCAAGACTCT, CTTCATCGCC, ACCGCCCTGC, TGGGTTCCGC, CGCCGGCGTC, 150CAGGCCGCCG, ACAACTTCGT, CGGCCTGACC, TGGGGCGAGA, CCAGCAACAA, 200CATCCAGAAA, TCCAAGTCGC, TGAACCGCAA, CCTGAACAGC, CCGAACCTCG, 250ACAAGGTGAT, CGACAACACC, GGCACCTGGG, GCATCCGCGC, CGGCCAGCAG, 300TTCGAGCAGG, GCCGCTACTA, CGCGACCTAC, GAGAACATCT, CCGACACCAG, 350CAGCGGCAAC, AAGCTGCGCC, AGCAGAACCT, GCTCGGCAGC, TACGACGCCT, 400TCCTGCCGAT, CGGCGACAAC, AACACCAAGC, TGTTCGGCGG, TGCCACCCTC, 450GGCCTGGTCA, AGCTGGAACA, GGACGGCAAG, GGCTTCAAGC, GCGACAGCGA, 500TGTCGGCTAC, GCTGCCGGGC, TGCAGGCCGG, TATCCTGCAG, GAGCTGAGCA, 550AGAATGCCTC, GATCGAAGGC, GGCTATCGTT, ACCTGCGCAC, CAACGCCAGC, 600ACCGAGATGA, CCCCGCATGG, CGGCAACAAG, CTGGGCTCCC, TGGACCTGCA, 650CAGCAGCTCG, CAATTCTACC, TGGGCGCCAA, CTACAAGTTC, TAAATGACCG, 700CGCAGCGCCC, GCGAGGGCAT, GCTTCGATGG, CCGGGCCGGA, AGGT, 744, (2) SEQ, ID, the information of NO:20:, (i) sequence signature:
(A) length: 2760 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: pseudomonas aeruginosa, (xi) sequence description: SEQ, ID, NO:20:CTGCAGCTGG, TCAGGCCGTT, TCCGCAACGC, TTGAAGTCCT, GGCCGATATA, 50CCGGCAGGGC, CAGCCATCGT, TCGACGAATA, AAGCCACCTC, AGCCATGATG, 100CCCTTTCCAT, CCCCAGCGGA, ACCCCGACAT, GGACGCCAAA, GCCCTGCTCC, 150TCGGCAGCCT, CTGCCTGGCC, GCCCCATTCG, CCGACGCGGC, GACGCTCGAC, 200AATGCTCTCT, CCGCCTGCCT, CGCCGCCCGG, CTCGGTGCAC, CGCACACGGC, 250GGAGGGCCAG, TTGCACCTGC, CACTCACCCT, TGAGGCCCGG, CGCTCCACCG, 300GCGAATGCGG, CTGTACCTCG, GCGCTGGTGC, GATATCGGCT, GCTGGCCAGG, 350GGCGCCAGCG, CCGACAGCCT, CGTGCTTCAA, GAGGGCTGCT, CGATAGTCGC, 400CAGGACACGC, CGCGCACGCT, GACCCTGGCG, GCGGACGCCG, GCTTGGCGAG, 450CGGCCGCGAA, CTGGTCGTCA, CCCTGGGTTG, TCAGGCGCCT, GACTGACAGG, 500CCGGGCTGCC, ACCACCAGGC, CGAGATGGAC, GCCCTGCATG, TATCCTCCGA, 550TCGGCAAGCC, TCCCGTTCGC, ACATTCACCA, CTCTGCAATC, CAGTTCATAA, 600ATCCCATAAA, AGCCCTCTTC, CGCTCCCCGC, CAGCCTCCCC, GCATCCCGCA, 650CCCTAGACGC, CCCGCCGCTC, TCCGCCGGCT, CGCCCGACAA, GAAAAACCAA, 700CCGCTCGATC, AGCCTCATCC, TTCACCCATC, ACAGGAGCCA, TCGCGATGCA, 750CCTGATACCC, CATTGGATCC, CCCTGGTCGC, CAGCCTCGGC, CTGCTCGCCG, 800GCGGCTCGTC, CGCGTCCGCC, GCCGAGGAAG, CCTTCGACCT, CTGGAACGAA, 850TGCGCCAAAG, CCTGCGTGCT, CGACCTCAAG, GACGGCGTGC, GTTCCAGCCG, 900CATGAGCGTC, GACCCGGCCA, TCGCCGACAC, CAACGGCCAG, GGCGTGCTGC, 950ACTACTCCAT, GGTCCTGGAG, GGCGGCAACG, ACGCGCTCAA, GCTGGCCATC, 1000GACAACGCCC, TCAGCATCAC, CAGCGACGGC, CTGACCATCC, GCCTCGAAGG, 1050CGGCGTCGAG, CCGAACAAGC, CGGTGCGCTA, CAGCTACACG, CGCCAGGCGC, 1100GCGGCAGTTG, GTCGCTGAAC, TGGCTGGTAC, CGATCGGCCA, CGAGAAGCCC, 1150TCGAACATCA, AGGTGTTCAT, CCACGAACTG, AACGCCGGCA, ACCAGCTCAG, 1200CCACATGTCG, CCGATCTACA, CCATCGAGAT, GGGCGACGAG, TTGCTGGCGA, 1250AGCTGGCGCG, CGATGCCACC, TTCTTCGTCA, GGGCGCACGA, GAGCAACGAG, 1300ATGCAGCCGA, CGCTCGCCAT, CAGCCATGCC, GGGGTCAGCG, TGGTCATGGC, 1350CCAGACCCAG, CCGCGCCGGG, AAAAGCGCTG, GAGCGAATGG, GCCAGCGGCA, 1400AGGTGTTGTG, CCTGCTCGAC, CCGCTGGACG, GGGTCTACAA, CTACCTCGCC, 1450CAGCAACGCT, GCAACCTCGA, CGATACCTGG, GAAGGCAAGA, TCTACCGGGT, 1500GCTCGCCGGC, AACCCGGCGA, AGCATGACCT, GGACATCAAA, CCCACGGTCA, 1550TCAGTCATCG, CCTGCACTTT, CCCGAGGGCG, GCAGCCTGGC, CGCGCTGACC, 1600GCGCACCAGG, CTTGCCACCT, GCCGCTGGAG, ACTTTCACCC, GTCATCGCCA, 1650GCCGCGCGGC, TGGGAACAAC, TGGAGCAGTG, CGGCTATCCG, GTGCAGCGGC, 1700TGGTCGCCCT, CTACCTGGCG, GCGCGGCTGT, CGTGGAACCA, GGTCGACCAG, 1750GTGATCCGCA, ACGCCCTGGC, CAGCCCCGGC, AGCGGCGGCG, ACCTGGGCGA, 1800AGCGATCCGC, GAGCAGCCGG, AGCAGGCCCG, TCTGGCCCTG, ACCCTGGCCG, 1850CCGCCGAGAG, CGAGCGCTTC, GTCCGGCAGG, GCACCGGCAA, CGACGAGGCC, 1900GGCGCGGCCA, ACGCCGACGT, GGTGAGCCTG, ACCTGCCCGG, TCGCCGCCGG, 1950TGAATGCGCG, GGCCCGGCGG, ACAGCGGCGA, CGCCCTGCTG, GAGCGCAACT, 2000ATCCCACTGG, CGCGGAGTTC, CTCGGCGACG, GCGGCGACGT, CAGCTTCAGC, 2050ACCCGCGGCA, CGCAGAACTG, GACGGTGGAG, CGGCTGCTCC, AGGCGCACCG, 2100CCAACTGGAG, GAGCGCGGCT, ATGTGTTCGT, CGGCTACCAC, GGCACCTTCC, 2150TCGAAGCGGC, GCAAAGCATC, GTCTTCGGCG, GGGTGCGCGC, GCGCAGCCAG, 2200GACCTCGACG, CGATCTGGCG, CGGTTTCTAT, ATCGCCGGCG, ATCCGGCGCT, 2250GGCCTACGGC, TACGCCCAGG, ACCAGGAACC, CGACGCACGC, GGCCGGATCC, 2300GCAACGGTGC, CCTGCTGCGG, GTCTATGTGC, CGCGCTCGAG, CCTGCCGGGC, 2350TTCTACCGCA, CCAGCCTGAC, CCTGGCCGCG, CCGGAGGCGG, CGGGCGAGGT, 2400CGAACGGCTG, ATCGGCCATC, CGCTGCCGCT, GCGCCTGGAC, GCCATCACCG, 2450GCCCCGAGGA, GGAAGGCGGG, CGCCTGGAGA, CCATTCTCGG, CTGGCCGCTG, 2500GCCGAGCGCA, CCGTGGTGAT, TCCCTCGGCG, ATCCCCACCG, ACCCGCGCAA, 2550CGTCGGCGGC, GACCTCGACC, CGTCCAGCAT, CCCCGACAAG, GAACAGGCGA, 2600TCAGCGCCCT, GCCGGACTAC, GCCAGCCAGC, CCGGCAAACC, GCCGCGCGAG, 2650GACCTGAAGT, AACTGCCGCG, ACCGGCCGGC, TCCCTTCGCA, GGAGCCGGCC, 2700TTCTCGGGGC, CTGGCCATAC, ATCAGGTTTT, CCTGATGCCA, GCCCAATCGA, 2750ATATGAATTC, 2760, (2) SEQ, ID, the information of NO:21:, (i) sequence signature:
(A) length: 172 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:21:TTGATGAAAT GCATCGATTA ATAAATTTTC ATGTACGATT AAAACGTTTT 50TACCCTTACC TTTTCGTACT ACCTCTGCCT GAAGTTGACC ACCTTTAAAG 100TGATTCGTTG AAATCCATTA TGCTCATTAT TAATACGATC TATAAAAACA 150AATGGAATGT GATGATCGAT GA 172 (2) SEQ ID NO:22: (i) sequence signature:
(A) length: 155 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:22:GTTCCATTGA CTCTGTATCA CCTGTTGTAA CGAACATCCA TATGTCCTGA 50AACTCCAACC ACAGGTTTGA CCACTTCCAA TTTCAGACCA CCAAGTTTGA 100CACGTGAAGA TTCATCTTCT AATATTTCGG AATTAATATC ATATTATTTA 150AATAG 155 (2) SEQ ID NO:23: (i) sequence signature:
(A) length: 145 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus, (xi) sequence description: SEQ ID NO:23:ACATAGAAAA ACTCAAAAGA TTTACTTTTT TCAAATGGAA AATAAGGGTA 50CACACGATAT TTCCCGTCAT CTTCAGTTAC CGGTACAACA TCCTCTTTAT 100TAACCTGCAC ATAATCTGAC TCCGCTTCAC TCATCAAACT ACTAA 145, (2) information of SEQ ID NO:24:, (i) sequence signature:
(A) length: 266 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Staphylococcus saprophyticus (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TTTCACTGGA ATTACATTTC GCTCATTACG TACAGTGACA ATCGCGTCAG 50ATAGTTTCTT CTGGTTAGCT TGACTCTTAA CAATCTTGTC TAAATTTTGT 100TTAATTCTTT GATTCGTACT AGAAATTTTA CTTCTAATTC CTTGTAATTC 150ATAACTTGCA TTATCATATA AATCATAAGT ATCACATTTT TGATGAATAC 200TTTGATATAA ATCTGACAAT ACAGGCAGTT GCTCCATTCT ATCGTTAAGA 250ATAGGGTAAT TAATAG 266 (2 ) SEQ ID NO: 25 of the information: (i) sEQUENCE CHARACTERISTICS:
(A) length: 845 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Hemophilus influenzae, (xi) sequence description:, SEQ, ID, NO:25:TGTTAAATTT, CTTTAACAGG, GATTTTGTTA, TTTAAATTAA, ACCTATTATT, 50TTGTCGCTTC, TTTCACTGCA, TCTACTGCTT, GAGTTGCTTT, TTCTGAAACC, 100GCCTCTTTCA, TTTCACTTGC, TTTTTCTGAT, GCTGCTTCTT, TCATTTCGCC, 150TACTTTTTCT, GACGCTGCTT, CTGTTGCTGA, TTTAATTACT, TCTTTCGCAT, 200CTTCCACTTT, CTCTGCTACT, TTATTTTTCA, CGTCTGTAGA, AAGCTGCTGT, 250GCTTTTTCCT, TTACTTCAGT, CATTGTATTA, GCTGCAGCAT, CTTTTGTTTC, 300TGATGCGACT, GATGCTACAG, TTTGCTTCGT, ATCCTCAACT, TTTTGTTTTG, 350CTTCTTGCTT, ATCAAAACAA, CCTGTCACGA, CTAAAGCTGA, ACCTAAAACC, 400AATGCTAATG, TTAATTTTTT, CATTATTTTC, TCCATAGAAT, AATTTGATTG, 450TTACAAAGCC, CTATTACTTT, GATGCAGTTT, AGTTTACGGG, AATTTTCATA, 500AAAAGAAAAA, CAGTAATAGT, AAAACTTTAC, CTTTCTTTAA, AAAGATTACT, 550TTATAAAAAA, ACATCTAAGA, TATTGATTTT, TAATAGATTA, TAAAAAACCA, 600ATAAAAATTTTATTTTTTGT, AAAAAAAAAG, AATAGTTTAT, TTTAAATAAA, 650TTACAGGAGA, TGCTTGATGC, ATCAATATTT, CTGATTTATT, ACCATCCCAT, 700AATAATTGAG, CAATAGTTGC, AGGATAAAAT, GATATTGGAT, TTCGTTTTCC, 750ATACAGTTCA, GCAACAATTT, CTCCCACTAA, GGGCAAATGG, GAAACAATTA, 800ATACAGATTT, AACGCCCTCG, TCTTTTAGCA, CTTCTAAATA, ATCAA, 845, (2) SEQ, ID, the information of NO:26:, (i) sequence signature:
(A) length: 1598 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Hemophilus influenzae, (xi) sequence description: SEQ, ID, NO:26:GAATAGAGTT, GCACTCAATA, GATTCGGGCT, TTATAATTGC, CCAGATTTTT, 50ATTTATAACA, AAGGGTTCCA, AATGAAAAAA, TTTAATCAAT, CTCTATTAGC, 100AACTGCAATG, TTGTTGGCTG, CAGGTGGTGC, AAATGCGGCA, GCGTTTCAAT, 150TGGCGGAAGT, TTCTACTTCA, GGTCTTGGTC, GTGCCTATGC, GGGTGAAGCG, 200GCGATTGCAG, ATAATGCTTC, TGTCGTGGCA, ACTAACCCAG, CTTTGATGAG, 250TTTATTTAAA, ACGGCACAGT, TTTCCACAGG, TGGCGTTTAT, ATTGATTCTA, 300GAATTAATAT, GAATGGTGAT, GTAACTTCTT, ATGCTCAGAT, AATAACAAAT, 350CAGATTGGAA, TGAAAGCAAT, AAAGGACGGC, TCAGCTTCAC, AGCGTAATGT, 400TGTTCCCGGT, GCTTTTGTGC, CAAATCTTTA, TTTCGTTGCG, CCAGTGAATG, 450ATAAATTCGC, GCTGGGTGCT, GGAATGAATG, TCAATTTCGG, TCTAAAAAGT, 500GAATATGACG, ATAGTTATGA, TGCTGGTGTA, TTTGGTGGAA, AAACTGACTT, 550GAGTGCTATC, AACTTAAATT, TAAGTGGTGC, TTATCGAGTA, ACAGAAGGTT, 600TGAGCCTAGG, TTTAGGGGTA, AATGCGGTTT, ATGCTAAAGC, CCAAGTTGAA, 650CGGAATGCTG, GTCTTATTGC, GGATAGTGTT, AAGGATAACC, AAATAACAAG, 700CGCACTCTCA, ACACAGCAAG, AACCATTCAG, AGATCTTAAG, AAGTATTTGC, 750CCTCTAAGGA, CAAATCTGTT, GTGTCATTAC, AAGATAGAGC, CGCTTGGGGC, 800TTTGGCTGGA, ATGCAGGTGT, AATGTATCAA, TTTAATGAAG, CTAACAGAAT, 850TGGTTTAGCC, TATCATTCTA, AAGTGGACAT, TGATTTTGCT, GACCGCACTG, 900CTACTAGTTT, AGAAGCAAAT, GTCATCAAAG, AAGGTAAAAA, AGGTAATTTA, 950ACCTTTACAT, TGCCAGATTA, CTTAGAACTT, TCTGGTTTCC, ATCAATTAAC, 1000TGACAAACTT, GCAGTGCATT, ATAGTTATAA, ATATACCCAT, TGGAGTCGTT, 1050TAACAAAATT, ACATGCCAGC, TTCGAAGATG, GTAAAAAAGC, TTTTGATAAA, 1100GAATTACAAT, ACAGTAATAA, CTCTCGTGTT, GCATTAGGGG, CAAGTTATAA, 1150TCTTTATGAA, AAATTGACCT, TACGTGCGGG, TATTGCTTAC, GATCAAGCGG, 1200CATCTCGTCA, TCACCGTAGT, GCTGCAATTC, CAGATACCGA, TCGCACTTGG, 1250TATAGTTTAG, GTGCAACCTA, TAAATTCACG, CCGAATTTAT, CTGTTGATCT, 1300TGGCTATGCT, TACTTAAAAG, GCAAAAAAGT, TCACTTTAAA, GAAGTAAAA, 1350CAATAGGTGA, CAAACGTACA, TTGACATTGA, ATACAACTGC, AAATTATACT, 1400TCTCAAGCAC, ACGCAAATCT, TTACGGTTTG, AATTTAAATT, ATAGTTTCTA, 1450ATCCGTTAAA, AAATTTAGCA, TAATAAAGCA, CAATTCCACA, CTAAGTGTGC, 1500TTTTCTTTTA, TAAAACAAGG, CGAAAAATGA, CCGCACTTTA, TTACACTTAT, 1550TACCCCTCGC, CAGTCGGACG, GCTTTTGATT, TTATCTGACG, GCGAAACA, 1598, (2) SEQ, ID, the information of NO:27:, (i) sequence signature:
(A) length: 9100 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Haemophilus influenzae
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
GTCAAAAATT GCGTGCATTC TAGCGAAAAA ATGGGCTTTT GGGAACTGTG 50
GGATTTATTT AAAATCTTAG AAAATCTTAC CGCACTTTTA AGCTATAAAG 100
TGCGGTGAAA TTTAGTGGCG TTTATAATGG AGAATTACTC TGGTGTAATC 150
CATTCGACTG TCCAGCTTCC AGTACCTTCT GGAACTAATG TTTTTGTGAG 200
ATAAGGCAAA ATTTCTTTCA TTTGGGTTTC TAATGTCCAA GGTGGATTAA 250
TTACCACCAT ACCGCTCGCA GTCATTCCTC GTTGATCGCT ATCTGGGCGA 300
ACGGCGAGTT CAATTTTTAG AATTTTTCTA ATTCCCGTTG CTTCTAAACC 350
CTTAAAAATA CGTTTAGTTT GTTGGCGTAA TACAACAGGA TACCAAATCG 400
CATAAGTGCC AGTGGCAAAA CGTTTATAGC CCTCTTCAAT GGCTTTAACA 450
ACGAGATCAT AATCATCTTT TAATTCATAA GGCGGATCGA TGAGTACTAA 500
GCCTCGGCGT TCTTTTGGCG GAAGCGTTGC TTTGACTTGT TGAAAGCCAT 550
TGTCACATTT TACGGTGACA TTTTTGTCGT CGCTAAAATT ATTGCGAAGA 600
ATTGGATAAT CGCTAGGATG AAGCTCGGTC AATAGTGCGC GATCTTGTGA 650
GCGCAACAAT TCCGCGGCAA TTAATGGAGA ACCCGCGTAA TAACGTAGTT 700
CTTTGCCACC ATAATTGAGT TTTTTGATCA TTTTTACATA ACGAGCAATA 750
TCTTCGGGTA AATCTGTTTG ATCCCACAGG CGTCCAATAC CTTCTTTATA 800
TTCCCCCGTT TTTTCTGATT CATTTGAGGA TAAACGATAA CGCCCCACAC 850
CAGAGTGCGT ATCCAAATAA AAAAAGCCTT TTTCTTTGAG TTTAAGATTT 900
TCCAAAATGA GCATTAAAAC AATATGTTTC AAGACATCGG CATGATTGCC 950
AGCGTGAAAT GAGTGATGAT AACTCAGCAT AATATATTCC TTATATATTC 1000
CTTATTTGTT TAATAACGAA GGCGAGCCAA TTGACTCGCC CGATTACACA 1050
CTAAAGTGCG GTCATTTTTA GAAGAGTTCT TGTGGTTGCG TCGCTGGCGT 1100
ATTGCCTTCA TTATTTAAGC GTTGCTGTAA CTCAGTAGGA ACATAATAAC 1150
CACGCTCTTG CATTTCCGAA AGATAGGTAC GTGTCGGTTC TGTTCCCGCA 1200
ATAAAATATT CTTTGCGCCC ACCGTTTGGA GAAAGCAAAC CTGTCAAAGT 1250
ATCAATGTTT TTTTCCACAA TTTTTGGCGG TAGCGACAAT TTACGTTCTG 1300
GCTTATCACT CAAAGCCGTT TTCATATAAG TGATCCAAGC AGGCATTGCT 1350
GTTTTTGCTC CTGCTTCTCC ACGCCCAAGT ACTCGTTTGT TATCATCAAA 1400
CCCGACATAA GTTGTGGTTA CTAAGTTTGC ACCAAATCCC GCATACCAAG 1450
CCACTTTTGA ACTGTTGGTA GTACCTGTTT TACCGCCTAT ATCGCTACGT 1500
TTAATGCTTT GTGCAATACG CCAGCTGGTG CCTTTCCAGT CTAAACCTTG 1550
TTCGCCATAA ATTGCCGTAT TTAAGGCACT ACGAATGAGA AAAGCAAGTT 1600
CGCCACTAAT GACACGTGGC GCATATTCTA TTTTCGACGA AGCATTTTTT 1650
GCAGCAGCCA TTAAATCAAT CGCATCTTCT TTAAGTGCGG TCATATTTGA 1700
TTGTAATTCT GGCAGTTCAG GCACAGTTTC AGGTTGTTGA TCTAATTCTT 1750
CGCCATTGGT GCTGTCATCT GTTGGTTTTA AGGCATTCTC GCCTAAAGGA 1800
ATATTGGCAA AGCCGTTGAT TTTGTCTTTG GTTTCGCCAT AAATTACAGG 1850
TATATCATTA CATTCAATGC AAGCAATTTT AGGGTTTGCA ATAAATAAGT 1900
CTTTACCCGT GTTATCTTGA ATTTTTTCAA TGATATAAGG TTCAATGAGG 1950
AAGCCACCAT TATCAAACAC CGCATAAGCT CGCGCCATTT CTAATGGTGT 2000
GAAAGAGGCT GCGCCAAGTG CTAAGGCTTC ACTGGCAAAA TATTGATCAC 2050
GTTTAAAACC AAAACGTTGT AAAAATTCTG CTGTGAAATC AATACCTGCC 2100
GTTTGGATAG CACGAATAGC AATTATATTT TTGGATTGAC CTAATCCTAC 2150
GCGTAAACGC ATCGGGCCAT CATAACGATC AGGCGAGTTT TTCGGTTGCC 2200
ACATTTTTTG TCCCGGTTTT TGAATAGAAA TCGGGCTGTC TTGTAATACG 2250
CTTGAAAGTG TTAAGCCTTT TTCTAATGCT GCCGCGTAAA TAAATGGTTT 2300
GATAGAAGAA CCCACTTGAA CTAAAGACTG TGTGGCTCGA TTGAATTTAC 2350
TTTGTTCATA GCTAAAGCCA CCGACCACTG CTTCAATCGC ACCATTATCT 2400
GAATTAAGAG AAACTAATGC TGAATTTGCT GCGGGAATTT GTCCTAATTG 2450
CCATTCCCCA TTAGCACGCT GATGAATCCA AATTTGCTCG CCGACTTTCA 2500
CAGGATTGCT TCTGCCTGTC CAACGCATTG CATTGGTTGA TAAGGTCATT 2550
TTTTCCCCAG AAGCGAGCAA TATATCAGCA CCGCCTTTTA CAATTCCAAT 2600
CACTGCCGCA GGAATAAATG GCTCTGAATC AGGTAGTTTG CGTAGAAAAC 2650
CGACAATGCG ATCATTGTCC CAAGCGGCTT CATTTTTTTG CCATAATGGC 2700
GCGCCACCGC GATAACCGTG ACGCATATCG TAATCAATCA AGTTATTACG 2750
CACAGCTTTT TGGGCTTCAG CTTGGTCTTT TGAAAGTACA GTGGTAAATA 2800
CTTTATAACC ACTGGTGTAA GCATTTTCTT CGCCAAAACG ACGCACCATT 2850
TCTTGACGCA CCATTTCAGT GACATAATCG GCTCGAAATT CAAATTTTGC 2900
GCCGTGATAG CTCGCCACAA TCGGCTCTTT CAATGCAGCA TCATATTCTT 2950
CTTTGCTGAT GTATTTTTCA TCTAACATAC GGCTTAGCAC CACATTGCGG 3000
CGTTCTTCTG AACGTTTTAA AGAATAAAGC GGGTTCATTG TTGAAGGTGC 3050
TTTAGGTAAA CCAGCAATAA TCGCCATTTC CGATAAGGTC AATTCATTCA 3100
ATGATTTACC GAAATAGGTT TGTGCTGCCG CTGCAACACC ATAAGAACGA 3150
TAGCCTAAAA AGATTTTGTT TAAATAAAGC TCTAATATTT CTTGTTTGTT 3200
GAGAGTATTT TCGATTTCTA CCGCAAGCAC GGCTTCACGA GCTTTACGAA 3250
TAATGGTTTT TTCTGAGGTT AAGAAAAAGT TACGCGCTAA TTGTTGAGTA 3300
ATCGTACTTG CGCCTTGTGA TGCACCGCCA TTACTCACTG CGACAAACAA 3350
TGCACGGGCA ATGCCGATAG GGTCTAATCC GTGATGATCG TAAAAACGAC 3400
TGTCTTCCGT CGCTAAAAAT GCGTCAATTA AGCGTTGTGG CACATCGGCT 3450
AATTTCACTG GAATACGGCG TTGCTCACCC ACTTCGCCAA TTAATTTACC 3500
GTCAGCCGTA TAAATCTGCA TTGGTTGCTG TAATTCAACG GTTTTTAATG 3550
TTTCTACTGA GGGCAATTCA GATTTTAAGT GGAAATACAA CATTCCGCCT 3600
GCTACTAAAC CTAAAATACA TAAAGTTAAT AGGGTGTTTA ATATTAATTT 3650
TGCGATCCGC ATCGTAAAAT TCTCGCTTCG TTAATGAATA TTCTTGTCAA 3700
GAGACCTATG ATTTGGCTGT TAAGTATAAA AGATTCAGCC TTTAAAGAAT 3750
AGGAAAGAAT ATGCAATTCT CCCTGAAAAA TTACCGCACT TTACAAATCG 3800
GCATTCATCG TAAGCAGAGT TATTTTGATT TTGTGTGGTT TGATGATCTC 3850
GAACAGCCAC AAAGTTATCA AATCTTTGTT AATGATCGTT ATTTTAAAAA 3900
TCGTTTTTTA CAACAGCTAA AAACACAATA TCAAGGGAAA ACCTTTCCTT 3950
TGCAGTTTGT AGCAAGCATT CCCGCCCACT TAACTTGGTC GAAAGTATTA 4000
ATGTTGCCAC AAGTGTTAAA TGCGCAAGAA TGTCATCAAC AATGTAAATT 4050
TGTGATTGAA AAAGAGCTGC CTATTTTTTT AGAAGAATTG TGGTTTGATT 4100
ATCGTTCTAC CCCGTTAAAG CAAGGTTTTC GATTAGAGGT TACTGCAATT 4150
CGTAAAAGTA GCGCTCAAAC TTATTTGCAA GATTTTCAGC CATTTAATAT 4200
TAATATATTG GATGTTGCGT CAAATGCTGT TTTGCGTGCA TTTCAATATC 4250
TGTTGAATGA ACAAGTGCGG TCAGAAAATA CCTTATTTTT ATTTCAAGAA 4300
GATGACTATT GCTTGGCGAT TTGTGAAAGA TCTCAGCAAT CACAAATTTT 4350
ACAATCTCAC GAAAATTTGA CCGCACTTTA TGAACAATTT ACCGAACGTT 4400
TTGAAGGACA ACTTGAACAA GTTTTTGTTT ATCAAATTCC CTCAAGTCAT 4450
ACACCATTAC CCGAAAACTG GCAGCGAGTA GAAACAGAAC TCCCTTTTAT 4500
TGCGCTGGGC AACGCGCTAT GGCAAAAAGA TTTACATCAA CAAAAAGTGG 4550
GTGGTTAAAT GTCGATGAAT TTATTGCCTT GGCGTACTTA TCAACATCAA 4600
AAGCGTTTAC GTCGTTTAGC TTTTTATATC GCTTTATTTA TCTTGCTTGC 4650
TATTAATTTA ATGTTGGCTT TTAGCAATTT GATTGAACAA CAGAAACAAA 4700
ATTTGCAGGC ACAGCAAAAG TCGTTTGAAC AACTTAATCA ACAGCTTCAT 4750
AAAACTACCA TGCAAATTGA TCAGTTACGC ATTGCGGTGA AAGTTGGTGA 4800
AGTTTTGACA TCTATTCCCA ACGAGCAAGT AAAAAAGAGT TTACAACAGC 4850
TAAGTGAATT ACCTTTTCAA CAAGGAGAAC TGAATAAATT TAAACAAGAT 4900
GCCAATAACT TAAGCTTGGA AGGTAACGCG CAAGATCAAA CAGAATTTGA 4950
ACTGATTCAT CAATTTTTAA AGAAACATTT TCCCAATGTG AAATTAAGTC 5000
AGGTTCAACC TGAACAAGAT ACATTGTTTT TTCACTTTGA TGTGGAACAA 5050
GGGGCGGAAA AATGAAAGCT TTTTTTAACG ATCCTTTTAC TCCTTTTGGA 5100
AAATGGCTAA GTCAGCCTTT TTATGTGCAC GGTTTAACCT TTTTATTGCT 5150
ATTAAGTGCG GTGATTTTTC GCCCCGTTTT AGATTATATA GAGGGGAGTT 5200
CACGTTTCCA TGAAATTGAA AATGAGTTAG CGGTGAAACG TTCAGAATTG 5250
TTGCATCAAC AGAAAATTTT AACCTCTTTA CAACAGCAGT CGGAAAGTCG 5300
AAAACTTTCT CCAGAACTGG CTGCACAAAT TATTCCTTTG AATAAACAAA 5350
TTCAACGTTT AGCTGCGCGT AACGGTTTAT CTCAGCATTT ACGTTGGGAA 5400
ATGGGGCAAA AGCCTATTTT GCATTTACAG CTTACAGGTC ATTTTGAAAA 5450
AACGAAGACA TTTTTATCCG CACTTTTGGC TAATTCGTCA CAGCTTTCTG 5500
TAAGTCGGTT GCAATTTATG AAACCCGAAG ACGGCCCATT GCAAACCGAG 5550
ATCATTTTTC AGCTAGATAA GGAAACAAAA TGAAACATTG GTTTTTCCTG 5600
ATTATATTAT TTTTTATGAA TTGCAGTTGG GGACAAGATC CTTTCGATAA 5650
AACACAGCGT AACCGTTCTC AGTTTGATAA CGCACAAACA GTAATGGAGC 5700
AAACAGAAAT AATTTCCTCA GATGTGCCTA ATAATCTATG CGGAGCGGAT 5750
GAAAATCGCC AAGCGGCTGA AATTCCTTTG AACGCTTTAA AATTGGTGGG 5800
GGTAGTGATT TCTAAAGATA AAGCCTTTGC CTTGTTGCAA GATCAAGGTT 5850
TGCAAGTTTA CAGCGTTTTA GAGGGCGTTG ATGTGGCTCA AGAGGGCTAT 5900
ATTGTAGAAA AAATCAACCA AAACAATGTT CAATTTATGC GTAAGCTAGG 5950
AGAGCAATGT GATAGTAGTG AATGGAAAAA ATTAAGTTTT TAAAGGAAGA 6000
TTATGAAGAA ATATTTTTTA AAGTGCGGTT ATTTTTTAGT ATGTTTTTGT 6050
TTGCCATTAA TCGTTTTTGC TAATCCTAAA ACAGATAACG AACGTTTTTT 6100
TATTCGTTTA TCGCAAGCAC CTTTAGCTCA AACACTGGAG CAATTAGCTT 6150
TTCAACAAGA TGTGAATTTA GTGATTGGAG ATATATTGGA AAACAAGATC 6200
TCTTTGAAAT TAAACAATAT TGATATGCCA CGTTTGCTAC AAATAATCGC 6250
AAAAAGTAAG CATCTTACTT TGAATAAAGA TGATGGGATT TATTATTTAA 6300
ACGGCAGTCA ATCTGGCAAA GGTCAGGTTG CAGGAAATCT TACGACAAAT 6350
GAACCGCACT TAGTGAGTCA CACGGTAAAA CTCCATTTTG CTAAAGCTTC 6400
TGAATTAATG AAATCCTTAA CAACAGGAAG TGGCTCTTTG CTTTCTCCCG 6450
CTGGGAGCAT TACCTTTGAT GATCGCAGTA ATTTGCTGGT TATTCAGGAT 6500
GAACCTCGTT CTGTGCAAAA TATCAAAAAA CTGATTGCTG AAATGGATAA 6550
GCCTATTGAA CAGATCGCTA TTGAAGCGCG AATTGTGACA ATTACGGATG 6600
AGAGTTTGAA AGAACTTGGC GTTCGGTGGG GGATTTTTAA TCCAACTGAA 6650
AATGCAAGAC GAGTTGCGGG CAGCCTTACA GGCAATAGCT TTGAAAATAT 6700
TGCGGATAAT CTTAATGTAA ATTTTGCGAC AACGACGACA CCTGCTGGCT 6750
CTATAGCATT ACAAGTCGCC AAAATTAATG GGCGATTGCT TGATTTAGAA 6800
TTGAGTGCGT TGGAGCGTGA AAATAATGTA GAAATTATTG CAAGCCCTCG 6850
CTTACTCACT ACCAATAAGA AAAGTGCGAG CATTAAACAG GGGACAGAAA 6900
TTCCTTACAT CGTGAGTAAT ACTCGTAACG ATACGCAATC TGTGGAATTT 6950
CGTGAGGCGG TGCTTGGTTT GGAAGTGACG CCACATATTT CTAAAGATAA 7000
CAATATCTTA CTTGATTTAT TGGTAAGTCA AAATTCCCCT GGTTCTCGTG 7050
TCGCTTATGG ACAAAATGAG GTGGTTTCTA TTGATAAACA AGAAATTAAT 7100
ACTCAGGTTT TTGCCAAAGA TGGGGAAACC ATTGTGCTTG GCGGCGTATT 7150
TCACGATACA ATCACGAAAA GCGAAGATAA AGTGCCATTG CTTGGCGATA 7200
TACCCGTTAT TAAACGATTA TTTAGCAAAG AAAGTGAACG ACATCAAAAA 7250
CGTGAGCTAG TGATTTTCGT CACGCCACAT ATTTTAAAAG CAGGAGAAAA 7300
CGTTAGAGGC GTTGAAACAA AAAAGTGAGG GTAAAAAATA ACTTTTTAAA 7350
TGATGAATTT TTTTAATTTT CGCTGTATCC ACTGTCGTGG CAATCTTCAT 7400
ATCGCAAAAA ATGGGTTATG TTCAGGTTGC CAAAAACAAA TTAAATCTTT 7450
TCCTTATTGC GGTCATTGTG GTTCGGAATT GCAATATTAT GCGCAGCATT 7500
GTGGGAATTG TCTTAAACAA GAACCAAGTT GGGATAAGAT GGTCATTATT 7550
GGGCATTATA TTGAACCTCT TTCGATATTG ATTCAGCGTT TTAAATTTCA 7600
AAATCAATTT TGGATTGACC GCACTTTAGC TCGGCTTTTA TATCTTGCGG 7650
TACGTGATGC TAAACGAACG CATCAACTTA AATTGCCAGA GGCAATCATT 7700
CCAGTGCCTT TATATCATTT TCGTCAGTGG CGACGGGGTT ATAATCAGGC 7750
AGATTTATTA TCTCAGCAAT TAAGTCGTTG GCTGGATATT CCTAATTTGA 7800
ACAATATCGT AAAGCGTGTG AAACACACCT ATACTCAACG TGGTTTGAGT 7850
GCAAAAGATC GTCGTCAGAA TTTAAAAAAT GCCTTTTCTC TTGCTGTTTC 7900
GAAAAATGAA TTTCCTTATC GTCGTGTTGC GTTGGTGGAT GATGTGATTA 7950
CTACTGGTTC TACACTCAAT GAAATCTCAA AATTGTTGCG AAAATTAGGT 8000
GTGGAGGAGA TTCAAGTGTG GGGGCTGGCA CGAGCTTAAT ATAAAGCACT 8050
GGAAAAAAAA GCGCGATAAG CGTATTATTC CCGATACTTT CTCTCAAGTA 8100
TTTAGGACAT AATTATGGAA CAAGCAACCC AGCAAATCGC TATTTCTGAT 8150
GCCGCACAAG CGCATTTTCG AAAACTTTTA GACACCCAAG AAGAAGGAAC 8200
GCATATTCGT ATTTTCGCGG TTAATCCTGG TACGCCTAAT GCGGAATGTG 8250
GCGTATCTTA TTGCCCCCCG AATGCCGTGG AAGAAAGCGA TATTGAAATG 8300
AAATATAATA CTTTTTCTGC ATTTATTGAT GAAGTGAGTT TGCCTTTCTT 8350
AGAAGAAGCA GAAATTGATT ATGTTACCGA AGAGCTTGGT GCGCAACTGA 8400
CCTTAAAAGC ACCGAATGCC AAAATGCGTA AGGTGGCTGA TGATGCGCCA 8450
TTGATTGAAC GTGTTGAATA TGTAATTCAA ACTCAAATTA ACCCACAGCT 8500
TGCAAATCAC GGTGGACGTA TAACCTTAAT TGAAATTACT GAAGATGGTT 8550
ACGCAGTTTT ACAATTTGGT GGTGGCTGTA ACGGTTGTTC AATGGTGGAT 8600
GTTACGTTAA AAGATGGGGT AGAAAAACAA CTTGTTAGCT TATTCCCGAA 8650
TGAATTAAAA GGTGCAAAAG ATATAACTGA GCATCAACGT GGCGAACATT 8700
CTTATTATTA GTGAGTTATA AAAGAAGATT TATAATGACC GCACTTTTGA 8750
AAGTGCGGTT ATTTTTATGG AGAAAAAATG AAAATACTTC AACAAGATGA 8800
TTTTGGTTAT TGGTTGCTTA CACAAGGTTC TAATCTGTAT TTAGTGAATA 8850
ATGAATTGCC TTTTGGTATC GCTAAAGATA TTGATTTGGA AGGATTGCAG 8900
GCAATGCAAA TTGGGGAATG GAAAAATTAT CCGTTGTGGC TTGTGGCTGA 8950
GCAAGAAAGT GATGAACGAG AATATGTGAG TTTGAGTAAC TTGCTTTCAC 9000
TGCCAGAGGA TGAATTCCAT ATATTAAGCC GAGGTGTGGA AATTAATCAT 9050
TTTCTGAAAA CCCATAAATT CTGTGGAAAG TGCGGTCATA AAACACAACA 9100
(2) SEQ ID NO: 28 information about:
(I) SEQUENCE CHARACTERISTICS:
...
(A) length: 525 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis, (xi) sequence description: SEQ, ID, NO:28:AAAAATCGAC, TGCCGTCATT, TTCAACCACC, ACATAGCTCA, TATTCGCAAG, 50CCAATGTATT, GACCGTTGGG, AATAATAACA, GCCCCAAAAC, AATGAAACAT, 100ATGGTGATGA, GCCAAACATA, CTTTCCTGCA, GATTTTGGAA, TCATATCGCC, 150ATCAGCACCA, GTATGGTTTG, ACCAGTATTT, AACGCCATAG, ACATGTGTAA, 200AAAAATTAAA, TAACGGTGCA, AGCATGAGAC, CAACGGCACC, TGATGTACCT, 250TGTACGATGA, CCTCACCTGC, TGTGGCAACC, ATACCAAGTC, CATTGCCTGT, 300GATATTTTTG, CGAAAAGACA, AACTTACCAC, ACAGACCAAG, CCGATGATTG, 350AGATGACAAA, ATAAAACCAA, TCCAAATGCG, TGTGAGCTGT, TGTGGTCCAA, 400AATCCAGTAA, ATAGTGCAAT, AAATCCGCAA, ACAAACCAAA, GTAGCACCCA, 450GCTTGTTGTC, CAATCTTTTT, TACCAAAGCC, TGTGATGTTA, TCTAAAATAT, 500CAATTTTCAT, CAGATTTTCC, CTAAT, 525, (2) SEQ, ID, the information of NO:29:, (i) sequence signature:
(A) length: 466 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis, (xi) sequence description:, SEQ, ID, NO:29:TAATGATAAC, CAGTCAAGCA, AGCTCAAATC, AGGGTCAGCC, TGTTTTGAGC, 50TTTTTATTTT, TTGATCATCA, TGCTTAAGAT, TCACTCTGCC, ATTTTTTTAC, 100AACCTGCACC, ACAAGTCATC, ATCGCATTTG, CAAAAATGGT, ACAAACAAGC, 150CGTCAGCGAC, TTAAACAAAA, AAAGGCTCAA, TCTGCGTGTG, TGCGTTCACT, 200TTTACAAATC, ACCATGCACC, GCTTTGACAT, TGTTGGTGAA, TTTCATGACC, 250ATGCACACCC, TTATTATATT, AACTCAAATA, AAATACGCTA, CTTTGTCAGC, 300TTTAGCCATT, CAGATAATCA, AGTCGCTCTC, ATCATCAGCT, TAACACCTTG, 350TGCCATTGAC, ATAGAAGTTA, ACGATATTAA, ATACAGTGTG, GTTGAACGAT, 400ACTTTCATCC, CAATGAAATT, TATCTACTTA, CTCAATTTAG, CTCTACTGAT, 450AGGCAACAGC, TTATTA, 466, (2) SEQ, ID, the information of NO:30:, (i) sequence signature:
(A) length: 631 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumonia, (xi) sequence description: SEQ, ID, NO:30:GATCTTTGAT, TTTCATTGAG, TATTACTCTC, TCTTGTCACT, TCTTTCTATT, 50TTACCATAAA, GTCCAGCCTT, TGAAGAACTT, TTACTAGAAG, ACAAGGGGCT, 100TCTGTCTCTA, TTTGCCATCT, TAGGCATCAA, AAAAGAGGGG, TCATCCCTCT, 150TTACGAATTC, AATGCTACTA, GGGTATCCAA, ATACTGGTTG, TTGATGACTG, 200CCAAAATATA, GGTATCTGCT, TTCAAGAGGT, CATCTGGTCC, AAATTCAACA, 250TCCAATGGGG, AATTTTCCTG, CTCTCGGAAA, CCCAAAATAT, TCAGATTGTA, 300TTTGCCACGG, AGGTCTAATT, TACTTCAGAC, TTTGACCTGC, CCAAGACTGA, 350GGAATTTTCA, TCTCCACGAT, AGACACATTT, TTATCCAACT, GAAAGACATC, 400AACACTATTA, TGAAAAGAAT, GGTCTGTGCT, AGAGACTGCC, CCATTTCATA, 450CTCTGGCGAG, ATAACCGAGT, CAGCTCCAAT, CTTTTCTAGC, ACTTTCTTAG, 500CGGTCTGACT, TTTGACCTTA, GCAATAACAG, TCGGTACCCC, CAAACTCTTA, 550CAGTGCATAA, CCGCAAGCAC, ACTCGACTCC, AGATTTTCAC, CTGTCGCGAC, 600TACAACGGTA, TCGCAGGTAT, CAATCCCTGC, T, 631, (2) SEQ, ID, the information of NO:31:, (i) sequence signature:
(A) length: 3754 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity (ii) molecule type DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae
(xi) sequence description: SEQ, ID, NO:31:CCAATATTTT, GGTCAGCATA, GTGTTCTTTT, TCAGTGGTAA, CAGCTTGCAA, 50TACTTGAGCA, GAAATGGCAG, ATTTATCAAG, GAAAAAGTTA, ACGTAAGGTC, 100CTGTTGCGAC, AACTTTTTCA, AAGGCTTGGC, TGTTCATTTT, TTCAGCCAGT, 150TCAGCCGCAA, TCATTTGTGG, TGCTTTACGT, TCGACTTTTG, CAAGAGAAAA, 200AGCAGGGAAA, GCAATGTCTC, CCATTTCTGA, GTTTTTAGGG, GTTTCCAGTA, 250ACTTTAAAAT, AGCCTCTTGG, TCCAGGCTAT, CAATGATGCT, AGATAATTCG, 300CTAGCAATCA, ATTCTTTTGT, ATTCATTAAG, AGCTCCTTTT, TGGACTTTTC, 350TACTATTTTA, TCACAATTTT, AAAGAAAGAA, GAAAAAATTT, TTGAAATCTC, 400CTGTTTTTTT, GGTATAATAT, GGTTATAAAT, ATAGTTATAA, ATATAGTTAT, 450AAATATGCAC, GCAAGAGGAT, TTTATGAGAA, AAAGAGATCG, TCATCAGTTA, 500ATAAAAAAAA, TGATTACTGA, GGAGAAATTA, AGTACACAAA, AAGAAATTCA, 550AGATCGGTTG, GAGGCGCACA, ATGTTTGTGT, GACGCAGACA, ACCTTGTCTC, 600GTGATTTGCG, CGAAATCGGC, TTGACCAAGG, TCAAGAAAAA, TGATATGGTG, 650TATTATGTAC, TAGTAAATGA, GACAGAAAAG, ATTGATTTGG, TGGAATTTTT, 700GTCTCATCAT, TTAGAAGGTG, TTGCAAGAGC, AGAGTTTACC, TTGGTGCTTC, 750ATACCAAATT, GGGAGAAGCC, TCTGTTTTGG, CAAATATTGT, AGATGTAAAC, 800AAGGATCAAT, GCATTTTAGG, AACAGTTGCT, GGTGCCAATA, CCTTATTGGT, 850TATTTGTCGA, GATCAGCACG, TTGCCAAACT, CATGGAAGAT, CGTTTGCTAG, 900ATTTGATGAA, AGATAAGTAA, GGTCTTGGGA, GTTGCTCTCA, AGACTTATTT, 950TTGAAAAGGA, GAGACAGAAA, ATGGCGATAG, AAAAGCTATC, ACCCGGCATG, 1000CAACAGTATG, TGGATATTAA, AAAGCAATAT, CCAGATGCTT, TTTTGCTCTT, 1050TCGGATGGGT, GATTTTTATG, AATTATTTTA, TGAGGATGCG, GTCAATGCTG, 1100CGCAGATTCT, GGAAATTTCC, TTAACGAGTC, GCAACAAGAA, TGCCGACAAT, 1150CCGATCCCTA, TGGCGGGTGT, TCCCTATCAT, TCTGCCCAAC, AGTATATCGA, 1200TGTCTTGATT, GAGCAGGGTT, ATAAGGTGGC, TATCGCAGAG, CAGATGGAAG, 1250ATCCTAAACA, AGCAGTTGGG, GTTGTTAAAC, GAGAGGTTGT, TCAGGTCATT, 1300ACGCCAGGGA, CAGTGGTCGA, TAGCAGTAAG, CCGGACAGTC, AGAATAATTT, 1350TTTGGTTTCC, ATAGACCGCG, AAGGCAATCA, ATTTGGCCTA, GCTTATATGG, 1400ATTTGGTGAC, GGGTGACTTT, TATGTGACAG, GTCTTTTGGA, TTTCACGCTG, 1450GTTTGTGGGG, AAATCCGTAA, CCTCAAGGCT, CGAGAAGTGG, TGTTGGGTTA, 1500TGACTTGTCT, GAGGAAGAAG, AACAAATCCT, CAGCCGCCAG, ATGAATCTGG, 1550TACTCTCTTA, TGAAAAAGAA, AGCTTTGAAG, ACCTTCATTT, ATTGGATTTG, 1600CGATTGGCAA, CGGTGGAGCA, AACGGCATCT, AGTAAGCTGC, TCCAGTATGT, 1650TCATCGGACT, CAGATGAGGG, AATTGAACCA, CCTCAAACCT, GTTATCCGCT, 1700ACGAAATTAA, GGATTTCTTG, CAGATGGATT, ATGCGACCAA, GGCTAGTCTG, 1750GATTTGGTTG, AGAATGCTCG, CTCAGGTAAG, AAACAAGGCA, GTCTTTTCTG, 1800GCTTTTGGAT, GAAACCAAAA, CGGCTATGGG, GATGCGTCTC, TTGCGTTCTT, 1850GGATTCATCG, CCCCTTGATT, GATAAGGAAC, GAATCGTCCA, ACGTCAAGAA, 1900GTAGTGCAGG, TCTTTCTCGA, CCATTTCTTT, GAGCGTAGTG, ACTTGACAGA, 1950CAGTCTCAAG, GGTGTTTATG, ACATTGAGCG, CTTGGCTAGT, CGTGTTTCTT, 2000TTGGCAAAAC, CAATCCAAAG, GATCTCTTGC, AGTTGGCGAC, TACCTTGTCT, 2050AGTGTGCCAC, GGATTCGTGC, GATTTTAGAA, GGGATGGAGC, AACCTACTCT, 2100AGCCTATCTC, ATCGCACAAC, TGGATGCAAT, CCCTGAGTTG, GAGAGTTTGA, 2150TTAGCGCAGC, GATTGCTCCT, GAAGCTCCTC, ATGTGATTAC, AGATGGGGGA, 2200ATTATCCGGA, CTGGATTTGA, TGAGACTTTA, GACAAGTATC, GTTGCGTTCT, 2250CAGAGAAGGG, ACTAGCTGGA, TTGCTGAGAT, TGAGGCTAAG, GAGCGAGAAA, 2300ACTCTGGTAT, CAGCACGCTC, AAGATTGACT, ACAATAAAAA, GGATGGCTAC, 2350TATTTTCATG, TGACCAATTC, GCAACTGGGA, AATGTGCCAG, CCCACTTTTT, 2400CCGCAAGGCG, ACGCTGAAAA, ACTCAGAACG, CTTTGGAACC, GAAGAATTAG, 2450CCCGTATCGA, GGGAGATATG, CTTGAGGCGC, GTGAGAAGTC, AGCCAACCTC, 2500GAATACGAAA, TATTTATGCG, CATTCGTGAA, GAGGTCGGCA, AGTACATCCA, 2550GCGTTTACAA, GCTCTAGCCC, AAGGAATTGC, GACGGTTGAT, GTCTTACAGA, 2600GTCTGGCGGT, TGTGGCTGAA, ACCCAGCATT, TGATTCGACC, TGAGTTTGGT, 2650GACGATTCAC, AAATTGATAT, CCGGAAAGGG, CGCCATGCTG, TCGTTGAAAA, 2700GGTTATGGGG, GCTCAGACCT, ATATTCCAAA, TACGATTCAG, ATGGCAGAAG, 2750ATACCAGTAT, TCAATTGGTT, ACAGGGCCAA, ACATGAGTGG, GAAGTCTACC, 2800TATATGCGTC, AGTTAGCCAT, GACGGCGGTT, ATGGCCCAGC, TGGGTTCCTA, 2850TGTTCCTGCT, GAAAGCGCCC, ATTTACCGAT, TTTTGATGCG, ATTTTTACCC, 2900GTATCGGAGC, AGCAGATGAC, TTGGTTTCGG, GTCAGTCAAC, CTTTATGGTG, 2950GAGATGATGG, AGGCCAATAA, TGCCATTTCG, CATGCGACCA, AGAACTCTCT, 3000CATTCTCTTT, GATGAATTGG, GACGTGGAAC, TGCAACTTAT, GACGGGATGG, 3050CTCTTGCTCA, GTCCATCATC, GAATATATCC, ATGAGCACAT, CGGAGCTAAG, 3100ACCCTCTTTG, CGACCCACTA, CCATGAGTTG, ACTAGTCTGG, AGTCTAGTTT, 3150ACAACACTTG, GTCAATGTCC, ACGTGGCAAC, TTTGGAGCAG, GATGGGCAGG, 3200TCACCTTCCT, TCACAAGATT, GAACCGGGAC, CAGCTGATAA, ATCCTACGGT, 3250ATCCATGTTG, CCAAGATTGC, TGGCTTGCCA, GCAGACCTTT, TAGCAAGGGC, 3300GGATAAGATT, TTGACTCAGC, TAGAGAATCA, AGGAACAGAG, AGTCCTCCTC, 3350CCATGAGACA, AACTAGTGCT, GTCACTGAAC, AGATTTCACT, CTTTGATAGG, 3400GCAGAAGAGC, ATCCTATCCT, AGCAGAATTA, GCTAAACTGG, ATGTGTATAA, 3450TATGACACCT, ATGCAGGTTA, TGAATGTCTT, AGTAGAGTTA, AAACAGAAAC, 3500TATAAAACCA, AGACTCACTA, GTTAATCTAG, CTGTATCAAG, GAGACTTCTT, 3550TGACAATTCT, CCACTTTTTT, GCTAGAATAA, CATCACACAA, ACAGAATGAA, 3600AAGGGCTGAC, GCATTGTCGC, TCCCTTTTGT, CTATTTTTTA, AGGAGAAAGT, 3650ATGCTGATTC, AGAAAATAAA, AACCTACAAG, TGGCAGGCCC, TGCTTCGCTC, 3700CTGATGACAG, GCTTGATGGT, TGCTAGTTCA, CTTCTGCAAC, CGCGTTATCT, 3750GCAG, 3754, (2) SEQ, ID, the information of NO:32:, (i) sequence signature:
(A) length: 1337 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes, (xi) sequence description: SEQ, ID, NO:32:AACAAAATAA, AAGAACTTAC, CTATTTTCCA, TCCAAAATGT, TTAGCAATCA, 50TCATCTGCAA, GGCAACGTAT, TGCATGGCAT, TGATGTGATG, AGCAACTAAT, 100ATGTCATTAG, AACGTTGCGT, CAAACTAGCA, TCTAAATAAA, GATCGAAATG, 150CAGTTATCAA, AAATGCAAGC, TCCTATCGGC, CCTTGTTTTA, ATTATTACTC, 200ACATTGCCTT, AATGTATTTA, CTTGCTTATT, ATTAACTTTT, TTGCTAAGTT, 250AGTAGCGTCA, GTTATTCATT, GAAAGGACAT, TATTATGAAA, ATTCTTGTAA, 300CAGGCTTTGA, TCCCTTTGGC, GGCGAAGCTA, TTAATCCTGC, CCTTGAAGCT, 350ATCAAGAAAT, TGCCAGCAAC, CATTCATGGA, GCAGAAATCA, AATGTATTGA, 400AGTTCCAACG, GTTTTTCAAA, AATCTGCCGA, TGTGCTCCAG, CAGCATATCG, 450AAAGCTTTCA, ACCTGATGCA, GTCCTTTGTA, TTGGGCAAGC, TGGTGGCCGG, 500ACTGGACTAA, CGCCAGAACG, CGTTGCCATT, AATCAAGACG, ATGCTCGCAT, 550TCCTGATAAC, GAAGGGAATC, AGCCTATTGA, TACACCTATT, CGTGCAGATG, 600GTAAAGCAGC, TTATTTTTCA, ACCTTGCCAA, TCAAAGCGAT, GGTTGCTGCC, 650ATTCATCAGG, CTGGGCTTCC, TGCTTCTGTT, TCTAATACAG, CTGGTACCTT, 700TGTTTGCAAT, CATTTGATGT, ATCAAGCCCT, TTACTTAGTG, GATAAATATT, 750GTCCAAATGC, CAAAGCTGGG, TTTATGCATA, TTCCCTTTAT, GATGGAACAG, 800GTTGTTGATA, AACCTAATAC, AGCTGCCATG, AACCTCGATG, ATATTACAAG, 850AGGAATTGAG, GCTGCTATTT, TTGCCATTGT, CGATTTCAAA, GATCGTTCCG, 900ATTTAAAACG, TGTAGGGGGC, GCTACTCACT, GACTGTGACG, CTACTAAACC, 950TATTTTAAAA, AAACAGAGAT, ATGAACTAAC, TCTGTTTTTT, TTGTGCTAAA, 1000AATGAAAGAC, CTAGGGAAAC, TTTTCATCGG, TCTTTCTCAA, TTGTCATCTT, 1050AATCTAATAC, TACTTCTAAC, ATCAGCGGGT, ATAGTTTGCC, AGTAATTAAG, 1100AAACGTTGTT, GATCTAAATG, AGCAATCCCA, TTCAAAACAT, TAAGGTCAGG, 1150GTAATGGGAC, TTATCAAGAT, TTAAGGCTTT, TAACAAAGGA, CTAATATCAT, 1200AGGTGGCTAC, CACCTTTCCA, GAATCAGGTT, GGAGTTTGAC, AATAGTATTG, 1250GTTTGCCAAA, TATTGGCATA, GAGATAACCA, TCTACATACT, CTAATTCGTT, 1300AAGCATTGAG, ATAGGGACAC, TTTCTATAGC, AACTAGT, 1337, (2) SEQ, ID, the information of NO:33:, (i) sequence signature:
(A) length: 1837 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes, (xi) sequence description: SEQ, ID, NO:33:TCATGTTTGA, CAGCTTATCA, TCGATAAGCT, TACTTTTCGA, ATCAGGTCTA, 50TCCTTGAAAC, AGGTGCAACA, TAGATTAGGG, CATGGAGATT, TACCAGACAA, 100CTATGAACGT, ATATACTCAC, ATCACGCAAT, CGGCAATTGA, TGACATTGGA, 150ACTAAATTCA, ATCAATTTGT, TACTAACAAG, CAACTAGATT, GACAACTAAT, 200TCTCAACAAA, CGTTAATTTA, ACAACATTCA, AGTAACTCCC, ACCAGCTCCA, 250TCAATGCTTA, CCGTAAGTAA, TCATAACTTA, CTAAAACCTT, GTTACATCAA, 300GGTTTTTTCT, TTTTGTCTTG, TTCATGAGTT, ACCATAACTT, TCTATATTAT, 350TGACAACTAA, ATTGACAACT, CTTCAATTAT, TTTTCTGTCT, ACTCAAAGTT, 400TTCTTCATTT, GATATAGTCT, AATTCCACCA, TCACTTCTTC, CACTCTCTCT, 450ACCGTCACAA, CTTCATCATC, TCTCACTTTT, TCGTGTGGTA, ACACATAATC, 500AAATATCTTT, CCGTTTTTAC, GCACTATCGC, TACTGTGTCA, CCTAAAATAT, 550ACCCCTTATC, AATCGCTTCT, TTAAACTCAT, CTATATATAA, CATATTTCAT, 600CCTCCTACCT, ATCTATTCGT, AAAAAGATAA, AAATAACTAT, TGTTTTTTTT, 650GTTATTTTAT, AATAAAATTA, TTAATATAAG, TTAATGTTTT, TTAAAAATAT, 700ACAATTTTAT, TCTATTTATA, GTTAGCTATT, TTTTCATTGT, TAGTAATATT, 750GGTGAATTGT, AATAACCTTT, TTAAATCTAG, AGGAGAACCC, AGATATAAAA, 800TGGAGGAATA, TTAATGGAAA, ACAATAAAAA, AGTATTGAAG, AAAATGGTAT, 850TTTTTGTTTT, AGTGACATTT, CTTGGACTAA, CAATCTCGCA, AGAGGTATTT, 900GCTCAACAAG, ACCCCGATCC, AAGCCAACTT, CACAGATCTA, GTTTAGTTAA, 950AAACCTTCAA, AATATATATT, TTCTTTATGA, GGGTGACCCT, GTTACTCACG, 1000AGAATGTGAA, ATCTGTTGAT, CAACTTTTAT, CTCACGATTT, AATATATAAT, 1050GTTTCAGGGC, CAAATTATGA, TAAATTAAAA, ACTGAACTTA, AGAACCAAGA, 1100GATGGCAACT, TTATTTAAGG, ATAAAAACGT, TGATATTTAT, GGTGTAGAAT, 1150ATTACCATCT, CTGTTATTTA, TGTGAAAATG, CAGAAAGGAG, TGCATGTATC, 1200TACGGAGGGG, TAACAAATCA, TGAAGGGAAT, CATTTAGAAA, TTCCTAAAAA, 1250GATAGTCGTT, AAAGTATCAA, TCGATGGTAT, CCAAAGCCTA, TCATTTGATA, 1300TTGAAACAAA, TAAAAAAATG, GTAACTGCTC, AAGAATTAGA, CTATAAAGTT, 1350AGAAAATATC, TTACAGATAA, TAAGCAACTA, TATACTAATG, GACCTTCTAA, 1400ATATGAAACT, GGATATATAA, AGTTCATACC, TAAGAATAAA, GAAAGTTTTT, 1450GGTTTGATTT, TTTCCCTGAA, CCAGAATTTA, CTCAATCTAA, ATATCTTATG, 1500ATATATAAAG, ATAATGAAAC, GCTTGACTCA, AACACAAGCC, AAATTGAAGT, 1550CTACCTAACA, ACCAAGTAAC, TTTTTGCTTT, TGGCAACCTT, ACCTACTGCT, 1600GGATTTAGAA, ATTTTATTGC, AATTCTTTTA, TTAATGTAAA, AACCGCTCAT, 1650TTGATGAGCG, GTTTTGTCTT, ATCTAAAGGA, GCTTTACCTC, CTAATGCTGC, 1700AAAATTTTAA, ATGTTGGATT, TTTGTATTTG, TCTATTGTAT, TTGATGGGTA, 1750ATCCCATTTT, TCGACAGACA, TCGTCGTGCC, ACCTCTAACA, CCAAAATCAT, 1800AGACAGGAGC, TTGTAGCTTA, GCAACTATTT, TATCGTC, 1837, (2) SEQ, ID, the information of NO:34:, (i) sequence signature:
(A) length: 841 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae
(xi) sequence description: SEQ, ID, NO:34:GATCAATATG, TCCAAGAAAC, CACATGTTCC, TAAGACAAGA, GCTAACAGAC, 50TGGCCGTCAA, TAATAGTATT, GTTCTTTTTT, TCATCATTAC, TCCTTAACTA, 100GTGTTTAACT, GATTAATTAG, CCAGTAAATA, GTTTATCTTT, ATTTACACTA, 150TCTGTTAAGA, TATAGTAAAA, TGAAATAAGA, ACAGGACAGT, CAAATCGATT, 200TCTAACAATG, TTTTAGAAGT, AGAGGTATAC, TATTCTAATT, TCAATCTACT, 250ATATTTTGCA, CATTTTCATA, AAAAAAATGA, GAACTAGAAC, TCACATTCTG, 300CTCTCATTTT, TCGTTTTCCC, GTTCTCCTAT, CCTGTTTTTA, GGAGTTAGAA, 350AATGCTGCTA, CCTTTACTTA, CTCTCCTTTA, ATAAAGCCAA, TAGTTTTTCA, 400GCTTCTGCCA, TAATAGTATT, GTTGTCCTGG, GTGCCAAATA, GTAAATTATT, 450TTTTAATCCT, GTGAGAGTCT, CTTTGGCATT, GGACTTGATA, ATTGGATTCT, 500GGATTTTTCC, AAGTAAATCT, TCAGCCTCTC, TCAGTTTTCT, TAACCTTTCA, 550GTCTCGACCT, GAGGTTCTTC, TGATTCCTCT, GGTGATTCTT, CTGGTGATTC, 600TTCTTCTGGT, TCCTCTGTTG, GTTTTGGAGA, CTCTGGTTTC, TCGCTTTGCG, 650GTTTCTCTTC, TCGAGGGGTT, TCTTCCTCAG, GTTTTTCTGT, CTGAGGTTTC, 700TCCTCGTTTG, GTTTTTCCGT, TTGATTGGTA, TCAGCTTGAC, CATTTTTGTT, 750TCTTTGAACA, TGGTCGCTAG, CGTTACCAAA, ACCATTATCT, GAATGCGACG, 800, (2) SEQ, ID, the information of NO:35:, (i) sequence signature:
(A) length: 4500 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organisms: Streptococcus pneumoniae
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
GATCAGGACA GTCAAATCGA TTTCTAACAA TGTTTTAGAA GTAGATGTGT 50
ACTATTCTAG TTTCAATCTA TTATATTTAT AGAATTTTTT GTTGCTAGAT 100
TTGTCAAATT GCTTAAAATA ATTTTTTTCA GAAAGCAAAA GCCGATACCT 150
ATCGAGTAGG GTAGTTCTTG CTATCGTCAG GCTTGTCTGT AGGTGTTAAC 200
ACTTTTCAAA AATCTCTTCA AACAACGTCA GCTTTGCCTT GCCGTATATA 250
TGTTACTGAC TTCGTCAGTT CTATCTGCCA CCTCAAAACG GTGTTTTGAG 300
CTGACTTCGT CAGTTCTATC CACAACCTCA AAACAGTGTT TTGAGCTGAC 350
TTCGTCAGTT CTATCCACAA CCTCAAAACA GTGTTTTGAG CTGACTTTGT 400
CAGTCTTATC TACAACCTCA AAACAGTGTT TTGAGCATCA TGCGGCTAGC 450
TTCTTAGTTT GCTCTTTGAT TTTCATTGAG TATAAAAACA GATGAGTTTC 500
TGTTTTCTTT TTATGGACTA TAAATGTTCA GCTGAAACTA CTTTCAAGGA 550
CATTATTATA TAAAAGAATT TTTTGAAACT AAAATCTACT ATATTACACT 600
ATATTGAAAG CGTTTTAAAA ATGAGGTATA ATAAATTTAC TAACACTTAT 650
AAAAAGTGAT AGAATCTATC TTTATGTATA TTTAAAGATA GATTGCTGTA 700
AAAATAGTAG TAGCTATGCG AAATAACAGA TAGAGAGAAG GGATTGAAGC 750
TTAGAAAAGG GGAATAATAT GATATTTAAG GCATTCAAGA CAAAAAAGCA 800
GAGAAAAAGA CAAGTTGAAC TACTTTTGAC AGTTTTTTTC GACAGTTTTC 850
TGATTGATTT ATTTCTTCAC TTATTTGGGA TTGTCCCCTT TAAGCTGGAT 900
AAGATTCTGA TTGTGAGCTT GATTATATTT CCCATTATTT CTACAAGTAT 950
TTATGCTTAT GAAAAGCTAT TTGAAAAAGT GTTCGATAAG GATTGAGCAG 1000
GAAGTATGGT GTAAATAGCA TAAGCTGATG TCCATCATTT GCTTATAAAG 1050
AGATATTTTA GTTTAATTGC AGCGGTGTCC TGGTAGATAA ACTAGATTGG 1100
CAGGAGTCTG ATTGGAGAAA GGAGAGGGGA AATTTGGCAC CAATTTGAGA 1150
TAGTTTGTTT AGTTCATTTT TGTCATTTAA ATGAACTGTA GTAAAAGAAA 1200
GTTAATAAAA GACAAACTAA GTGCATTTTC TGGAATAAAT GTCTTATTTC 1250
AGAAATCGGG ATATAGATAT AGAGAGGAAC AGTATGAATC GGAGTGTTCA 1300
AGAACGTAAG TGTCGTTATA GCATTAGGAA ACTATCGGTA GGAGCGGTTT 1350
CTATGATTGT AGGAGCAGTG GTATTTGGAA CGTCTCCTGT TTTAGCTCAA 1400
GAAGGGGCAA GTGAGCAACC TCTGGCAAAT GAAACTCAAC TTTCGGGGGA 1450
GAGCTCAACC CTAACTGATA CAGAAAAGAG CCAGCCTTCT TCAGAGACTG 1500
AACTTTCTGG CAATAAGCAA GAACAAGAAA GGAAAGATAA GCAAGAAGAA 1550
AAAATTCCAA GAGATTACTA TGCACGAGAT TTGGAAAATG TCGAAACAGT 1600
GATAGAAAAA GAAGATGTTG AAACCAATGC TTCAAATGGT CAGAGAGTTG 1650
ATTTATCAAG TGAACTAGAT AAACTAAAGA AACTTGAAAA CGCAACAGTT 1700
CACATGGAGT TTAAGCCAGA TGCCAAGGCC CCAGCATTCT ATAATCTCTT 1750
TTCTGTGTCA AGTGCTACTA AAAAAGATGA GTACTTCACT ATGGCAGTTT 1800
ACAATAATAC TGCTACTCTA GAGGGGCGTG GTTCGGATGG GAAACAGTTT 1850
TACAATAATT ACAACGATGC ACCCTTAAAA GTTAAACCAG GTCAGTGGAA 1900
TTCTGTGACT TTCACAGTTG AAAAACCGAC AGCAGAACTA CCTAAAGGCC 1950
GAGTGCGCCT CTACGTAAAC GGGGTATTAT CTCGAACAAG TCTGAGATCT 2000
GGCAATTTCA TTAAAGATAT GCCAGATGTA ACGCATGTGC AAATCGGAGC 2050
AACCAAGCGT GCCAACAATA CGGTTTGGGG GTCAAATCTA CAGATTCGGA 2100
ATCTCACTGT GTATAATCGT GCTTTAACAC CAGAAGAGGT ACAAAAACGT 2150
AGTCAACTTT TTAAACGCTC AGATTTAGAA AAAAAACTAC CTGAAGGAGC 2200
GGCTTTAACA GAGAAAACGG ACATATTCGA AAGCGGGCGT AACGGTAAAC 2250
CAAATAAAGA TGGAATCAAG AGTTATCGTA TTCCAGCACT TCTCAAGACA 2300
GATAAAGGAA CTTTGATCGC AGGTGCAGAT GAACGCCGTC TCCATTCGAG 2350
TGACTGGGGT GATATCGGTA TGGTCATCAG ACGTAGTGAA GATAATGGTA 2400
AAACTTGGGG TGACCGAGTA ACCATTACCA ACTTACGTGA CAATCCAAAA 2450
GCTTCTGACC CATCGATCGG TTCACCAGTG AATATCGATA TGGTGTTGGT 2500
TCAAGATCCT GAAACCAAAC GAATCTTTTC TATCTATGAC ATGTTCCCAG 2550
AAGGGAAGGG AATCTTTGGA ATGTCTTCAC AAAAAGAAGA AGCCTACAAA 2600
AAAATCGATG GAAAAACCTA TCAAATCCTC TATCGTGAAG GAGAAAAGGG 2650
AGCTTATACC ATTCGAGAAA ATGGTACTGT CTATACACCA GATGGTAAGG 2700
CGACAGACTA TCGCGTTGTT GTAGATCCTG TTAAACCAGC CTATAGCGAC 2750
AAGGGGGATC TATACAAGGG TAACCAATTA CTAGGCAATA TCTACTTCAC 2800
AACAAACAAA ACTTCTCCAT TTAGAATTGC CAAGGATAGC TATCTATGGA 2850
TGTCCTACAG TGATGACGAC GGGAAGACAT GGTCAGCGCC TCAAGATATT 2900
ACTCCGATGG TCAAAGCCGA TTGGATGAAA TTCTTGGGTG TAGGTCCTGG 2950
AACAGGAATT GTACTTCGGA ATGGGCCTCA CAAGGGACGG ATTTTGATAC 3000
CGGTTTATAC GACTAATAAT GTATCTCACT TAAATGGCTC GCAATCTTCT 3050
CGTATCATCT ATTCAGATGA TCATGGAAAA ACTTGGCATG CTGGAGAAGC 3100
GGTCAACGAT AACCGTCAGG TAGACGGTCA AAAGATCCAC TCTTCTACGA 3150
TGAACAATAG ACGTGCGCAA AATACAGAAT CAACGGTGGT ACAACTAAAC 3200
AATGGAGATG TTAAACTCTT TATGCGTGGT TTGACTGGAG ATCTTCAGGT 3250
TGCTACAAGT AAAGACGGAG GAGTGACTTG GGAGAAGGAT ATCAAACGTT 3300
ATCCACAGGT TAAAGATGTC TATGTTCAAA TGTCTGCTAT CCATACGATG 3350
CACGAAGGAA AAGAATACAT CATCCTCAGT AATGCAGGTG GACCGAAACG 3400
TGAAAATGGG ATGGTCCACT TGGCACGTGT CGAAGAAAAT GGTGAGTTGA 3450
CTTGGCTCAA ACACAATCCA ATTCAAAAAG GAGAGTTTGC CTATAATTCG 3500
CTCCAAGAAT TAGGAAATGG GGAGTATGGC ATCTTGTATG AACATACTGA 3550
AAAAGGACAA AATGCCTATA CCCTATCATT TAGAAAATTT AATTGGGACT 3600
TTTTGAGCAA AGATCTGATT TCTCCTACCG AAGCGAAAGT GAAGCGAACT 3650
AGAGAGATGG GCAAAGGAGT TATTGGCTTG GAGTTCGACT CAGAAGTATT 3700
GGTCAACAAG GCTCCAACCC TTCAATTGGC AAATGGTAAA ACAGCACGCT 3750
TCATGACCCA GTATGATACA AAAACCCTCC TATTTACAGT GGATTCAGAG 3800
GATATGGGTC AAAAAGTTAC AGGTTTGGCA GAAGGTGCAA TTGAAAGTAT 3850
GCATAATTTA CCAGTCTCTG TGGCGGGCAC TAAGCTTTCG AATGGAATGA 3900
ACGGAAGTGA AGCTGCTGTT CATGAAGTGC CAGAATACAC AGGCCCATTA 3950
GGGACATCCG GCGAAGAGCC AGCTCCAACA GTCGAGAAGC CAGAATACAC 4000
AGGCCCACTA GGGACATCCG GCGAAGAGCC AGCCCCGACA GTCGAGAAGC 4050
CAGAATACAC AGGCCCACTA GGGACAGCTG GTGAAGAAGC AGCTCCAACA 4100
GTCGAGAAGC CAGAATTTAC AGGGGGAGTT AATGGTACAG AGCCAGCTGT 4150
TCATGAAATC GCAGAGTATA AGGGATCTGA TTCGCTTGTA ACTCTTACTA 4200
CAAAAGAAGA TTATACTTAC AAAGCTCCTC TTGCTCAGCA GGCACTTCCT 4250
GAAACAGGAA ACAAGGAGAG TGACCTCCTA GCTTCACTAG GACTAACAGC 4300
TTTCTTCCTT GGTCTGTTTA CGCTAGGGAA AAAGAGAGAA CAATAAGAGA 4350
AGAATTCTAA ACATTTGATT TTGTAAAAAT AGAAGGAGAT AGCAGGTTTT 4400
CAAGCCTGCT ATCTTTTTTT GATGACATTC AGGCTGATAC GAAATCATAA 4450
GAGGTCTGAA ACTACTTTCA GAGTAGTCTG TTCTATAAAA TATAGTAGAT 4500
(2) SEQ ID NO: 36 information about:
(I) SEQUENCE CHARACTERISTICS:
...
(A) length: 705 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: MRSE, (xi) sequence description: SEQ, ID, NO:36:GATCCAAGCT, TATCGATATC, ATCAAAAAGT, TGGCGAACCT, TTTCAAATTT, 50TGGTTCAAAT, TCTTGAGATG, TATAGAATTC, AAAATATTTA, CCATTTGCAT, 100AGTCTGATTG, CTCAAAGTCT, TGATACTTTT, CTCCACGCTC, TTTTGCAATT, 150TCCATTGAAC, GTTCGATGGA, ATAATAGTTC, ATAATCATAA, AGAATATATT, 200AGCAAAGTCT, TTTGCTTCTT, CAGATTCATA, GCCAATTTTA, TTTTTAGCTA, 250GATAACCATG, TAAGTTCATT, ACTCCTAGTC, CAACAGAATG, TAGTTCACTA, 300TTCGCTTTTT, TTACACCTGG, TGCATTTTGA, ATATTTGCTT, CATCACTTAC, 350AACTGTAAGA, GCATCCATAC, CTGTGAACAC, AGAATCTCTG, AATTTACCTG, 400ATTCCATAAC, ATTCACTATA, TTCAATGAGC, CTAAGTTACA, TGAAATATCT, 450CTTTTAATTT, CATCTTCAAT, TCCATAGTCG, TTAATTACTG, ATGTCTCTTG, 500TAATTGGAAA, ATTTCAGTAC, ATAAATTACT, CATTTTAATT, TGCCCAATAT, 550TTGAATTCGC, ATGTACTTTG, TTTGCATTAT, CTTTAAACAT, AAGATATGGA, 600TAACCAGACT, GTAATTGTGT, TTGTGCAATC, ATATTTAACA, TTTCACGTGC, 650GTCTTTTTTC, TTTTTATCGA, TTTCGAACCC, GGGGTACCGA, ATTCCTCGAG, 700TCTAG, 705, (2) SEQ, ID, the information of NO:37:, (i) sequence signature:
(A) length: 442 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus aureus, (xi) sequence description:, SEQ, ID, NO:37:GATCAATCTT, TGTCGGTACA, CGATATTCTT, CACGACTAAA, TAAACGCTCA, 50TTCGCGATTT, TATAAATGAA, TGTTGATAAC, AATGTTGTAT, TATCTACTGA, 100AATCTCATTA, CGTTGCATCG, GAAACATTGT, GTTCTGTATG, TAAAAGCCGT, 150CTTGATAATC, TTTAGTAGTA, CCGAAGCTGG, TCATACGAGA, GTTATATTTT, 200CCAGCCAAAA, CGATATTTTT, ATAATCATTA, CGTGAAAAAG, GTTTCCCTTC, 250ATTATCACAC, AAATATTTTA, GCTTTTCAGT, TTCTATATCA, ACTGTAGCTT, 300CTTTATCCAT, ACGTTGAATA, ATTGTACGAT, TCTGACGCAC, CATCTTTTGC, 350ACACCTTTAA, TGTTATTTGT, TTTAAAAGCA, TGAATAAGTT, TTTCAACACA, 400ACGATGTGAA, TCTTCTAAGA, AGTCACCGTA, AAATGAAGGA, TC, 442, (2) SEQ, ID, the information of NO:38:, (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis (xi) sequence description: the information of SEQ ID NO:38:GCAATACAGG GAAAAATGTC 20 (2) SEQ ID NO:39: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis (xi) sequence description: the information of SEQ ID NO:39:CTTCATCAAA CAATTAACTC 20 (2) SEQ ID NO:40: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis (xi) sequence description: the information of SEQ ID NO:40:GAACAGAAGA AGCCAAAAAA 20 (2) SEQ ID NO:41: (i) row feature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: enterococcus faecalis (xi) sequence description: the information of SEQ ID NO:41:GCAATCCCAA ATAATACGGT 20 (2) SEQ ID NO:42: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:42:CTTTCCAGC GTCATATTG 19 (2) SEQ ID NO:43: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:43:GATCTCGACA AAATGGTGA 19 (2) SEQ ID NO:44: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:44:CACCCGCTTG CGTGGCAAGC TGCCC 25 (2) SEQ ID NO:45: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:45:CGTTTGTGGA TTCCAGTTCC ATCCG 25 (2) SEQ ID NO:46: (i) sequence signature:
(A) length: 17 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:46:TCACCCGCTT GCGTGGC 17 (2) SEQ ID NO:47: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:48 SEQ ID NO:47:GGAACTGGAA TCCACAAAC 192): (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:48:TGAAGCACTG GCCGAAATGC GT 25 (2) SEQ ID NO:49: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source: (A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:49:GATGTACAGG ATTCGTTGAATT 25 (2) SEQ ID NO:50: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:50:TAGCGAAGGC GTAGCAGAAA CTAAC 25 (2) SEQ ID NO:51: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:51:GCAACCCGAA CTCAACGCCG GATTT 25 (2) SEQ ID NO:52: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:52:ATACACAAGG GTCGCATCTG CGGCC 25 (2) SEQ ID NO:53: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:53:TGCGTATGCA TTGCAGACCT TGTGGC 26 (2) SEQ ID NO:54:
(i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:54:GCTTTCACTG GATATCGCGC TTGGG 25 (2) SEQ ID NO:55: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:55:GCAACCCGAA CTCAACGCC 19 (2) SEQ ID NO:56: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:56:GCAGATGCGA CCCTTGTGT 19 (2) SEQ ID NO:57: (i) sequence signature:
(A) length: 23 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:57:GTGGTGTCGT TCAGCGCTTT CAC 23 (2) SEQ ID NO:58: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:58:GCGATATTCA CACCCTACGC CA 25 (2) SEQ ID NO:59: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:59:GTCGAAAATG CCGGAAGAGG G 26 (2) SEQ ID NO:60: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:60:ACTGAGCTGC AGACCGGTAA AACTC 26 (2) SEQ ID NO:61: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:61:GACAGTCAGT TCGTC 19 (2) SEQ ID NO:62: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:62:CGTAGGGTGT ATCGC 19 (2) SEQ ID NO:63: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:63:CGTGATGGAT ATTCTTAACG C 26 (2) SEQ ID NO:64: (i) sequence signature:
(A) length: 23 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source: (A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:64:ACCAAACTGT TGAGCCGCCT GGA 23 (2) SEQ ID NO:65: (i) sequence signature:
(A) length: 23 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source: (A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:65:GTGATCGCCC CTCATCTGCT ACT 23 (2) SEQ ID NO:66: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:66:CGCCCTTCGT TAAGAATATC CATCA 26 (2) SEQ ID NO:67: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:67:TCGCCCCTCA GCTACT 19 (2) SEQ ID NO:68: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:68:GATCGTGATG GATATTCTT 19 (2) SEQ ID NO:69: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:69:CAGGAAGATG CTGCACCGGTTTG 25 (2) SEQ ID NO:70: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:70:TGGTTCACTG ACTTTGCGAT GTTTC 25 (2) SEQ ID NO:71:
(i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:71:TCGAGGATGG CATGCACTAG AAAAT 25 (2) SEQ ID NO:72: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:72:CGCTGATTAG GTTTCGCTAA AATCTTATTA 30 (2) SEQ ID NO:73: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:73:TTGATCCTCA TTTTATTAAT CACATGACCA 30 (2) SEQ ID NO:74: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source: (A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:74:GAAACATCGC AAAGTCAGT 19 (2) SEQ ID NO:75: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:75:ATAAAATGAG GATCAAGTTC 20 (2) SEQ ID NO:76: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:76:CCGCCTTTAG CATTAATTGG TGTTTATAGT 30 (2) SEQ ID NO:77: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:77:CCTATTGCAG ATACCTTAAA TGTCGGC 30 (2) SEQ ID NO:78: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:78:AGTAAAATGA AATAAGAACA GGACAG 26 (2) SEQ ID NO:79: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:79:AAAACAGGAT AGGAGAACGG GAAAA 25 (2) SEQ ID NO:80: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:80:TTGAGTGATG ATTTCACTGA CTCCC 25 (2) SEQ ID NO:81: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:81:GTCAGACAGT GATGCTGACG ACACA 25 (2) SEQ ID NO:82: (i) sequence signature:
(A) length: 27 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:82:TGGTTGTCAT GCTGTTTGTG TGAAAAT 27 (2) SEQ ID NO:83: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:83:CGAGCGGGTG GTGTTCATC 19 (2) SEQ ID NO:84: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:84:CAAGTCGTCG TCGGAGGGA 19 (2) SEQ ID NO:85: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:85:TCGCTGTTCA TCAAGACCC 19 (2) SEQ ID NO:86: (i) sequence signature:
(A) length: 19 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:86:CCGAGAACCA GACTTCATC 19 (2) SEQ ID NO:87: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:87:AATGCGGCTG TACCTCGGCG CTGGT 25 (2) SEQ ID NO:88: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:88:GGCGGAGGGC CAGTTGCACC TGCA 25 (2) SEQ ID NO:89: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:89:AGCCCTGCTC CTCGGCAGCC TCTGC 25 (2) SEQ ID NO:90: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:90:TGGCTTTTGC AACCGCGTTC AGGTT 25 (2) SEQ ID NO:91: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:90:GCGCCCGCGA GGGCATGCTT CGATG 25 (2) SEQ ID NO:92: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa
(xi) sequence description: the information of SEQ ID NO:92:ACCTGGGCGC CAACTACAAG TTCTA 25 (2) SEQ ID NO:93: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:93:GGCTACGCTG CCGGGCTGCA GGCCG 25 (2) SEQ ID NO:94: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:94:CCGATCTACA CCATCGAGAT GGCG 25 (2) SEQ ID NO:95: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Pseudomonas aeruginosa (xi) sequence description: the information of SEQ ID NO:95:GAGCGCGGCT ATGTGTTCGT CT 25 (2) SEQ ID NO:96: (i) sequence signature:
(A) length: 29 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:96:CGTTTTTACC CTTACCTTTT CGTACTACC 29 (2) SEQ ID NO:97: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:97:TCAGGCAGAG GTAGTACGAA AAGGTAAGGG 30 (2) SEQ ID NO:98: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:98:CGTTTTTACC CTTACCTTTT CGTACT 26 (2) SEQ ID NO:99: (i) sequence signature:
(A) length: 28 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:99:ATCGATCATC ACATTCCATT TGTTTTTA 28 (2) SEQ ID NO:100: (i) sequence signature:
(A) length: 27 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:100:CACCAAGTTT GACACGTGAA GATTCAT 27 (2) SEQ ID NO:101: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:101:ATGAGTGAAG CGGAGTCAGA TTATGTGCAG 30 (2) SEQ ID NO:102: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:102:CGCTCATTAC GTACAGTGAC AATCG 25 (2) SEQ ID NO:103: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:103:CTGGTTAGCT TGACTCTTAA CAATCTTGTC 30 (2) SEQ ID NO:104: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:104:GACGCGATTG TCACTGTACG TAATGAGCGA 30 (2) SEQ ID NO:105: (i) sequence signature:
(A) length: 28 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Haemophilus influenzae (xi) sequence description: the information of SEQ ID NO:105:GCGTCAGAAA AAGTAGGCGA AATGAAAG 28 (2) SEQ ID NO:106: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Haemophilus influenzae (xi) sequence description: the information of SEQ ID NO:106:AGCGGCTCTA TCTTGTAATG ACACA 25 (2) SEQ ID NO:107: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Haemophilus influenzae (xi) sequence description: the information of SEQ ID NO:107:GAAACGTGAA CTCCCCTCTA TATAA 25 (2) SEQ ID NO:108: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:108:GCCCCAAAAC AATGAAACAT ATGGT 25 (2) SEQ ID NO:109: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:109:CTGCAGATTT TGGAATCATA TCGCC 25 (2) SEQ ID NO:110: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:110:TGGTTTGACC AGTATTTAAC GCCAT 25 (2) SEQ ID NO:111: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:111:CAACGGCACC TGATGTACCT TGTAC 25 (2) SEQ ID NO:112: (i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:112:GGCACCTGAT GTACCTTG 18 (2) SEQ ID NO:113: (i) sequence signature:
(A) length: 17 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:113:AACAGCTCAC ACGCATT 17 (2) SEQ ID NO:114: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:114:TTACAACCTG CACCACAAGT CATCA 25 (2) SEQ ID NO:115: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:115:GTACAAACAA GCCGTCAGCG ACTTA 25 (2) SEQ ID NO:116: (i) sequence signature:
(A) length: 23 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:116:CAATCTGCGT GTGTGCGTTC ACT 23 (2) SEQ ID NO:117: (i) sequence signature:
(A) length: 26 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:117:GCTACTTTGT CAGCTTTAGC CATTCA 26 (2) SEQ ID NO:118: (i) sequence signature:
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:118:TGTTTTGAGC TTTTTATTTT TTGA 24 (2) SEQ ID NO:119: (i) sequence signature:
(A) length: 22 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:119:CGCTGACGGC TTGTTTGTAC CA 22 (2) SEQ ID NO:120: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:120:TCTGTGCTAG AGACTGCCCC ATTTC 25 (2) SEQ ID NO:121: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:121:CGATGTCTTG ATTGAGCAGG GTTAT 25 (2) SEQ ID NO:122: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:122:ATCCCACCTT AGGCGGCTGG CTCCA 25 (2) SEQ ID NO:123: (i) sequence signature:
(A) length: 31 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:123:ACGTCAAGTC ATCATGGCCC TTACGAGTAG G 31 (2) SEQ ID NO:124: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:124:GTGTGACGGG CGGTGTGTAC AAGGC 25 (2) SEQ ID NO:125: (i) sequence signature:
(A) length: 28 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:125:GAGTTGCAGA CTCCAATCCG GACTACGA 28 (2) SEQ ID NO:126: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:126:GGAGGAAGGT GGGGATGACG 20 (2) SEQ ID NO:127: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:127:ATGGTGTGAC GGGCGGTGTG 20 (2) SEQ ID NO:128: (i) sequence signature:
(A) length: 32 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:128:CCCTATACAT CACCTTGCGG TTTAGCAGAG AG 32 (2) SEQ ID NO:129: (i) sequence signature:
(A) length: 28 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:129:GGGGGGACCA TCCTCCAAGG CTAAATAC 28 (2) SEQ ID NO:130: (i) sequence signature:
(A) length: 32 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) is sequence description (xi): the information of SEQ ID NO:130:CGTCCACTTT CGTGTTTGCA GAGTGCTGTG TT 32 (2) SEQ ID NO:131: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:131:CAGGAGTACG GTGATTTTTA 20 (2) SEQ ID NO:132: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: intestinal bacteria (xi) sequence description: the information of SEQ ID NO:132:ATTTCTGGTT TGGTCATACA 20 (2) SEQ ID NO:133: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:133:CGGGAGTCAG TGAAATCATC 20 (2) SEQ ID NO:134: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: proteus mirabilis (xi) sequence description: the information of SEQ ID NO:134:CTAAAATCGC CACACCTCTT 20 (2) SEQ ID NO:135: (i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:135:GCAGCGTGGT GTCGTTCA 18 (2) SEQ ID NO:136: (i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:136:AGCTGGCAAC GGCTGGTC 18 (2) SEQ ID NO:137: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:137:ATTCACACCC TACGCAGCCA 20 (2) SEQ ID NO:138: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Klebsiella pneumonia (xi) sequence description: the information of SEQ ID NO:138:ATCCGGCAGC ATCTCTTTGT 20 (2) SEQ ID NO:139: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:139:CTGGTTAGCT TGACTCTTAA CAATC 25 (2) SEQ ID NO:140: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Staphylococcus saprophyticus (xi) sequence description: the information of SEQ ID NO:140:TCTTAACGAT AGAATGGAGC AACTG 25 (2) SEQ ID NO:141: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes (xi) sequence description: the information of SEQ ID NO:141:TGAAAATTCT TGTAACAGGC 20 (2) SEQ ID NO:142: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes (xi) sequence description: the information of SEQ ID NO:142:GGCCACCAGC TTGCCCAATA 20 (2) SEQ ID NO:143: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes (xi) sequence description: the information of SEQ ID NO:143:ATATTTTCTT TATGAGGGTG 20 (2) SEQ ID NO:144: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pyogenes (xi) sequence description: the information of SEQ ID NO:144:ATCCTTAAAT AAAGTTGCCA 20 (2) SEQ ID NO:145: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus epidermidis (xi) sequence description: the information of SEQ ID NO:145:ATCAAAAAGT TGGCGAACCT TTTCA 25 (2) SEQ ID NO:146: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus epidermidis (xi) sequence description: the information of SEQ ID NO:146:CAAAAGAGCG TGGAGAAAAG TATCA 25 (2) SEQ ID NO:147: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus epidermidis (xi) sequence description: the information of SEQ ID NO:147:TCTCTTTTAA TTTCATCTTC AATTCCATAG 30 (2) SEQ ID NO:148: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: staphylococcus epidermidis (xi) sequence description: the information of SEQ ID NO:148:AAACACAATT ACAGTCTGGT TATCCATATC 30 (2) SEQ ID NO:149: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus aureus (xi) sequence description: the information of SEQ ID NO:149:CTTCATTTTA CGGTGACTTC TTAGAAGATT 30 (2) SEQ ID NO:150: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus aureus (xi) sequence description: the information of SEQ ID NO:150:TCAACTGTAG CTTCTTTATC CATACGTTGA 30 (2) SEQ ID NO:151: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus aureus
(xi) sequence description: the information of SEQ ID NO:151:ATATTTTAGC TTTTCAGTTT CTATATCAAC 30 (2) SEQ ID NO:152: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus aureus
(xi) sequence description: the information of SEQ ID NO:152:AATCTTTGTC GGTACACGAT ATTCTTCACG 30 (2) SEQ ID NO:153: (i) sequence signature:
(A) length: 30 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus aureus (xi) sequence description: the information of SEQ ID NO:153:CGTAATGAGA TTTCAGTAGA TAATACAACA 30 (2) SEQ ID NO:154: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Haemophilus influenzae (xi) sequence description: the information of SEQ ID NO:154:TTTAACGATC CTTTTACTCC TTTTG 25 (2) SEQ ID NO:155: (i) sequence signature:
(A) length: 25 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: Haemophilus influenzae (xi) sequence description: the information of SEQ ID NO:155:ACTGCTGTTG TAAAGAGGTT AAAAT 25 (2) SEQ ID NO:156: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:156:ATTTGGTGAC GGGTGACTTT 20 (2) SEQ ID NO:157: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:157:GCTGAGGATT TGTTCTTCTT 20 (2) SEQ ID NO:158: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:158:GAGCGGTTTC TATGATTGTA 20 (2) SEQ ID NO:159: (i) sequence signature:
(A) length: 20 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: streptococcus pneumoniae (xi) sequence description: the information of SEQ ID NO:159:ATCTTTCCTT TCTTGTTCTT 20 (2) SEQ ID NO:160: (i) sequence signature:
(A) length: 18 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): DNA (genome) (vi) primary source:
(A) organism: morazella catarrhalis (xi) sequence description: the information of SEQ ID NO:160:GCTCAAATCA GGGTCAGC 18 (2) SEQ ID NO:161: (i) sequence signature:
(A) length: 861 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:161:ATGAGTATTC, AACATTTCCG, TGTCGCCCTT, ATTCCCTTTT, TTGCGGCATT, 50TTGCCTTCCT, GTTTTTGCTC, ACCCAGAAAC, GCTGGTGAAA, GTAAAAGATG, 100CTGAAGATCA, GTTGGGTGCA, CGAGTGGGTT, ACATCGAACT, GGATCTCAAC, 150AGCGGTAAGA, TCCTTGAGAG, TTTTCGCCCC, GAAGAACGTT, TTCCAATGAT, 200GAGCACTTTT, AAAGTTCTGC, TATGTGGCGC, GGTATTATCC, CGTGTTGACG, 250CCGGGCAAGA, GCAACTCGGT, CGCCGCATAC, ACTATTCTCA, GAATGACTTG, 300GTTGAGTACT, CACCAGTCAC, AGAAAAGCAT, CTTACGGATG, GCATGACAGT, 350AAGAGAATTA, TGCAGTGCTG, CCATAACCAT, GAGTGATAAC, ACTGCGGCCA, 400ACTTACTTCT, GACAACGATC, GGAGGACCGA, AGGAGCTAAC, CGCTTTTTTG, 450CACAACATGG, GGGATCATGT, AACTCGCCTT, GATCGTTGGG, AACCGGAGCT, 500GAATGAAGCC, ATACCAAACG, ACGAGCGTGA, CACCACGATG, CCTGCAGCAA, 550TGGCAACAAC, GTTGCGCAAA, CTATTAACTG, GCGAACTACT, TACTCTAGCT, 600TCCCGGCAAC, AATTAATAGA, CTGGATGGAG, GCGGATAAAG, TTGCAGGACC, 650ACTTCTGCGC, TCGGCCCTTC, CGGCTGGCTG, GTTTATTGCT, GATAAATCTG, 700GAGCCGGTGA, GCGTGGGTCT, CGCGGTATCA, TTGCAGCACT, GGGGCCAGAT, 750GGTAAGCCCT, CCCGTATCGT, AGTTATCTAC, ACGACGGGGA, GTCAGGCAAC, 800TATGGATGAA, CGAAATAGAC, AGATCGCTGA, GATAGGTGCC, TCACTGATTA, 850AGCATTGGTA, A, 861, (2) SEQ, ID, the information of NO:162:, (i) sequence signature:
(A) length: 918 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:162:ATGTTAAATA, AGTTAAAAAT, CGGCACATTA, TTATTGCTGA, CATTAACGGC, 50TTGTTCGCCC, AATTCTGTTC, ATTCGGTAAC, GTCTAATCCG, CAGCCTGCTA, 100GTGCGCCTGT, GCAACAATCA, GCCACACAAG, CCACCTTTCA, ACAGACTTTG, 150GCGAATTTGG, AACAGCAGTA, TCAAGCCCGA, ATTGGCGTTT, ATGTATGGGA, 200TACAGAAACG, GGACATTCTT, TGTCTTATCG, TGCAGATGAA, CGCTTTGCTT, 250ATGCGTCCAC, TTTCAAGGCG, TTGTTGGCTG, GGGCGGTGTT, GCAATCGCTG, 300CCTGAAAAAG, ATTTAAATCG, TACCATTTCA, TATAGCCAAA, AAGATTTGGT, 350TAGTTATTCT, CCCGAAACCC, AAAAATACGT, TGGCAAAGGC, ATGACGATTG, 400CCCAATTATG, TGAAGCAGCC, GTGCGGTTTA, GCGACAACAG, CGCGACCAAT, 450TTGCTGCTCA, AAGAATTGGG, TGGCGTGGAA, CAATATCAAC, GTATTTTGCG, 500ACAATTAGGC, GATAACGTAA, CCCATACCAA, TCGGCTAGAA, CCCGATTTAA, 550ATCAAGCCAA, ACCCAACGAT, ATTCGTGATA, CGAGTACACC, CAAACAAATG, 600GCGATGAATT, TAAATGCGTA, TTTATTGGGC, AACACATTAA, CCGAATCGCA, 650AAAAACGATT, TTGTGGAATT, GGTTGGACAA, TAACGCAACA, GGCAATCCAT, 700TGATTCGCGC, TGCTACGCCA, ACATCGTGGA, AAGTGTACGA, TAAAAGCGGG, 750GCGGGTAAAT, ATGGTGTACG, CAATGATATT, GCGGTGGTTC, GCATACCAAA, 800TCGCAAACCG, ATTGTGATGG, CAATCATGAG, TACGCAATTT, ACCGAAGAAG, 850CCAAATTCAA, CAATAAATTA, GTAGAAGATG, CAGCAAAGCA, AGTATTTCAT, 900ACTTTACAGC, TCAACTAA, 918, (2) SEQ, ID, the information of NO:163:, (i) sequence signature:
(A) length: 864 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:163:ATGCGTTATA, TTCGCCTGTG, TATTATCTCC, CTGTTAGCCA, CCCTGCCGCT, 50GGCGGTACAC, GCCAGCCCGC, AGCCGCTTGA, GCAAATTAAA, CTAAGCGAAA, 100GCCAGCTGTC, GGGCCGCGTA, GGCATGATAG, AAATGGATCT, GGCCAGCGGC, 150CGCACGCTGA, CCGCCTGGCG, CGCCGATGAA, CGCTTTCCCA, TGATGAGCAC, 200CTTTAAAGTA, GTGCTCTGCG, GCGCAGTGCT, GGCGCGGGTG, GATGCCGGTG, 250ACGAACAGCT, GGAGCGAAAG, ATCCACTATC, GCCAGCAGGA, TCTGGTGGAC, 300TACTCGCCGG, TCAGCGAAAA, ACACCTTGCC, GACGCAATGA, CGGTCGGCGA, 350ACTCTGCGCC, GCCGCCATTA, CCATGAGCGA, TAACAGCGCC, GCCAATCTGC, 400TACTGGCCAC, CGTCGGCGGC, CCCGCAGGAT, TGACTGCCTT, TTTGCGCCAG, 450ATCGGCGACA, ACGTCACCCG, CCTTGACCGC, TGGGAAACGG, AACTGAATGA, 500GGCGCTTCCC, GGCGACGCCC, GCGACACCAC, TACCCCGGCC, AGCATGGCCG, 550CGACCCTGCG, CAACGTTGGC, CTGACCAGCC, AGCGTCTGAG, CGCCCGTTCG, 600CAACGGCAGC, TGCTGCAGTG, GATGGTGGAC, GATCGGGTCG, CCGGACCGTT, 650GATCCGCTCC, GTGCTGCCGG, CGGGCTGGTT, TATCGCCGAT, AAGACCGGAG, 700CTGGCGAGCG, GGGTGCGCGC, GGGATTGTCG, CCCTGCTTGG, CCCGAATAAC, 750AAAGCAGAGC, GCATTGTGGT, GATTTATCTG, CGGGATACCC, CGGCGAGCAT, 800GGCCGAGCGA, AATCAGCAAA, TCGCCGGGAT, CGGCAAGGCG, CTGTACGAGC, 850ACTGGCAACG, CTAA, 864, (2) SEQ, ID, the information of NO:164:, (i) sequence signature:
(A) length: 534 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:164:ATGGACACAA, CGCAGGTCAC, ATTGATACAC, AAAATTCTAG, CTGCGGCAGA, 50TGAGCGAAAT, CTGCCGCTCT, GGATCGGTGG, GGGCTGGGCG, ATCGATGCAC, 100GGCTAGGGCG, TGTAACACGC, AAGCACGATG, ATATTGATCT, GACGTTTCCC, 150GGCGAGAGGC, GCGGCGAGCT, CGAGGCAATA, GTTGAAATGC, TCGGCGGGCG, 200CGTCATGGAG, GAGTTGGACT, ATGGATTCTT, AGCGGAGATC, GGGGATGAGT, 250TACTTGACTG, CGAACCTGCT, TGGTGGGCAG, ACGAAGCGTA, TGAAATCGCG, 300GAGGCTCCGC, AGGGCTCGTG, CCCAGAGGCG, GCTGAGGGCG, TCATCGCCGG, 350GCGGCCAGTC, CGTTGTAACA, GCTGGGAGGC, GATCATCTGG, GATTACTTTT, 400ACTATGCCGA, TGAAGTACCA, CCAGTGGACT, GGCCTACAAA, GCACATAGAG, 450TCCTACAGGC, TCGCATGCAC, CTCACTCGGG, GCGGAAAAGG, TTGAGGTCTT, 500GCGTGCCGCT, TTCAGGTCGC, GATATGCGGC, CTAA, 534, (2) SEQ, ID, the information of NO:165:, (i) sequence signature:
(A) length: 465 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:165:ATGGGCATCA, TTCGCACATG, TAGGCTCGGC, CCTGACCAAG, TCAAATCCAT, 50GCGGGCTGCT, CTTGATCTTT, TCGGTCGTGA, GTTCGGAGAC, GTAGCCACCT, 100ACTCCCAACA, TCAGCCGGAC, TCCGATTACC, TCGGGAACTT, GCTCCGTAGT, 150AAGACATTCA, TCGCGCTTGC, TGCCTTCGAC, CAAGAAGCGG, TTGTTGGCGC, 200TCTCGCGGCT, TACGTTCTGC, CCAGGTTTGA, GCAGCCGCGT, AGTGAGATCT, 250ATATCTATGA, TCTCGCAGTC, TCCGGCGAGC, ACCGGAGGCA, GGGCATTGCC, 300ACCGCGCTCA, TCAATCTCCT, CAAGCATGAG, GCCAACGCGC, TTGGTGCTTA, 350TGTGATCTAC, GTGCAAGCAG, ATTACGGTGA, CGATCCCGCA, GTGGCTCTCT, 400ATACAAAGTT, GGGCATACGG, GAAGAAGTGA, TGCACTTTGA, TATCGACCCA, 450AGTACCGCCA, CCTAA, 465, (2) SEQ, ID, the information of NO:166:, (i) sequence signature:
(A) length: 861 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:166:ATGCATACGC, GGAAGGCAAT, AACGGAGGCG, CTTCAAAAAC, TCGGAGTCCA, 50AACCGGTGAC, CTATTGATGG, TGCATGCCTC, ACTTAAAGCG, ATTGGTCCGG, 100TCGAAGGAGG, AGCGGAGACG, GTCGTTGCCG, CGTTACGCTC, CGCGGTTGGG, 150CCGACTGGCA, CTGTGATGGG, ATACGCATCG, TGGGACCGAT, CACCCTACGA, 200GGAGACTCGT, AATGGCGCTC, GGTTGGATGA, CAAAACCCGC, CGTACCTGGC, 250CGCCGTTCGA, CCCGCAACG, GCCGGGACTT, ACCGTGGGTT, CGGCCTGCTG, 300AATCAGTTTC, TGGTTCAAGC, CCCCGGCGCG, CGGCGCAGCG, CGCACCCCGA, 350TGCATCGATG, GTCGCGGTTG, GTCCACTGGC, TGAAACGCTG, ACGGAGCCTC, 400ACAAGCTCGG, TCACGCCTTG, GGGGAAGGGT, CGCCCGTCGA, GCGGTTCGTT, 450CGCCTTGGCG, GGAAGGCCCT, GCTGTTGGGT, GCGCCGCTAA, ACTCCGTTAC, 500CGCATTGCAC, TACGCCGAGG, CGGTTGCCGA, TATCCCCAAC, AAACGGCGGG, 550TGACGTATGA, GATGCCGATG, CTTGGAAGCA, ACGGCGAAGT, CGCCTGGAAA, 600ACGGCATCGG, ATTACGATTC, AAACGGCATT, CTCGATTGCT, TTGCTATCGA, 650AGGAAAGCCG, GATGCGGTCG, AAACTATAGC, AAATGCTTAC, GTGAAGCTCG, 700GTCGCCATCG, AGAAGGTGTC, GTGGGCTTTG, CTCAGTGCTA, CCTGTTCGAC, 750GCGCAGGACA, TCGTGACGTT, CGGCGTCACC, TATCTTGAGA, AGCATTTCGG, 800AACCACTCCG, ATCGTGCCAG, CACACGAAGT, CGCCGAGTGC, TCTTGCGAGC, 850CTTCAGGTTA, G, 861, (2) SEQ, ID, the information of NO:167:, (i) sequence signature:
(A) length: 816 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:167:ATGACCGATT, TGAATATCCC, GCATACACAC, GCGCACCTTG, TAGACGCATT, 50TCAGGCGCTC, GGCATCCGCG, CGGGGCAGGC, GCTCATGCTG, CACGCATCCG, 100TTAAAGCAGT, GGGCGCGGTG, ATGGGCGGCC, CCAATGTGAT, CTTGCAGGCG, 150CTCATGGATG, CGCTCACGCC, CGACGGCACG, CTGATGATGT, ATGCGGGATG, 200GCAAGACATC, CCCGACTTTA, TCGACTCGCT, GCCGGACGCG, CTCAAGGCCG, 250TGTATCTTGA, GCAGCACCCA, CCCTTTGACC, CCGCCACCGC, CCGCGCCGTG, 300CGCGAAAACA, GCGTGCTAGC, GGAATTTTTG, CGCACATGGC, CGTGCGTGCA, 350TCGCAGCGCA, AACCCCGAAG, CCTCTATGGT, GGCGGTAGGC, AGGCAGGCCG, 400CTTTGCTGAC, CGCTAATCAC, GCGCTGGATT, ATGGCTACGG, AGTCGAGTCG, 450CCGCTGGCTA, AACTGGTGGC, AATAGAAGGA, TACGTGCTGA, TGCTTGGCGC, 500GCCGCTGGAT, ACCATCACAC, TGCTGCACCA, CGCGGAATAT, CTGGCCAAGA, 550TGCGCCACAA, GAACGTGGTC, CGCTACCCGT, GCCCGATTCT, GCGGGACGGG, 600CGCAAAGTGT, GGGTGACCGT, TGAGGACTAT, GACACCGGTG, ATCCGCACGA, 650CGATTATAGT, TTTGAGCAAA, TCGCGCGCGA, TTATGTGGCG, CAGGGCGGCG, 700GCACACGCGG, CAAAGTCGGT, GATGCGGATG, CTTACCTGTT, CGCCGCGCAG, 750GACCTCACAC, GGTTTGCGGT, GCAGTGGCTT, GAATCACGGT, TCGGTGACTC, 800AGCGTCATAC, GGATAG, 816, (2) SEQ, ID, the information of NO:168:, (i) sequence signature:
(A) length: 498 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:168:ATGCTCTATG, AGTGGCTAAA, TCGATCTCAT, ATCGTCGAGT, GGTGGGGCGG, 50AGAAGAAGCA, CGCCCGACAC, TTGCTGACGT, ACAGGAACAG, TACTTGCCAA, 100GCGTTTTAGC, GCAAGAGTCC, GTCACTCCAT, ACATTGCAAT, GCTGAATGGA, 150GAGCCGATTG, GGTATGCCCA, GTCGTACGTT, GCTCTTGGAA, GCGGGGACGG, 200ATGGTGGGAA, GAAGAAACCG, ATCCAGGAGT, ACGCGGAATA, GACCAGTTAC, 250TGGCGAATGC, ATCACAACTG, GGCAAAGGCT, TGGGAACCAA, GCTGGTTCGA, 300GCTCTGGTTG, AGTTGCTGTT, CAATGATCCC, GAGGTCACCA, AGATCCAAAC, 350GGACCCGTCG, CCGAGCAACT, TGCGAGCGAT, CCGATGCTAC, GAGAAAGCGG, 400GGTTTGAGAG, GCAAGGTACC, GTAACCACCC, CAGATGGTCC, AGCCGTGTAC, 450ATGGTTCAAA, CACGCCAGGC, ATTCGAGCGA, ACACGCAGTG, ATGCCTAA, 498, (2) SEQ, ID, the information of NO:169:, (i) sequence signature:
(A) length: 2007 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:169:ATGAAAAAGA, TAAAAATTGT, TCCACTTATT, TTAATAGTTG, TAGTTGTCGG, 50GTTTGGTATA, TATTTTTATG, CTTCAAAAGA, TAAAGAAATT, AATAATACTA, 100TTGATGCAAT, TGAAGATAAA, AATTTCAAAC, AAGTTTATAA, AGATAGCAGT, 150TATATTTCTA, AAAGCGATAA, TGGTGAAGTA, GAAATGACTG, AACGTCCGAT, 200AAAAATATAT, AATAGTTTAG, GCGTTAAAGA, TATAAACATT, CAGGATCGTA, 250AAATAAAAAA, AGTATCTAAA, AATAAAAAAC, GAGTAGATGC, TCAATATAAA, 300ATTAAAACAA, ACTACGGTAA, CATTGATCGC, AACGTTCAAT, TTAATTTTGT, 350TAAAGAAGAT, GGTATGTGGA, AGTTAGATTG, GGATCATAGC, GTCATTATTC, 400CAGGAATGCA, GAAAGACCAA, AGCATACATA, TTGAAAATTT, AAAATCAGAA, 450CGTGGTAAAA, TTTTAGACCG, AAACAATGTG, GAATTGGCCA, ATACAGGAAC, 500ACATATGAGA, TTAGGCATCG, TTCCAAAGAA, TGTATCTAAA, AAAGATTATA, 550AAGCAATCGC, TAAAGAACTA, AGTATTTCTG, AAGACTATAT, CAACAACAAA, 600TGGATCAAAA, TTGGGTACAA, GATGATACCT, TCGTTCCACT, TTAAAACCGT, 650TAAAAAAATG, GATGAATATT, TAAGTGATTT, CGCAAAAAAA, TTTCATCTTA, 700CAACTAATGA, AACAGAAAGT, CGTAACTATC, CTCTAGAAAA, AGCGACTTCA, 750CATCTATTAG, GTTATGTTGG, TCCCATTAAC, TCTGAAGAAT, TAAAACAAAA, 800AGAATATAAA, GGCTATAAAG, ATGATGCAGT, TATTGGTAAA, AAGGGACTCG, 850AAAAACTTTA, CGATAAAAAG, CTCCAACATG, AAGATGGCTA, TCGTGTCACA, 900ATCGTTGACG, ATAATAGCAA, TACAATCGCA, CATACATTAA, TAGAGAAAAA, 950GAAAAAAGAT, GGCAAAGATA, TTCAACTAAC, TATTGATGCT, AAAGTTCAAA, 1000AGAGTATTTA, TAACAACATG, AAAAATGATT, ATGGCTCAGG, TACTGCTATC, 1050CACCCTCAAA, CAGGTGAATT, ATTAGCACTT, GTAAGCACAC, CTTCATATGA, 1100CGTCTATCCA, TTTATGTATG, GCATGAGTAA, CGAAGAATAT, AATAAATTAA, 1150CCGAAGATAA, AAAAGAACCT, CTGCTCAACA, AGTTCCAGAT, TACAACTTCA, 1200CCAGGTTCAA, CTCAAAAAAT, ATTAACAGCA, ATGATTGGGT, TAAATAACAA, 1250AACATTAGAC, GATAAAACAA, GTTATAAAAT, CGATGGTAAA, GGTTGGCAAA, 1300AAGATAAATC, TTGGGGTGGT, TACAACGTTA, CAAGATATGA, AGTGGTAAAT, 1350GGTAATATCG, ACTTAAAACA, AGCAATAGAA, TCATCAGATA, ACATTTTCTT, 1400TGCTAGAGTA, GCACTCGAAT, TAGGCAGTAA, GAAATTTGAA, AAAGGCATGA, 1450AAAAACTAGG, TGTTGGTGAA, GATATACCAA, GTGATTATCC, ATTTTATAAT, 1500GCTCAAATTT, CAAACAAAAA, TTTAGATAAT, GAAATATTAT, TAGCTGATTC, 1550AGGTTACGGA, CAAGGTGAAA, TACTGATTAA, CCCAGTACAG, ATCCTTTCAA, 1600TCTATAGCGC, ATTAGAAAAT, AATGGCAATA, TTAACGCACC, TCACTTATTA, 1650AAAGACACGA, AAAACAAAGT, TTGGAAGAAA, AATATTATTT, CCAAAGAAAA, 1700TATCAATCTA, TTAAATGATG, GTATGCAACA, AGTCGTAAAT, AAAACACATA, 1750AAGAAGATAT, TTATAGATCT, TATGCAAACT, TAATTGGCAA, ATCCGGTACT, 1800GCAGAACTCA, AAATGAAACA, AGGAGAAAGT, GGCAGACAAA, TTGGGTGGTT, 1850TATATCATAT, GATAAAGATA, ATCCAAACAT, GATGATGGCT, ATTAATGTTA, 1900AAGATGTACA, AGATAAAGGA, ATGGCTAGCT, ACAATGCCAA, AATCTCAGGT, 1950AAAGTGTATG, ATGAGCTATA, TGAGAACGGT, AATAAAAAAT, ACGATATAGA, 2000TGAATAA, 2007, (2) SEQ, ID, the information of NO:170:, (i) sequence signature:
(A) length: 2607 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:170:ATGAATAACA, TCGGCATTAC, TGTTTATGGA, TGTGAGCAGG, ATGAGGCAGA, 50TGCATTCCAT, GCTCTTTCGC, CTCGCTTTGG, CGTTATGGCA, ACGATAATTA, 100ACGCCAACGT, GTCGGAATCC, AACGCCAAAT, CCGCGCCTTT, CAATCAATGT, 150ATCAGTGTGG, GACATAAATC, AGAGATTTCC, GCCTCTATTC, TTCTTGCGCT, 200GAAGAGAGCC, GGTGTGAAAT, ATATTTCTAC, CCGAAGCATC, GGCTGCAATC, 250ATATAGATAC, AACTGCTGCT, AAGAGAATGG, GCATCACTGT, CGACAATGTG, 300GCGTACTCGC, CGGATAGCGT, TGCCGATTAT, ACTATGATGC, TAATTCTTAT, 350GGCAGTACGC, AACGTAAAAT, CGATTGTGCG, CTCTGTGGAA, AAACATGATT, 400TCAGGTTGGA, CAGCGACCGT, GGCAAGGTAC, TCAGCGACAT, GACAGTTGGT, 450GTGGTGGGAA, CGGGCCAGAT, AGGCAAAGCG, GTTATTGAGC, GGCTGCGAGG, 500ATTTGGATGT, AAAGTGTTGG, CTTATAGTCG, CAGCCGAAGT, ATAGAGGTAA, 550ACTATGTACC, GTTTGATGAG, TTGCTGCAAA, ATAGCGATAT, CGTTACGCTT, 600CATGTGCCGC, TCAATACGGA, TACGCACTAT, ATTATCAGCC, ACGAACAAAT, 650ACAGAGAATG, AAGCAAGGAG, CATTTCTTAT, CAATACTGGG, CGCGGTCCAC, 700TTGTAGATAC, CTATGAGTTG, GTTAAAGCAT, TAGAAAACGG, GAAACTGGGC, 750GGTGCCGCAT, TGGATGTATT, GGAAGGAGAG, GAAGAGTTTT, TCTACTCTGA, 800TTGCACCCAA, AAACCAATTG, ATAATCAATT, TTTACTTAAA, CTTCAAAGAA, 850TGCCTAACGT, GATAATCACA, CCGCATACGG, CCTATTATAC, CGAGCAAGCG, 900TTGCGTGATA, CCGTTGAAAA, AACCATTAAA, AACTGTTTGG, ATTTTGAAAG, 950GAGACAGGAG, CATGAATAGA, ATAAAAGTTG, CAATACTGTT, TGGGGGTTGC, 1000TCAGAGGAGC, ATGACGTATC, GGTAAAATCT, GCAATAGAGA, TAGCCGCTAA, 1050CATTAATAAA, GAAAAATACG, AGCCGTTATA, CATTGGAATT, ACGAAATCTG, 1100GTGTATGGAA, AATGTGCGAA, AAACCTTGCG, CGGAATGGGA, AAACGACAAT, 1150TGCTATTCAG, CTGTACTCTC, GCCGGATAAA, AAAATGCACG, GATTACTTGT, 1200TAAAAAGAAC, CATGAATATG, AAATCAACCA, TGTTGATGTA, GCATTTTCAG, 1250CTTTGCATGG, CAAGTCAGGT, GAAGATGGAT, CCATACAAGG, TCTGTTTGAA, 1300TTGTCCGGTA, TCCCTTTTGT, AGGCTGCGAT, ATTCAAAGCT, CAGCAATTTG, 1350TATGGACAAA, TCGTTGACAT, ACATCGTTGC, GAAAAATGCT, GGGATAGCTA, 1400CTCCCGCCTT, TTGGGTTATT, AATAAAGATG, ATAGGCCGGT, GGCAGCTACG, 1450TTTACCTATC, CTGTTTTTGT, TAAGCCGGCG, CGTTCAGGCT, CATCCTTCGG, 1500TGTGAAAAAA, GTCAATAGCG, CGGACGAATT, GGACTACGCA, ATTGAATCGG, 1550CAAGACAATA, TGACAGCAAA, ATCTTAATTG, AGCAGGCTGT, TTCGGGCTGT, 1600GAGGTCGGTT, GTGCGGTATT, GGGAAACAGT, GCCGCGTTAG, TTGTTGGCGA, 1650GGTGGACCAA, ATCAGGCTGC, AGTACGGAAT, CTTTCGTATT, CATCAGGAAG, 1700TCGAGCCGGA, AAAAGGCTCT, GAAAACGCAG, TTATAACCGT, TCCCGCAGAC, 1750CTTTCAGCAG, AGGAGCGAGG, ACGGATACAG, GAAACGGCAA, AAAAAATATA, 1800TAAAGCGCTC, GGCTGTAGAG, GTCTAGCCCG, TGTGGATATG, TTTTTACAAG, 1850ATAACGGCCG, CATTGTACTG, AACGAAGTCA, ATACTCTGCC, CGGTTTCACG, 1900TCATACAGTC, GTTATCCCCG, TATGATGGCC, GCTGCAGGTA, TTGCACTTCC, 1950CGAACTGATT, GACCGCTTGA, TCGTATTAGC, GTTAAAGGGG, TGATAAGCAT, 2000GGAAATAGGA, TTTACTTTTT, TAGATGAAAT, AGTACACGGT, GTTCGTTGGG, 2050ACGCTAAATA, TGCCACTTGG, GATAATTTCA, CCGGAAAACC, GGTTGACGGT, 2100TATGAAGTAA, ATCGCATTGT, AGGGACATAC, GAGTTGGCTG, AATCGCTTTT, 2150GAAGGCAAAA, GAACTGGCTG, CTACCCAAGG, GTACGGATTG, CTTCTATGGG, 2200ACGGTTACCG, TCCTAAGCGT, GCTGTAAACT, GTTTTATGCA, ATGGGCTGCA, 2250CAGCCGGAAA, ATAACCTGAC, AAAGGAAAGT, TATTATCCCA, ATATTGACCG, 2300AACTGAGATG, ATTTCAAAAG, GATACGTGGC, TTCAAAATCA, AGCCATAGCC, 2350GCGGCAGTGC, CATTGATCTT, ACGCTTTATC, GATTAGACAC, GGGTGAGCTT, 2400GTACCAATGG, GGAGCCGATT, TGATTTTATG, GATGAACGCT, CTCATCATGC, 2450GGCAAATGGA, ATATCATGCA, ATGAAGCGCA, AAATCGCAGA, CGTTTGCGCT, 2500CCATCATGGA, AAACAGTGGG, TTTGAAGCAT, ATAGCCTCGA, ATGGTGGCAC, 2550TATGTATTAA, GAGACGAACC, ATACCCCAAT, AGCTATTTTG, ATTTCCCCGT, 2600TAAATAA, 2607, (2) SEQ, ID, the information of NO:171:, (i) sequence signature:
(A) length: 1288 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:171:GGATCCATCA, GGCAACGACG, GGCTGCTGCC, GGCCATCAGC, GGACGCAGGG, 50AGGACTTTCC, GCAACCGGCC, GTTCGATGCG, GCACCGATGG, CCTTCGCGCA, 100GGGGTAGTGA, ATCCGCCAGG, ATTGACTTGC, GCTGCCCTAC, CTCTCACTAG, 150TGAGGGGCGG, CAGCGCATCA, AGCGGTGAGC, GCACTCCGGC, ACCGCCAACT, 200TTCAGCACAT, GCGTGTAAAT, CATCGTCGTA, GAGACGTCGG, AATGGCCGAG, 250CAGATCCTGC, ACGGTTCGAA, TGTCGTAACC, GCTGCGGAGC, AAGGCCGTCG, 300CGAACGAGTG, GCGGAGGGTG, TGCGGTGTGG, CGGGCTTCGT, GATGCCTGCT, 350TGTTCTACGG, CACGTTTGAA, GGCGCGCTGA, AAGGTCTGGT, CATACATGTG, 400ATGGCGACGC, ACGACACCGC, TCCGTGGATC, GGTCGAATGC, GTGTGCTGCG, 450CAAAAACCCA, GAACCACGGC, CAGGAATGCC, CGGCGCGCGG, ATACTTCCGC, 500TCAAGGGCGT, CGGGAAGCGC, AACGCCGCTG, CGGCCCTCGG, CCTGGTCCTT, 550CAGCCACCAT, GCCCGTGCAC, GCGACAGCTG, CTCGCGCAGG, CTGGGTGCCA, 600AGCTCTCGGG, TAACATCAAG, GCCCGATCCT, TGGAGCCCTT, GCCCTCCCGC, 650ACGATGATCG, TGCCGTGATC, GAAATCCAGA, TCCTTGACCC, GCAGTTGCAA, 700ACCCTCACTG, ATCCGCATGC, CCGTTCCATA, CAGAAGCTGG, GCGAACAAAC, 750GATGCTCGCC, TTCCAGAAAA, CCGAGGATGC, GAACCACTTC, ATCCGGGGTC, 800AGCACCACCG, GCAAGCGCCG, CGACGGCCGA, GGTCTTCCGA, TCTCCTGAAG, 850CCAGGGCAGA, TCCGTGCACA, GCACCTTGCC, GTAGAAGAAC, AGCAAGGCCG, 900CCAATGCCTG, ACGATGCGTG, GAGACCGAAA, CCTTGCGCTC, GTTCGCCAGC, 950CAGGACAGAA, ATGCCTCGAC, TTCGCTGCTG, CCCAAGGTTG, CCGGGTGACG, 1000CACACCGTGG, AAACGGATGA, AGGCACGAAC, CCAGTGGACA, TAAGCCTGTT, 1050CGGTTCGTAA, GCTGTAATGC, AAGTAGCGTA, TGCGCTCACG, CAACTGGTCC, 1100AGAACCTTGA, CCGAACGCAG, CGGTGGTAAC, GGCGCAGTGG, CGGTTTTCAT, 1150GGCTTGTTAT, GACTGTTTTT, TTGTACAGTC, TATGCCTCGG, GCATCCAAGC, 1200AGCAAGCGCG, TTACGCCGTG, GGTCGATGTT, TGATGTTATG, GAGCAGCAAC, 1250GATGTTACGC, AGCAGGGCAG, TCGCCCTAAA, ACAAAGTT, 1288, (2) SEQ, ID, the information of NO:172:, (i) sequence signature:
(A) length: 1650 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:172:GTTAGATGCA, CTAAGCACAT, AATTGCTCAC, AGCCAAACTA, TCAGGTCAAG, 50TCTGCTTTTA, TTATTTTTAA, GCGTGCATAA, TAAGCCCTAC, ACAAATTGGG, 100AGATATATCA, TGAAAGGCTG, GCTTTTTCTT, GTTATCGCAA, TAGTTGGCGA, 150AGTAATCGCA, ACATCCGCAT, TAAAATCTAG, CGAGGGCTTT, ACTAAGCTTG, 200CCCCTTCCGC, CGTTGTCATA, ATCGGTTATG, GCATCGCATT, TTATTTTCTT, 250TCTCTGGTTC, TGAAATCCAT, CCCTGTCGGT, GTTGCTTATG, CAGTCTGGTC, 300GGGACTCGGC, GTCGTCATAA, TTACAGCCAT, TGCCTGGTTG, CTTCATGGGC, 350AAAAGCTTGA, TGCGTGGGGC, TTTGTAGGTA, TGGGGCTCAT, AATTGCTGCC, 400TTTTTGCTCG, CCCGATCCCC, ATCGTGGAAG, TCGCTGCGGA, GGCCGACGCC, 450ATGGTGACGG, TGTTCGGCAT, TCTGAATCTC, ACCGAGGACT, CCTTCTTCGA, 500TGAGAGCCGG, CGGCTAGACC, CCGCCGGCGC, TGTCACCGCG, GCGATCGAAA, 550TGCTGCGAGT, CGGATCAGAC, GTCGTGGATG, TCGGACCGGC, CGCCAGCCAT, 600CCGGACGCGA, GGCCTGTATC, GCCGGCCGAT, GAGATCAGAC, GTATTGCGCC, 650GCTCTTAGAC, GCCCTGTCCG, ATCAGATGCA, CCGTGTTTCA, ATCGACAGCT, 700TCCAACCGGA, AACCCAGCGC, TATGCGCTCA, AGCGCGGCGT, GGGCTACCTG, 750AACGATATCC, AAGGATTTCC, TGACCCTGCG, CTCTATCCCG, ATATTGCTGA, 800GGCGGACTGC, AGGCTGGTGG, TTATGCACTC, AGCGCAGCGG, GATGGCATCG, 850CCACCCGCAC, CGGTCACCTT, CGACCCGAAG, ACGCGCTCGA, CGAGATTGTG, 900CGGTTCTTCG, AGGCGCGGGT, TTCCGCCTTG, CGACGGAGCG, GGGTCGCTGC, 950CGACCGGCTC, ATCCTCGATC, CGGGGATGGG, ATTTTTCTTG, AGCCCCGCAC, 1000CGGAAACATC, GCTGCACGTG, CTGTCGAACC, TTCAAAAGCT, GAAGTCGGCG, 1050TTGGGGCTTC, CGCTATTGGT, CTCGGTGTCG, CGGAAATCCT, TCTTGGGCGC, 1100CACCGTTGGC, CTTCCTGTAA, AGGATCTGGG, TCCAGCGAGC, CTTGCGGCGG, 1150AACTTCACGC, GATCGGCAAT, GGCGCTGACT, ACGTCCGCAC, CCACGCGCCT, 1200GGAGATCTGC, GAAGCGCAAT, CACCTTCTCG, GAAACCCTCG, CGAAATTTCG, 1250CAGTCGCGAC, GCCAGAGACC, GAGGGTTAGA, TCATGCCTAG, CATTCACCTT, 1300CCGGCCGCCC, GCTAGCGGAC, CCTGGTCAGG, TTCCGCGAAG, GTGGGCGCAG, 1350ACATGCTGGG, CTCGTCAGGA, TCAAACTGCA, CTATGAGGCG, GCGGTTCATA, 1400CCGCGCCAGG, GGAGCGAATG, GACAGCGAGG, AGCCTCCGAA, CGTTCGGGTC, 1450GCCTGCTCGG, GTGATATCGA, CGAGGTTGTG, CGGCTGATGC, ACGACGCTGC, 1500GGCGTGGATG, TCCGCCAAGG, GAACGCCCGC, CTGGGACGTC, GCGCGGATCG, 1550ACCGGACATT, CGCGGAGACC, TTCGTCCTGA, GATCCGAGCT, CCTAGTCGCG, 1600AGTTGCAGCG, ACGGCATCGT, CGGCTGTTGC, ACCTTGTCGG, CCGAGGATCC, 1650, (2) SEQ, ID, the information of NO:173:, (i) sequence signature:
(A) length: 630 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:173:ATGGGTCCGA, ATCCTATGAA, AATGTATCCT, ATAGAAGGAA, ACAAATCAGT, 50ACAATTTATC, AAACCTATTT, TAGAAAAATT, AGAAAATGTT, GAGGTTGGAG, 100AATACTCATA, TTATGATTCT, AAGAATGGAG, AAACTTTTGA, TAAGCAAATT, 150TTATATCATT, ATCCAATCTT, AAACGATAAG, TTAAAAATAG, GTAAATTTTG, 200CTCAATAGGA, CCAGGTGTAA, CTATTATTAT, GAATGGAGCA, AATCATAGAA, 250TGGATGGCTC, AACATATCCA, TTTAATTTAT, TTGGTAATGG, ATGGGAGAAA, 300CATATGCCAA, AATTAGATCA, ACTACCTATT, AAGGGGGATA, CAATAATAGG, 350TAATGATGTA, TGGATAGGAA, AAGATGTTGT, AATTATGCCA, GGAGTAAAAA, 400TCGGGGATGG, TGCAATAGTA, GCTGCTAATT, CTGTTGTTGT, AAAAGATATA, 450GCGCCATACA, TGTTAGCTGG, AGGAAATCCT, GCTAACGAAA, TAAAACAAAG, 500ATTTGATCAA, GATACAATAA, ATCAGCTGCT, TGATATAAAA, TGGTGGAATT, 550GGCCAATAGA, CATTATTAAT, GAGAATATAG, ATAAAATTCT, TGATAATAGC, 600ATCATTAGAG, AAGTCATATG, GAAAAAATGA, 630, (2) SEQ, ID, the information of NO:174:, (i) sequence signature:
(A) length: 1440 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:174:ATGAATATAG, TTGAAAATGA, AATATGTATA, AGAACTTTAA, TAGATGATGA, 50TTTTCCTTTG, ATGTTAAAAT, GGTTAACTGA, TGAAAGAGTA, TTAGAATTTT, 100ATGGTGGTAG, AGATAAAAAA, TATACATTAG, AATCATTAAA, AAAACATTAT, 150ACAGAGCCTT, GGGAAGATGA, AGTTTTTAGA, GTAATTATTG, AATATAACAA, 200TGTTCCTATT, GGATATGGAC, AAATATATAA, AATGTATGAT, GAGTTATATA, 250CTGATTATCA, TTATCCAAAA, ACTGATGAGA, TAGTCTATGG, TATGGATCAA, 300TTTATAGGAG, AGCCAAATTA, TTGGAGTAAA, GGAATTGGTA, CAAGATATAT, 350TAAATTGATT, TTTGAATTTT, TGAAAAAAGA, AAGAAATGCT, AATGCAGTTA, 400TTTTAGACCC, TCATAAAAAT, AATCCAAGAG, CAATAAGGGC, ATACCAAAAA, 450TCTGGTTTTA, GAATTATTGA, AGATTTGCCA, GAACATGAAT, TACACGAGGG, 500CAAAAAAGAA, GATTGTTATT, TAATGGAATA, TAGATATGAT, GATAATGCCA, 550CAAATGTTAA, GGCAATGAAA, TATTTAATTG, AGCATTACTT, TGATAATTTC, 600AAAGTAGATA, GTATTGAAAT, AATCGGTAGT, GGTTATGATA, GTGTGGCATA, 650TTTAGTTAAT, AATGAATACA, TTTTTAAAAC, AAAATTTAGT, ACTAATAAGA, 700AAAAAGGTTA, TGCAAAAGAA, AAAGCAATAT, ATAATTTTTT, AAATACAAAT, 750TTAGAAACTA, ATGTAAAAAT, TCCTAATATT, GAATATTCGT, ATATTAGTGA, 800TGAATTATCT, ATACTAGGTT, ATAAAGAAAT, TAAAGGAACT, TTTTTAACAC, 850CAGAAATTTA, TTCTACTATG, TCAGAAGAAG, AACAAAATTT, GTTAAAACGA, 900GATATTGCCA, GTTTTTTAAG, ACAAATGCAC, GGTTTAGATT, ATACAGATAT, 950TAGTGAATGT, ACTATTGATA, ATAAACAAAA, TGTATTAGAA, GAGTATATAT, 1000TGTTGCGTGA, AACTATTTAT, AATGATTTAA, CTGATATAGA, AAAAGATTAT, 1050ATAGAAAGTT, TTATGGAAAG, ACTAAATGCA, ACAACAGTTT, TTGAGGGTAA, 1100AAAGTGTTTA, TGCCATAATG, ATTTTAGTTG, TAATCATCTA, TTGTTAGATG, 1150GCAATAATAG, ATTAACTGGA, ATAATTGATT, TTGGAGATTC, TGGAATTATA, 1200GATGAATATT, GTGATTTTAT, ATACTTACTT, GAAGATAGTG, AAGAAGAAAT, 1250AGGAACAAAT, TTTGGAGAAG, ATATATTAAG, AATGTATGGA, AATATAGATA, 1300TTGAGAAAGC, AAAAGAATAT, CAAGATATAG, TTGAAGAATA, TTATCCTATT, 1350GAAACTATTG, TTTATGGAAT, TAAAAATATT, AAACAGGAAT, TTATCGAAAA, 1400TGGTAGAAAA, GAAATTTATA, AAAGGACTTA, TAAAGATTGA, 1440, (2) SEQ, ID, the information of NO:175:, (i) sequence signature:
(A) length: 660 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:175:TTGAATTTAA, ACAATGACCA, TGGACCTGAT, CCCGAAAATA, TTTTACCGAT, 50AAAAGGGAAT, CGGAATCTTC, AATTTATAAA, ACCTACTATA, ACGAACGAAA, 100ACATTTTGGT, GGGGGAATAT, TCTTATTATG, ATAGTAAGCG, AGGAGAATCC, 150TTTGAAGATC, AAGTCTTATA, TCATTATGAA, GTGATTGGAG, ATAAGTTGAT, 200TATAGGAAGA, TTTTGTTCAA, TTGGTCCCGG, AACAACATTT, ATTATGAATG, 250GTGCAAACCA, TCGGATGGAT, GGATCAACAT, ATCCTTTTCA, TCTATTCAGG, 300ATGGGTTGGG, AGAAGTATAT, GCCTTCCTTA, AAAGATCTTC, CCTTGAAAGG, 350GGACATTGAA, ATTGGAAATG, ATGTATGGAT, AGGTAGAGAT, GTAACCATTA, 400TGCCTGGGGT, GAAAATTGGG, GACGGGGCAA, TCATTGCTGC, AGAAGCTGTT, 450GTCACAAAGA, ATGTTGCTCC, CTATTCTATT, GTCGGTGGAA, ATCCCTTAAA, 500ATTTATAAGA, AAAAGGTTTT, CTGATGGAGT, TATCGAAGAA, TGGTTAGCTT, 550TACAATGGTG, GAATTTAGAT, ATGAAAATTA, TTAATGAAAA, TCTTCCCTTC, 600ATAATAAATG, GAGATATCGA, AATGCTGAAG, AGAAAAAGAA, AACTTCTAGA, 650TGACACTTGA, 660, (2) SEQ, ID, the information of NO:176:, (i) sequence signature:
(A) length: 1569 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:176:ATGAAAATAA, TGTTAGAGGG, ACTTAATATA, AAACATTATG, TTCAAGATCG, 50TTTATTGTTG, AACATAAATC, GCCTAAAGAT, TTATCAGAAT, GATCGTATTG, 100GTTTAATTGG, TAAAAATGGA, AGTGGAAAAA, CAACGTTACT, TCACATATTA, 150TATAAAAAAA, TTGTGCCTGA, AGAAGGTATT, GTAAAACAAT, TTTCACATTG, 200TGAACTTATT, CCTCAATTGA, AGCTCATAGA, ATCAACTAAA, AGTGGTGGTG, 250AAGTAACACG, AAACTATATT, CGGCAAGCGC, TTGATAAAAA, TCCAGAACTG, 300CTATTAGCAG, ATGAACCAAC, AACTAACTTA, GATAATAACT, ATATAGAAAA, 350ATTAGAACAG, GATTTAAAAA, ATTGGCATGG, AGCATTTATT, ATAGTTTCAC, 400ATGATCGCGC, TTTTTTAGAT, AACTTGTGTA, CTACTATATG, GGAAATTGAC, 450GAGGGAAGAA, TAACTGAATA, TAAGGGGAAT, TATAGTAACT, ATGTTGAACA, 500AAAAGAATTA, GAAAGACATC, GAGAAGAATT, AGAATATGAA, AAATATGAAA, 550AAGAAAAGAA, ACGATTGGAA, AAAGCTATAA, ATATAAAAGA, ACAGAAAGCT, 600CAACGAGCAA, CTAAAAAACC, GAAAAACTTA, AGTTTATCTG, AAGGCAAAAT, 650AAAAGGAGCA, AAGCCATACT, TTGCAGGTAA, GCAAAAGAAG, TTACGAAAAA, 700CTGTAAAATC, TCTAGAAACC, AGACTAGAAA, AACTTGAAAG, CGTCGAAAAG, 750AGAAACGAAC, TTCCTCCACT, TAAAATGGAT, TTAGTGAACT, TAGAAAGTGT, 800AAAAAATAGA, ACTATAATAC, GTGGTGAAGA, TGTCTCGGGT, ACAATTGAAG, 850GACGGGTATT, GTGGAAAGCA, AAAAGTTTTA, GTATTCGCGG, AGGAGACAAG, 900ATGGCAATTA, TCGGATCTAA, TGGTACAGGA, AAGACAACGT, TTATTAAAAA, 950AATTGTGCAT, GGGAATCCTG, GTATTTCATT, ATCGCCATCT, GTCAAAATCG, 1000GTTATTTTAG, CCAAAAAATA, GATACATTAG, AATTAGATAA, GAGCATTTTA, 1050GAAAATGTTC, AATCTTCTTC, ACAACAAAAT, GAAACTCTTA, TTCGAACTAT, 1100TCTAGCTAGA, ATGCATTTTT, TTAGAGATGA, TGTTTATAAA, CCAATAAGTG, 1150TCTTAAGTGG, TGGAGAGCGA, GTTAAAGTAG, CACTAACTAA, AGTATTCTTA, 1200AGTGAAGTTA, ATACGTTGGT, ACTAGATGAA, CCAACAAACT, TTCTTGATAT, 1250GGAAGCTATA, GAGGCGTTTG, AATCTTTGTT, AAAGGAATAT, AATGGCAGTA, 1300TAATCTTTGT, ATCTCACGAT, CGTAAATTTA, TCGAAAAAGT, AGCCACTCGA, 1350ATAATGACAA, TTGATAATAA, AGAAATAAAA, ATATTTGATG, GCACATATGA, 1400ACAATTTAAA, CAAGCTGAAA, AGCCAACAAG, GAATATTAAA, GAAGATAAAA, 1450AACTTTTACT, TGAGACAAAA, ATTACAGAAG, TACTCAGTCG, ATTGAGTATT, 1500GAACCTTCGG, AAGAATTAGA, ACAAGAGTTT, CAAAACTTAA, TAAATGAAAA, 1550AAGAAATTTG, GATAAATAA, 1569, (2) SEQ, ID, the information of NO:177:, (i) sequence signature:
(A) length: 1467 base pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: linearity, (ii) molecule type: DNA, (xi) sequence description: SEQ, ID, NO:177:ATGGAACAAT, ATACAATTAA, ATTTAACCAA, ATCAATCATA, AATTGACAGA, 50TTTACGATCA, CTTAACATCG, ATCATCTTTA, TGCTTACCAA, TTTGAAAAAA, 100TAGCACTTAT, TGGGGGTAAT, GGTACTGGTA, AAACCACATT, ACTAAATATG, 150ATTGCTCAAA, AAACAAAACC, AGAATCTGGA, ACAGTTGAAA, CGAATGGCGA, 200AATTCAATAT, TTTGAACAGC, TTAACATGGA, TGTGGAAAAT, GATTTTAACA, 250CGTTAGACGG, TAGTTTAATG, AGTGAACTCC, ATATACCTAT, GCATACAACC, 300GACAGTATGA, GTGGTGGTGA, AAAAGCAAAA, TATAAATTAC, GTAATGTCAT, 350ATCAAATTAT, AGTCCGATAT, TACTTTTAGA, TGAACCTACA, AATCACTTGG, 400ATAAAATTGG, TAAAGATTAT, CTGAATAATA, TTTTAAAATA, TTACTATGGT, 450ACTTTAATTA, TAGTAAGTCA, CGATAGAGCA, CTTATAGACC, AAATTGCTGA, 500CACAATTTGG, GATATACAAG, AAGATGGCAC, AATAAGAGTG, TTTAAAGGTA, 550ATTACACACA, GTATCAAAAT, CAATATGAAC, AAGAACAGTT, AGAACAACAA, 600CGTAAATATG, AACAGTATAT, AAGTGAAAAA, CAAAGATTGT, CCCAAGCCAG, 650TAAAGCTAAA, CGAAATCAAG, CGCAACAAAT, GGCACAAGCA, TCATCAAAAC, 700AAAAAAATAA, AAGTATAGCA, CCAGATCGTT, TAAGTGCATC, AAAAGAAAAA, 750GGCACGGTTG, AGAAGGCTGC, TCAAAAACAA, GCTAAGCATA, TTGAAAAAAG, 800AATGGAACAT, TTGGAAGAAG, TTGAAAAACC, ACAAAGTTAT, CATGAATTCA, 850ATTTTCCACA, AAATAAAATT, TATGATATCC, ATAATAATTA, TCCAATCATT, 900GCACAAAATC, TAACATTGGT, TAAAGGAAGT, CAAAAACTGC, TAACACAAGT, 950ACGATTCCAA, ATACCATATG, GCAAAAATAT, AGCGCTCGTA, GGTGCAAATG, 1000GTGTAGGTAA, GACAACTTTA, CTTGAAGCTA, TTTACCACCA, AATAGAGGGA, 1050ATTGATTGTT, CTCCTAAAGT, GCAAATGGCA, TACTATCGTC, AACTTGCTTA, 1100TGAAGACATG, CGTGACGTTT, CATTATTGCA, ATATTTAATG, GATGAAACGG, 1150ATTCATCAGA, ATCATTCAGT, AGAGCTATTT, TAAATAACTT, GGGTTTAAAT, 1200GAAGCACTTG, AGCGTTCTTG, TAATGTTTTG, AGTGGTGGGG, AAAGAACGAA, 1250ATTATCGTTA, GCAGTATTAT, TTTCAACGAA, AGCGAATATG, TTAATTTTGG, 1300ATGAACCAAC, TAATTTTTTA, GATATTAAAA, CATTAGAAGC, ATTAGAAATG, 1350TTTATGAATA, AATATCCTGG, AATCATTTTG, TTTACATCAC, ATGATACAAG, 1400GTTTGTTAAA, CATGTATCAG, ATAAAAAATG, GGAATTAACA, GGACAATCTA, 1450TTCATGATAT, AACTTAA, 1467
Claims (131)
1. method of in suspection includes any sample of bacterial nucleic acid, using probe (fragment and/or oligonucleotide) and/or amplimer, described probe and/or amplimer are special for existence and/or its amount that detects nucleic acid, general and sensitivity, described nucleic acid derives from the bacterial species that is selected from down group: intestinal bacteria, Klebsiella pneumonia, Pseudomonas aeruginosa, proteus mirabilis, streptococcus pneumoniae, streptococcus aureus, staphylococcus epidermidis, enterococcus faecalis, Staphylococcus saprophyticus, streptococcus pyogenes, Haemophilus influenzae and morazella catarrhalis, wherein said bacterial nucleic acid or its variant or part comprise can with the target area of the selection of said probe or primer hybridization, this method may further comprise the steps: said sample is contacted with described probe or primer, and detect existence and/or the hybridization probe of its amount or existence and/or its amount of amplified production of the said any bacterial species of indication.
2. method that limits as claim 1, this method is to use the method for probe (fragment and/or oligonucleotide) and/or amplimer in suspection includes any sample of bacterial nucleic acid, described probe and/or amplimer are general and sensitivity for the existence that detects any bacterial nucleic acid and/or its amount, wherein said nucleic acid or its variant or part comprise can with the target area of the selection of said probe or primer hybridization, this method may further comprise the steps: said sample is contacted with described probe or primer, and detect existence and/or the hybridization probe of its amount or existence and/or its amount of amplified production of the said any bacterium of indication.
3. method that limits as claim 1, this method is to use the method for probe (fragment and/or oligonucleotide) and/or amplimer in suspection includes any sample of bacterial nucleic acid, described probe and/or amplimer are special, general and sensitivity for the existence that detects nucleic acid and/or its amount, and said nucleic acid derives to be selected from down organizes antibiotics resistance gene: bla
Tem, bla
Rob, bla
Shv, aadB, aacC1, aacC2, aacC3, aacA4, mecA, vanA-vanH-vanX, satA, aacA-aphD, vat, vga, msrA, sul and int.Wherein said nucleic acid or its variant or part comprise can with the target area of the selection of said probe or primer hybridization, this method may further comprise the steps: said sample is contacted with described probe or primer, and detect existence and/or the hybridization probe of its amount or existence and/or its amount of amplified production of the said antibiotics resistance gene of indication.
4. claim 1,2 and 3 arbitrary methods, this method is directly being carried out on the sample that obtains from human patients, animal, environment or food.
5. claim 1,2 and 3 arbitrary methods, this method is directly carried out on the sample of being made up of one or more bacterial colonys.
6. the arbitrary method of claim 1 to 5, wherein said bacterial nucleic acid are by the method amplification that is selected from down group:
A) polymerase chain reaction (PCR),
B) ligase chain reaction,
C) based on the amplification of nucleotide sequence,
D) keep sequence replicating automatically,
E) strand displacement amplification,
F) branched DNA signal amplification,
G) nested PCR and
H) multiplex PCR.
7. the method for claim 6 is wherein by the said nucleic acid of pcr amplification.
8. the method for claim 7, wherein said PCR scheme is modified to determine the existence of said nucleic acid in one hour, this scheme is by only carrying out under 55 ℃ under the annealing steps in 1 second and 95 ℃ the only denaturing step in a second to each amplification cycles, and do not carry out any extension step.
9. one kind is used for directly from test sample or from the colibacillary method of bacterial colony detection, discriminating and/or quantitative analysis, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:3, SEQ IDNO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on coli strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect existence or its intensity of the said mark of colibacillary existence on said inert solid support or in the said sample of the indication in said solution and/or its amount.
10. method that limits as claim 9, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-227 Nucleotide, and this sequence is included in SEQ ID NO:3 or its complementary sequence,
2) length is the oligonucleotide of 12-278 Nucleotide, and this sequence is included in SEQ ID NO:4 or its complementary sequence,
3) length is the oligonucleotide of 12-1596 Nucleotide, and this sequence is included in SEQ ID NO:5 or its complementary sequence,
4) length is the oligonucleotide of 12-2703 Nucleotide, and this sequence is included in SEQ ID NO:6 or its complementary sequence,
5) length is the oligonucleotide of 12-1391 Nucleotide, this sequence be included in SEQ ID NO:7 or its complementary sequence and
The variant of their specifically and at large annealed combination on coli strain and the representative.
11. the method for claim 10, the said probe that wherein is used to detect the Escherichia coli nucleic acid sequence is selected from down group: SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:48, SEQID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ IDNO:53, SEQ ID NO:54 and their complementary sequence.
12. one kind is detected, and intestinal bacteria in the test sample exist and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the e. coli dna that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of colibacillary existence and/or its amount in the said test sample of detection indication.
13. the method for claim 12, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:42 and SEQ ID NO:43,
B) SEQ ID NO:46 and SEQ ID NO:47,
C) SEQ ID NO:55 and SEQ ID NO:56, and
D) SEQ ID NO:131 and SEQ ID NO:132.
14. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis Klebsiella pneumonia, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:8, SEQ IDNO:9, SEQ ID NO:10, SEQ ID NO:11, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on Klebsiella pneumonia bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection Klebsiella pneumonia on said inert solid support or in the said sample of the indication in said solution and/or its amount.
15. a method that limits as claim 14, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-238 Nucleotide, and this sequence is included in SEQ ID NO:8 or its complementary sequence,
2) length is the oligonucleotide of 12-385 Nucleotide, and this sequence is included in SEQ ID NO:9 or its complementary sequence,
3) length is the oligonucleotide of 12-462 Nucleotide, and this sequence is included in SEQ ID NO:10 or its complementary sequence,
4) length is the oligonucleotide of 12-730 Nucleotide, this sequence be included in SEQ ID NO:11 or its complementary sequence and
The variant of their specifically and at large annealed combination on coli strain and the representative.
16. the method for claim 15, the said probe that wherein is used to detect the Klebsiella pneumonia nucleotide sequence is selected from down group: SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69 and their complementary sequence.
17. one kind is detected, and Klebsiella pneumonia in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the Klebsiella pneumonia DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:8, SEQ ID NO:9, SEQ IDNO:10, SEQ ID NO:11;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of Klebsiella pneumonia and/or its amount in the said test sample of detection indication.
18. the method for claim 17, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:61 and SEQ ID NO:62,
B) SEQ ID NO:67 and SEQ ID NO:68,
C) SEQ ID NO:135 and SEQ ID NO:136, and
D) SEQ ID NO:137 and SEQ ID NO:138.
19. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis proteus mirabilis, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:12, SEQ IDNO:13, SEQ ID NO:14, SEQ ID NO:15, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on proteus mirabilis bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection proteus mirabilis on said inert solid support or in the said sample of the indication in said solution and/or its amount.
20. a method that limits as claim 19, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-225 Nucleotide, and this sequence is included in SEQ ID NO:12 or its complementary sequence,
2) length is the oligonucleotide of 12-402 Nucleotide, and this sequence is included in SEQ ID NO:13 or its complementary sequence,
3) length is the oligonucleotide of 12-157 Nucleotide, and this sequence is included in SEQ ID NO:14 or its complementary sequence,
4) length is the oligonucleotide of 12-1348 Nucleotide, this sequence be included in SEQ ID NO:15 or its complementary sequence and
The variant of their specifically and at large annealed combination on proteus mirabilis bacterial strain and the representative.
21. the method for claim 10, the said probe that wherein is used to detect the proteus mirabilis nucleotide sequence is selected from down group: SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82 and their complementary sequence.
22. one kind is detected, and proteus mirabilis in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the proteus mirabilis DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:12, SEQ ID NO:13, SEQ IDNO:14, SEQ ID NO:15;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of proteus mirabilis and/or its amount in the said test sample of detection indication.
23. the method for claim 22, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:74 and SEQ ID NO:75 and
B) SEQ ID NO:133 and SEQ ID NO:134.
24. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis Staphylococcus saprophyticus, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on Staphylococcus saprophyticus bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection Staphylococcus saprophyticus on said inert solid support or in the said sample of the indication in said solution and/or its amount.
25. a method that limits as claim 24, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-172 Nucleotide, and this sequence is included in SEQ ID NO:21 or its complementary sequence,
2) length is the oligonucleotide of 12-155 Nucleotide, and this sequence is included in SEQ ID NO:22 or its complementary sequence,
3) length is the oligonucleotide of 12-145 Nucleotide, and this sequence is included in SEQ ID NO:23 or its complementary sequence,
4) length is the oligonucleotide of 12-265 Nucleotide, this sequence be included in SEQ ID NO:24 or its complementary sequence and
The variant of their specifically and at large annealed combination on Staphylococcus saprophyticus bacterial strain and the representative.
26. the method for claim 25, the said probe that wherein is used to detect the Staphylococcus saprophyticus nucleotide sequence is selected from down group: SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104 and their complementary sequence.
27. a seizure test is tested, and Staphylococcus saprophyticus in the sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the Staphylococcus saprophyticus DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:21, SEQ ID NO:22, SEQ IDNO:23, SEQ ID NO:24;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of Staphylococcus saprophyticus and/or its amount in the said test sample of detection indication.
28. the method for claim 27, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:98 and SEQ ID NO:99 and
B) SEQ ID NO:139 and SEQ ID NO:140.
29 1 kinds are used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis morazella catarrhalis, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:28, SEQ IDNO:29, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on morazella catarrhalis bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection morazella catarrhalis on said inert solid support or in the said sample of the indication in said solution and/or its amount.
30. a method that limits as claim 29, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-526 Nucleotide, and this sequence is included in SEQ ID NO:28 or its complementary sequence,
2) length is the oligonucleotide of 12-466 Nucleotide, this sequence be included in SEQ ID NO:29 or its complementary sequence and
The variant of their specifically and at large annealed combination on morazella catarrhalis strain and the representative.
31. the method for claim 30, the said probe that wherein is used to detect the morazella catarrhalis nucleotide sequence is selected from down group: SEQ ID NO:108, SEQ ID NO:109, SEQ IDNO:110, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:115, SEQID NO:116, SEQ ID NO:117 and their complementary sequence.
32. one kind is detected, and morazella catarrhalis in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the morazella catarrhalis DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:28 and SEQ ID NO:29;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of morazella catarrhalis and/or its amount in the said test sample of detection indication.
33. the method for claim 13, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:112 and SEQ ID NO:113,
B) SEQ ID NO:118 and SEQ ID NO:119, and
C) SEQ ID NO:160 and SEQ ID NO:119.
34. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis Pseudomonas aeruginosa, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:16, SEQ IDNO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on pseudomonas aeruginosa strains or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection Pseudomonas aeruginosa on said inert solid support or in the said sample of the indication in said solution and/or its amount.
35. a method that limits as claim 35, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-2167 Nucleotide, and this sequence is included in SEQ ID NO:16 or its complementary sequence,
2) length is the oligonucleotide of 12-1872 Nucleotide, and this sequence is included in SEQ ID NO:17 or its complementary sequence,
3) length is the oligonucleotide of 12-3451 Nucleotide, and this sequence is included in SEQ ID NO:18 or its complementary sequence,
4) length is the oligonucleotide of 12-744 Nucleotide, and this sequence is included in SEQ ID NO:19 or its complementary sequence,
5) length is the oligonucleotide of 12-2760 Nucleotide, this sequence be included in SEQ ID NO:20 or its complementary sequence and
The variant of their specifically and at large annealed combination on pseudomonas aeruginosa strains and the representative.
36. the method for claim 35, the said probe that wherein is used to detect the Pseudomonas aeruginosa nucleotide sequence is selected from down group: SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95 and their complementary sequence.
37. one kind is detected, and Pseudomonas aeruginosa in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the Pseudomonas aeruginosa DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:16, SEQ ID NO:17, SEQ IDNO:18, SEQ ID NO:19, SEQ ID NO:20;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of Pseudomonas aeruginosa and/or its amount in the said test sample of detection indication.
38. the method for claim 12, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:83 and SEQ ID NO:84, and
B) SEQ ID NO:85 and SEQ ID NO:86,
39. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis staphylococcus epidermidis, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: its complementary sequence of SEQ ID NO:36, its part and its variant, said probe specificity ground and at large annealed combination on staphylococcus epidermidis bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect on the said inert solid support or existence or its intensity of the said mark of the staphylococcic existence of said sample mesocuticle of the indication in said solution and/or its amount.
40. method that limits as claim 9, wherein said probe is selected from the oligonucleotide that length is 12-705 Nucleotide, this sequence is included among the SEQ ID NO:36 and its annealed combination variant on staphylococcus epidermidis bacterial strain and the representative specifically and at large.
41. one kind is detected, and test sample mesocuticle staphylococcus exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the staphylococcus epidermidis DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:36;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the detection indication staphylococcic existence of said test sample mesocuticle and/or its amount.
42. the method for claim 41, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:145 and SEQ ID NO:146, and
B) SEQ ID NO:147 and SEQ ID NO:148.
43. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis streptococcus aureus, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:37, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on staphylococcus aureus strains or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection streptococcus aureus on said inert solid support or in the said sample of the indication in said solution and/or its amount.
44. method that limits as claim 9, wherein said probe is selected from the oligonucleotide that length is 12-442 Nucleotide, this sequence is included among the SEQ ID NO:37 and its annealed combination variant on staphylococcus epidermidis bacterial strain and the representative specifically and at large.
45. one kind is detected, and streptococcus aureus in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the streptococcus aureus DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:37;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of streptococcus aureus and/or its amount in the said test sample of detection indication.
46. the method for claim 45, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:149 and SEQ ID NO:150,
B) SEQ ID NO:149 and SEQ ID NO:151, and
C) SEQ ID NO:152 and SEQ ID NO:153,
47. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis Haemophilus influenzae, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:25, SEQ IDNO:26, SEQ ID NO:27, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on Haemophilus influenzae bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection Haemophilus influenzae on said inert solid support or in the said sample of the indication in said solution and/or its amount.
48. a method that limits as claim 47, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-845 Nucleotide, and this sequence is included in SEQ ID NO:25 or its complementary sequence,
2) length is the oligonucleotide of 12-1598 Nucleotide, and this sequence is included in SEQ ID NO:26 or its complementary sequence,
3) length is the oligonucleotide of 12-9100 Nucleotide, and this sequence is included in SEQ IDNO:27 or its complementary sequence,
The variant of their specifically and at large annealed combination on Haemophilus influenzae bacterial strain and the representative.
49. the method for claim 48, the said probe that wherein is used to detect the Haemophilus influenzae nucleotide sequence is selected from down group: SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107 and their complementary sequence.
50. one kind is detected, and Haemophilus influenzae in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the Haemophilus influenzae DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:25, SEQ ID NO:26, SEQ IDNO:27;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of Haemophilus influenzae and/or its amount in the said test sample of detection indication.
51. the method for claim 50, wherein said at least one pair of primer are selected from SEQ ID NO:154 and SEQ ID NO:155.
52. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis streptococcus pneumoniae, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:30, SEQ IDNO:31, SEQ ID NO:34, SEQ ID NO:35, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on S. pneumoniae strains or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection streptococcus pneumoniae on said inert solid support or in the said sample of the indication in said solution and/or its amount.
53. a method that limits as claim 52, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-631 Nucleotide, and this sequence is included in SEQ ID NO:30 or its complementary sequence,
2) length is the oligonucleotide of 12-3754 Nucleotide, and this sequence is included in SEQ ID NO:31 or its complementary sequence,
3) length is the oligonucleotide of 12-841 Nucleotide, and this sequence is included in SEQ ID NO:34 or its complementary sequence,
4) length is the oligonucleotide of 12-4500 Nucleotide, this sequence be included in SEQ ID NO:35 or its complementary sequence and
The variant of their specifically and at large annealed combination on S. pneumoniae strains and the representative.
54. the method for claim 53, the said probe that wherein is used to detect the streptococcus pneumoniae nucleotide sequence is selected from down group: SEQ ID NO:120, SEQ ID NO:121 and their complementary sequence.
55. one kind is detected, and streptococcus pneumoniae in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the pneumococcal dna that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:30, SEQ ID NO:31, SEQ IDNO:34, SEQ ID NO:35;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of streptococcus pneumoniae and/or its amount in the said test sample of detection indication.
56. the method for claim 55, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:78 and SEQ ID NO:79,
B) SEQ ID NO:156 and SEQ ID NO:157, and
C) SEQ ID NO:158 and SEQ ID NO:159.
57. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis streptococcus pyogenes, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:32, SEQ IDNO:33, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on streptococcus pyogenes bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection streptococcus pyogenes on said inert solid support or in the said sample of the indication in said solution and/or its amount.
58. a method that limits as claim 57, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-1337 Nucleotide, and this sequence is included in SEQ ID NO:32 or its complementary sequence,
2) length is the oligonucleotide of 12-1837 Nucleotide, this sequence be included in SEQ ID NO:33 or its complementary sequence and
The variant of their specifically and at large annealed combination on streptococcus pyogenes bacterial strain and the representative.
59. one kind is detected, and streptococcus pyogenes in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the streptococcus pyogenes DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:32, SEQ ID NO:33;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of streptococcus pyogenes and/or its amount in the said test sample of detection indication.
60. the method for claim 59, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:141 and SEQ ID NO:142, and
B) SEQ ID NO:143 and SEQ ID NO:144,
61. one kind is used for directly from test sample or from the method for bacterial colony detection, discriminating and/or quantitative analysis enterococcus faecalis, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:1, SEQ IDNO:2, its complementary sequence, its part and its variant, said probe specificity ground and at large annealed combination on enterococcus faecalis bacterial strain or representative, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) existence or its intensity of the said mark of the existence of detection enterococcus faecalis on said inert solid support or in the said sample of the indication in said solution and/or its amount.
62. a method that limits as claim 61, wherein said probe is selected from down group:
1) length is the oligonucleotide of 12-1817 Nucleotide, and this sequence is included in SEQ ID NO:1 or its complementary sequence,
2) length is the oligonucleotide of 12-2275 Nucleotide, this sequence be included in SEQ ID NO:2 or its complementary sequence and
The variant of their specifically and at large annealed combination on enterococcus faecalis bacterial strain and the representative.
63. one kind is detected, and enterococcus faecalis in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the enterococcus faecalis DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from one of following sequence: SEQ ID NO:1, SEQ ID NO:2;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of enterococcus faecalis and/or its amount in the said test sample of detection indication.
64. the method for claim 63, wherein said at least one pair of primer is selected from down group:
A) SEQ ID NO:38 and SEQ ID NO:39, and
B) SEQ ID NO:40 and SEQ ID NO:41.
65. one kind is used for directly detecting the method for any bacterial species from test sample or from bacterial colony, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with general probe, thereby formation hybridization complex, the sequence of said probe is selected from down group: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ IDNO:6, SEQ ID NO:7 and its complementary sequence, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect on said inert solid support or the existence of the said mark of the existence of the said any bacterial species in the said sample of the indication in said solution and/or its amount or its intensity.
66. one kind is detected, and any bacterial species in the test sample exists and/or the method for its amount, this method comprises the following steps:
A) handle said sample with the aqueous solution that comprises a pair of universal primer, one of said primer can be optionally and the hybridization of one of two complementary strands of the said any bacterial species DNA that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and the sequence of said primer is that SEQ ID NO:126 and SEQ IDNO:127 limit;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) existence and/or its amount of the target sequence of the said amplification of the existence of said any bacterial species and/or its amount in the said test sample of detection indication.
67. directly evaluate by bacterial antibiotic resistance gene bla for one kind from test sample or from bacterial colony
Tem(TEM-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:161, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding β-Nei Xiananmei, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene TEM-1 mediation.
68. a method that limits as claim 67, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:161 hybridization.
69. in test sample, evaluate for one kind by bacterial antibiotic resistance gene bla
Tem(TEM-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding β-Nei Xiananmei that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:161;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene TEM-1 mediation.
70. directly evaluate by bacterial antibiotic resistance gene bla for one kind from test sample or from bacterial colony
Rob(ROB-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:162, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding β-Nei Xiananmei, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene ROB-1 mediation.
71. a method that limits as claim 70, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:162 hybridization.
72. in test sample, evaluate for one kind by bacterial antibiotic resistance gene bla
Rob(ROB-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding β-Nei Xiananmei that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:162;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene ROB-1 mediation.
73. directly evaluate by bacterial antibiotic resistance gene bla for one kind from test sample or from bacterial colony
SHV(SHV-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:163, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding β-Nei Xiananmei, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene SHV-1 mediation.
74. a method that limits as claim 73, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:163 hybridization.
75. in test sample, evaluate for one kind by bacterial antibiotic resistance gene bla
Shv(SHV-1) method to the bacterial resistance of β-Nei Xiananleikangshengsu of mediation, this method may further comprise the steps: a) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding β-Nei Xiananmei that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:163;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene SHV-1 mediation.
76. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aadB from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:164, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside adenylyl transferase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aadB mediation.
77. a method that limits as claim 76, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:164 hybridization.
78. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene aadB mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside adenylyl transferase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:164;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aadB mediation.
79. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aacC1 from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:165, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC1 mediation.
80. a method that limits as claim 79, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:165 hybridization.
81. one kind appraisal is by the method to the bacterial resistance of β-Nei Xiananleikangshengsu of bacterial antibiotic resistance gene aacC1 mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:165;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC1 mediation.
82. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aacC2 from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:166, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC2 mediation.
83. a method that limits as claim 82, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:166 hybridization.
84. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene aacC2 mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:166;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC2 mediation.
85. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aacC3 from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:167, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC3 mediation.
86. a method that limits as claim 87, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:167 hybridization.
87. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene aacC3 mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:167;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacC3 mediation.
88. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aacA4 from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:168, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacA4 mediation.
89. a method that limits as claim 88, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:168 hybridization.
90. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene aacA4 mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:168;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacA4 mediation.
91. one kind directly from test sample or from the method to the bacterial resistance of β-Nei Xiananleikangshengsu of bacterial colony appraisal by bacterial antibiotic resistance gene mecA mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:169, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of Renicillin binding protein, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene mecA mediation.
92. a method that limits as claim 91, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:169 hybridization.
93. one kind appraisal is by the method to the bacterial resistance of β-Nei Xiananleikangshengsu of bacterial antibiotic resistance gene mecA mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the Renicillin binding protein that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:169;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene mecA mediation.
94. one kind directly from test sample or from the method to the bacterial resistance of vancomycin of bacterial colony appraisal by bacterial antibiotic resistance gene vanH, vanA and vanX mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:170, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding vancomycin-resistance protein, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of vancomycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vanH, vanA and vanX mediation.
95. a method that limits as claim 94, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:170 hybridization.
96. one kind appraisal is by the method to the bacterial resistance of vancomycin of bacterial antibiotic resistance gene vanH, vanA and vanX mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding vancomycin-resistance protein that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:170;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of vancomycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vanH, vanA and vanX mediation.
97. one kind directly from test sample or from the method to the bacterial resistance of streptogramin A of bacterial colony appraisal by bacterial antibiotic resistance gene satA mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:173, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding streptogramin A Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of streptogramin A of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene satA mediation.
98. a method that limits as claim 97, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ ID NO:173 hybridization.
99. one kind appraisal is by the method to the bacterial resistance of streptogramin A of bacterial antibiotic resistance gene satA mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding streptogramin A Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:173;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of streptogramin A of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene satA mediation.
100. directly evaluate the method to the antibiotic bacterial resistance of aminoglycosides that is mediated by bacterial antibiotic resistance gene aacA-aphD from test sample or from bacterial colony for one kind, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:174, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding aminoglycoside Transacetylase-phosphotransferase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacA-aphD mediation.
101. a method that limits as claim 100, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:174 hybridization.
102. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene aacA-aphD mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding aminoglycoside acetyl acyltransferase-phosphotransferase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:174;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of aminoglycosides antibiotic bacterial resistance of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene aacA-aphD mediation.
103. one kind directly from test sample or from the method to the bacterial resistance of virginiamycin of bacterial colony appraisal by bacterial antibiotic resistance gene vat mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:175, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding virginiamycin Transacetylase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of virginiamycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vat mediation.
104. a method that limits as claim 103, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:175 hybridization.
105. one kind appraisal is by the method to the antibiotic bacterial resistance of aminoglycosides of bacterial antibiotic resistance gene vat mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding virginiamycin Transacetylase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:175;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of virginiamycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vat mediation.
106. one kind directly from test sample or from the method to the bacterial resistance of virginiamycin of bacterial colony appraisal by bacterial antibiotic resistance gene vga mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:176, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the protein-bonded said bacterial antibiotic resistance gene of coding ATP-, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of virginiamycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vga mediation.
107. a method that limits as claim 106, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:176 hybridization.
108. one kind appraisal is by the method to the bacterial resistance of virginiamycin of bacterial antibiotic resistance gene vga mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the protein-bonded said bacterial antibiotic resistance gene of coding ATP-that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:176;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of virginiamycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene vga mediation.
109. one kind directly from test sample or from the method to the bacterial resistance of erythromycin of bacterial colony appraisal by bacterial antibiotic resistance gene nsrA mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:177, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding erythromycin resistance protein, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of erythromycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene msrA mediation.
110. a method that limits as claim 109, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:177 hybridization.
111. one kind appraisal is by the method to the bacterial resistance of erythromycin of bacterial antibiotic resistance gene msrA mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding erythromycin resistance protein that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:177;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of erythromycin of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene msrA mediation.
112. one kind directly from test sample or from the method to the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of bacterial colony appraisal by bacterial antibiotic resistance gene int mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:171, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the said bacterial antibiotic resistance gene of coding intergrase, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene int mediation.
113. a method that limits as claim 112, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:171 hybridization.
114. one kind appraisal is by the method to the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of bacterial antibiotic resistance gene int mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the said bacterial antibiotic resistance gene of the coding intergrase that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:171;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene int mediation.
115. one kind directly from test sample or from the method to the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of bacterial colony appraisal by bacterial antibiotic resistance gene sul mediation, this method may further comprise the steps:
A) with sample or from the DNA of bacteria deposition of the bacterial population of the homogeneous in fact of this sample separation be fixed on the inert solid support or be retained in the solution, perhaps
Be inoculated on the inert solid support with said sample or from the bacterial population of the homogeneous in fact of this sample separation, and original position dissolves the sample or the isolated bacterial of said inoculation, discharging DNA of bacteria,
Said DNA of bacteria comes down to single stranded form;
B) under the condition that can make probe nucleotide and said DNA of bacteria selective cross, said single stranded DNA is contacted with probe, thereby formation hybridization complex, said probe comprises at least a single-chain nucleic acid, the nucleotide sequence of this nucleic acid is selected from down group: SEQ ID NO:172, its complementary sequence, its part and its variant, said probe specificity ground annealed combination is to the proteinic said bacterial antibiotic resistance gene of coding sulfonamide resistance, said mixture is detected by marking method, mark is present on the said probe or mark is present on the first reaction member of said marking method, and said first reacts the member and be present in the reaction of second on said probe member reaction; And
C) detect in existence and/or its intensity to the said mark of the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene sul mediation.
116. a method that limits as claim 115, wherein said probe comprise the oligonucleotide that is at least 12 Nucleotide with the length of SEQ IDNO:172 hybridization.
117. one kind appraisal is by the method to the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of bacterial antibiotic resistance gene sul mediation in test sample, this method may further comprise the steps:
A) handle said sample with comprising at least one pair of length for the aqueous solution of the Oligonucleolide primers of at least 12 Nucleotide, one of said primer can be optionally and the hybridization of one of two complementary strands of the proteinic said bacterial antibiotic resistance gene of coding sulfonamide resistance that contains target sequence, another of said primer can with another hybridization of said chain, so that form extension products, this product contains the target sequence as template, and said at least one pair of primer is selected from SEQ ID NO:172;
B) extension products that contains target sequence of synthetic each said primer, and the said target sequence (if present) that increases is to detectable level; And
C) detect in existence and/or its amount to the said amplified target sequence of the bacterial resistance of β-Nei Xiananleikangshengsu, aminoglycosides microbiotic, paraxin and/or trimethoprim of indication on the said inert solid support or in said solution by bacterial antibiotic resistance gene sul mediation.
118. nucleic acid, this nucleic acid has SEQ ID NO:1-37, SEQ ID NO:161-177, its part and the arbitrary nucleotide sequence of its variant, when with single stranded form, described nucleic acid is hybridized with target bacteria DNA at large and specifically as probe or primer.
119. oligonucleotide with the arbitrary nucleotide sequence of SEQ ID NO:38-160.
120. a recombinant plasmid, this plasmid comprises the nucleic acid that limits as claim 118.
121. a recombinant host, this host is by the recombinant plasmid transformed mistake according to claim 120.
122. the recombinant host according to claim 121, wherein said host is intestinal bacteria.
123. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial species of any combination of quantitative analysis claim 9,14,19,24,29,34,39,43,47,52, arbitrary qualification of 57 and 61, and this test kit comprises the probe of any combination that this paper limits.
124. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial species of any combination of quantitative analysis claim 10,11,15,16,20,21,25,26,30,31,35,36,40,44,48,49,53,54,58, arbitrary qualification of 62 and 65, and this test kit comprises the oligonucleotide probe of any combination that this paper limits.
125. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial species of any combination of quantitative analysis claim 12,13,17,18,22,23,27,28,32,33,37,38,41,42,45,46,50,51,55,56,59,60,63, arbitrary qualification of 64 and 66, and this test kit comprises the primer of any combination that this paper limits.
126. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial resistance gene of any combination of quantitative analysis claim 67,70,73,76,79,82,85,88,91,94,97,100,103, arbitrary qualification of 106 and 109, and this test kit comprises the probe of any combination that this paper limits.
127. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial resistance gene of any combination of quantitative analysis claim 68,71,74,77,80,83,86,89,92,95,98,101,104, arbitrary qualification of 107 and 110, and this test kit comprises the oligonucleotide probe of any combination that this paper limits.
128. diagnostic kit, it is used to detect and/or the nucleic acid of the bacterial resistance gene of any combination of quantitative analysis claim 69,72,75,78,81,84,87,90,93,96,99,102,105, arbitrary qualification of 111, and this test kit comprises the primer of any combination that this paper limits.
129. diagnostic kit, it is used for detecting simultaneously and/or the nucleic acid of the bacterial species of any combination that quantitative analysis claim 123 limits, and this test kit comprises all or part of probe of any combination of antibiotics resistance gene of arbitrary qualification of the bacterial probe of any combination that this paper limits and SEQ ID NO:161-177.
130. diagnostic kit, it is used for detecting simultaneously and/or the nucleic acid of the bacterial species of any combination that quantitative analysis claim 124 limits, and this test kit comprises the bacterium oligonucleotide probe of any combination that this paper limits and hybridizes to the oligonucleotide probe of any combination on the antibiotics resistance gene of arbitrary qualification of SEQ ID NO:161-177.
131. diagnostic kit, it is used for detecting simultaneously and/or the nucleic acid of the bacterial species of any combination that quantitative analysis claim 125 limits, and this test kit comprises the primer of any combination that this paper limits and is annealed to the primer of any combination on the antibiotics resistance gene of arbitrary qualification of SEQ ID NO:161-177.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95195699A CN1161060A (en) | 1994-09-12 | 1995-09-12 | Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/304,732 | 1994-09-12 | ||
| CN95195699A CN1161060A (en) | 1994-09-12 | 1995-09-12 | Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1161060A true CN1161060A (en) | 1997-10-01 |
Family
ID=5082944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95195699A Pending CN1161060A (en) | 1994-09-12 | 1995-09-12 | Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1161060A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296488C (en) * | 2003-06-19 | 2007-01-24 | 中国药品生物制品检定所 | Detection of main pathogenic microorganism in medicine |
| CN1322121C (en) * | 1997-10-31 | 2007-06-20 | 俄克拉何马大学董事会 | Hyaluronan synthase gene and uses thereof |
| CN1327894C (en) * | 1998-04-02 | 2007-07-25 | 俄克拉何马大学董事会 | Nucleic acid encoding hyaluronan synthase and method of use |
| CN101153329B (en) * | 2007-09-21 | 2010-11-03 | 珠海市疾病预防控制中心 | Primer, detection method and detection reagent kit for detecting staphylococcus aureus |
| CN101469326B (en) * | 2007-12-25 | 2011-05-04 | 天津生物芯片技术有限责任公司 | Nucleotide specific to ITS of Balcillus proteus mirabilis and use thereof |
| CN102251289A (en) * | 2011-04-22 | 2011-11-23 | 上海市动物疫病预防控制中心 | Method for constructing haemophilus parasuis genome library and screened immune protein |
| CN105936931A (en) * | 2016-04-15 | 2016-09-14 | 山东畜牧兽医职业学院 | Kit for fluorescence quantitative PCR detection of poultry-farm enterobacteriaceae drug-resistant gene and detection method thereof |
| CN106018027A (en) * | 2016-05-27 | 2016-10-12 | 甘肃农业大学 | Preparation method of scanning electron microscope sample |
| CN108456738A (en) * | 2017-05-15 | 2018-08-28 | 中国农业科学院兰州兽医研究所 | A kind of method of TaqMan real-time fluorescence quantitative PCRs detection staphylococcus saprophyticus |
| CN110656191A (en) * | 2019-11-08 | 2020-01-07 | 甘肃农业大学 | Method for simultaneously detecting various bacterial pathogenic microorganisms |
| CN111733269A (en) * | 2020-08-17 | 2020-10-02 | 江苏集萃药康生物科技有限公司 | Nucleic acid composition, kit and method for detecting staphylococcus aureus and klebsiella pneumoniae |
| CN115851773A (en) * | 2022-11-14 | 2023-03-28 | 无锡新晨宇生物工程有限公司 | Creation and application of aromatic amide biosensor |
-
1995
- 1995-09-12 CN CN95195699A patent/CN1161060A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322121C (en) * | 1997-10-31 | 2007-06-20 | 俄克拉何马大学董事会 | Hyaluronan synthase gene and uses thereof |
| CN1327894C (en) * | 1998-04-02 | 2007-07-25 | 俄克拉何马大学董事会 | Nucleic acid encoding hyaluronan synthase and method of use |
| CN1296488C (en) * | 2003-06-19 | 2007-01-24 | 中国药品生物制品检定所 | Detection of main pathogenic microorganism in medicine |
| CN101153329B (en) * | 2007-09-21 | 2010-11-03 | 珠海市疾病预防控制中心 | Primer, detection method and detection reagent kit for detecting staphylococcus aureus |
| CN101469326B (en) * | 2007-12-25 | 2011-05-04 | 天津生物芯片技术有限责任公司 | Nucleotide specific to ITS of Balcillus proteus mirabilis and use thereof |
| CN102251289A (en) * | 2011-04-22 | 2011-11-23 | 上海市动物疫病预防控制中心 | Method for constructing haemophilus parasuis genome library and screened immune protein |
| CN105936931A (en) * | 2016-04-15 | 2016-09-14 | 山东畜牧兽医职业学院 | Kit for fluorescence quantitative PCR detection of poultry-farm enterobacteriaceae drug-resistant gene and detection method thereof |
| CN106018027A (en) * | 2016-05-27 | 2016-10-12 | 甘肃农业大学 | Preparation method of scanning electron microscope sample |
| CN106018027B (en) * | 2016-05-27 | 2018-11-27 | 甘肃农业大学 | A kind of sample preparation methods of scanning electron microscope |
| CN108456738A (en) * | 2017-05-15 | 2018-08-28 | 中国农业科学院兰州兽医研究所 | A kind of method of TaqMan real-time fluorescence quantitative PCRs detection staphylococcus saprophyticus |
| CN108456738B (en) * | 2017-05-15 | 2021-08-31 | 中国农业科学院兰州兽医研究所 | A kind of TaqMan real-time fluorescent quantitative PCR detection method of Staphylococcus saprophytic |
| CN110656191A (en) * | 2019-11-08 | 2020-01-07 | 甘肃农业大学 | Method for simultaneously detecting various bacterial pathogenic microorganisms |
| CN111733269A (en) * | 2020-08-17 | 2020-10-02 | 江苏集萃药康生物科技有限公司 | Nucleic acid composition, kit and method for detecting staphylococcus aureus and klebsiella pneumoniae |
| CN115851773A (en) * | 2022-11-14 | 2023-03-28 | 无锡新晨宇生物工程有限公司 | Creation and application of aromatic amide biosensor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6001564A (en) | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories | |
| US5994066A (en) | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories | |
| US20020055101A1 (en) | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories | |
| AU745787B2 (en) | Enterococcus faecalis polynucleotides and polypeptides | |
| CA2448975C (en) | Sequences for detection and identification of methicillin-resistant staphyloccocus aureus | |
| Zwiefka et al. | Transcription termination factor rho: the site of bicyclomycin inhibition in Escherichia coli | |
| KR100923598B1 (en) | Surface protein of Streptococcus piogenes | |
| CN1636062A (en) | Novel streptococcus pneumonia open reading frames encoding polypeptide antigens and uses thereof | |
| CN1338005A (en) | Neisseria genomic sequences and methods of their use | |
| CN1161060A (en) | Specific and universal probe and amplification primer for rapidly detecting and identifying common bacterial pathogens and antibiotic resistance genes in clinical samples in routine diagnosis of microbiological laboratories | |
| KR20080031504A (en) | Genes from Actinobacillus succino genes 130 Ｚ (ATC 55618) for the production of chemicals from the C4-path of actinobacillus succino genes | |
| CA2378687A1 (en) | Nucleotide sequences of moraxella catarrhalis genome | |
| CN113832043A (en) | Recombinant acid-tolerant yeast with improved lactic acid production ability | |
| JPH09252787A (en) | Nucleotide sequence of Mycoplasma genitalium genome or fragments thereof and use thereof | |
| JP2005502315A5 (en) | ||
| KR102064765B1 (en) | Novel bacteriophage having pathogen E. coli―specific antibacterial activity and use thereof | |
| CN1800413A (en) | Helicobacter pylori pathogenicity island disease gene detection chip | |
| NZ501596A (en) | Probes to detect and identify common bacterial pathogens and antibiotic resistance genes | |
| CN1735689A (en) | Bacterial virulence genes | |
| CN1911959A (en) | Neisseria genomic sequences and their use | |
| KR20230079107A (en) | Genetically modified Methylobacillus bacteria with improved properties | |
| CN1257279C (en) | Nucleotide peculiar to 0-antigen of 0163 type bacillus coli | |
| TW202225403A (en) | Process | |
| JP2003289867A (en) | Aconitase gene of acetobacter, acetobacter bred by using the gene, and method for producing vinegar by using the acetobacter | |
| CN1186516A (en) | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: Diagnosis of infection (I, C, I), Inc. Applicant before: M G Berger Dragon Applicant before: P. H Roy Applicant before: M. Ouellette |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: M G BERGERON P H ROY M. OUELLETTE TO: INFECT AND DIAGNOSE (I·C·I) CO.,LTD. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |